Note: Descriptions are shown in the official language in which they were submitted.
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
PROPYL CANNABINOID HEMP PLANTS, METHODS OF PRODUCING AND
METHODS OF USING THEM
CROSS REFERENCE TO RELATED APPLICATIONS
[00011 The current application claims the benefit of priority to U.S. Plant
Patent Application
15/999,236, filed on August 28, 2018, which itself claims priority to U.S.
Provisional Application
Serial No. 62/596,561, filed December 8, 2017, each of which is hereby
incorporated by reference
in its entirety.
FIELD OF THE INVENTION
[0002] The invention relates to Specialty Cannabis hemp plants with low A9-
tetrahydrocannabinol
and high propyl cannabinoid contents, as well as compositions mimicking the
cannabinoid and
Terpene Profiles of said plants, and methods for making and using said
cannabis plants and
compositions.
BACKGROUND OF THE INVENTION
100031 Cannabis is a genus of flowering plants that includes at least three
species, Cannabis
sativa, Cannabis indica, and Cannabis ruderalis as determined by plant
phenotypes and secondary
metabolite profiles. In practice however, cannabis nomenclature is often used
incorrectly or
interchangeably. Cannabis literature can be found referring to all cannabis
varieties as "sativas" or
all cannabinoid-producing plants as "indicas." Indeed the promiscuous crosses
of indoor cannabis
breeding programs have made it difficult to distinguish varieties; with most
cannabis being sold in
the United States, having features of both sativa and indica species.
(0004j Modern classification methods of cannabis plants now rely on the
chemical phenotypes of
cannabis inflorescences to categorize plants in a manner that provides
meaningful information
about the plants expected organoleptic and medicinal effects. One of the major
factors in
classifying a new cannabis strain is the plant's cannabinoid profile. Best
known for its production
of A9-tetrahydrocannabinol (THC), and A9-tetrahydrocannabinolic acid (THCA),
cannabis plants
have actually been reported to produce at least 85 different cannabinoids.
Surveys of analyzed
cannabis inflorescences, however, show that almost all known cannabis
varieties available today
have been bred to produce high levels of THC, at the expense of other
cannabinoid constituents.
1
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
100051 Hemp, also known as industrial hemp, is a type of cannabis plant grown
specifically for
the industrial uses of its derived products. In the United States, hemp has
been defined as any
cannabis plant that has no more than three-tenths of one percent (i.e., 0.3%)
concentration of THC.
Several European countries similarly define hemp as a cannabis plant that has
no more than two-
tenths of one percent (i.e., 0.2%) concentration of THC.
[00061 Hemp lines with the requisite low quantities of THC have traditionally
been produced by
selectively breeding plants to either not express the THCA synthase gene, or
alternatively, to not
produce cannabinoids at all. These breeding approaches result in hemp plants
with low
cannabinoid diversity, and reduced medicinal properties. Moreover, many hemp
plants with null
or unexpressed THCA synthase enzymes continue to produce low levels of THC,
which can
sometimes exceed legal limits if permitted to go past maturity, resulting in
total loss of a crop. The
Colorado Department of Agriculture for example, requires growers to destroy
their entire crop, if
even one plant tests higher than 0.3% (8 CCR 1203-23 5.53).
[90071 There thus remains a need for novel cannabis hemp varieties with
further protections
against excess THC accumulation, and with the ability to produce additional
cannabinoids with
individual or synergistic recreational and medicinal applications. The present
invention addresses
some of the shortcomings of the prior art by providing for Specialty Cannabis
plants with novel
cannabinoid profiles providing for improved recreational and medicinal
effects.
SUMMARY OF THE INVENTION
(0008j According to the methods and compositions of the present invention,
plants, plant parts,
plant tissues and plant cells are produced to contain novel and useful
combinations of cannabinoids
with improved recreational and medicinal effects.
[0009] In some embodiments, the Specialty Cannabis plants, plant parts, plant
tissues and plant
cells of the present disclosure comprise no more than 0.3% THC content, while
also accumulating
propyl cannabinoids.
[00101 In some embodiments, the present disclosure teaches, a cannabis hemp
plant, or an asexual
clone of said cannabis hemp plant, or a plant part, tissue, or cell thereof,
which is capable of
producing a female inflorescence, said inflorescence comprising: a) a
functional BD allele; b) a
propyl cannabinoid max content of at least 1.0% by weight; c) a
tetrahydrocannabinol (THC max)
2
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
content of no more than 0.3% by weight, wherein the contents of all
cannabinoids are measured
by high performance liquid chromatography (HPLC) and calculated based on dry
weight of the
inflorescence.
100111 In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part, tissue, or cell thereof of the present disclosure is
represented by a
representative sample of seed producing said plant that has been deposited
under NCIMB Nos.
43258, 43259, and 43260.
[00121 In some embodiments, the present disclosure teaches a terpene
producing, diploid cannabis
hemp plant cell from a female inflorescence (i) a cannabis hemp plant, (ii) an
asexual clone of the
plant, or (iii) a part of the plant, wherein said cannabis hemp plant, asexual
clone of the plant or
part of the plant produces the female inflorescence, said inflorescence
comprising: a) a functional
BD allele; b) a propyl cannabinoid max content of at least 1.0% by weight; c)
a
tetrahydrocannabinol (THC max) content of no more than 0.3% by weight, wherein
the contents
of all cannabinoids are measured by high performance liquid chromatography
(HPLC) and
calculated based on dry weight of the inflorescence; wherein and wherein
samples of seed that
produce plants comprising a), b), and c) have been deposited under NCIMB Nos.
43258, 43259,
and 43260.
100131 In some embodiments, the present disclosure teaches a dry sinsemilla
cannabis
inflorescence comprising: a) a BD allele; b) a propyl cannabinoid max content
of at least 1.0% by
weight; c) a tetrahydrocannabinol (THC max) content of no more than 0.3% by
weight, wherein
the contents of all cannabinoids are measured by high performance liquid
chromatography (HPLC)
and calculated based on dry weight of the inflorescence; wherein and wherein
samples of seed that
produce plants comprising a), b), and c) are obtainable from seed deposited
under NCIMB Nos.
43258, 43259, and 43260.
[00141 In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part (e.g., inflorescence), tissue, or cell thereof does not
comprise a functional BT
allele.
9015] In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part (e.g., inflorescence), tissue, or cell thereof
comprises a BD/BD genotype.
3
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
10016] In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part (e.g., inflorescence), tissue, or cell thereof
comprises a Bo/BD genotype.
10017] In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part (e.g., inflorescence), tissue, or cell thereof
comprises a terpene oil content
greater than about 1.0% by weight; wherein the terpene oil content is the
additive content of
terpinolene, alpha phellandrene, beta ocimene, carene, limonene, gamma
terpinene, alpha pinene,
alpha terpinene, beta pinene, fenchol, camphene, alpha terpineol, alpha
humulene, beta
caryophyllene, linalool, caryophyllene oxide, and myrcene as measured by GC-
FID and calculated
based on dry weight of the inflorescence.
[00181 In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part (e.g., inflorescence), tissue, or cell thereof
comprises a terpene oil content
greater than about 1.5% by weight.
10019] In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part (e.g., inflorescence), tissue, or cell thereof
comprises a terpene oil content
greater than about 2.0% by weight.
[00201 In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part (e.g., inflorescence), tissue, or cell thereof
comprises a propyl cannabinoid
max content of at least 2% by weight.
[0021] In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part (e.g., inflorescence), tissue, or cell thereof
comprises a propyl cannabinoid
max content of at least 3% by weight.
190221 In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part (e.g., inflorescence), tissue, or cell thereof
comprises a THC max content of
no more than 0.2% by weight.
[0023] In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part (e.g., inflorescence), tissue, or cell thereof
comprises a THC max content of
no more than 0.1% by weight.
4
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
100241 In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part (e.g., inflorescence), tissue, or cell thereof
comprises a THC max content of
no more than 0.01% by weight.
100251 In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part (e.g., inflorescence), tissue, or cell thereof
comprises a THC max content of
no more than 0.00% by weight.
0026] In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part (e.g., inflorescence), tissue, or cell thereof
comprises a Terpene Profile in
which myrcene is not the dominant terpene; wherein the Terpene Profile is
defined as terpinolene,
alpha phellandrene, beta ocimene, carene, limonene, gamma terpinene, alpha
pinene, alpha
terpinene, beta pinene, fenchol, camphene, alpha terpineol, alpha humulene,
beta caryophyllene,
linalool, caryophyllene oxide, and myrcene.
10027] In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part (e.g., inflorescence), tissue, or cell thereof comprise
a Terpene Profile wherein
the first or second most abundant terpene in the Terpene Profile is
terpinolene.
(00281 In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part (e.g., inflorescence), tissue, or cell thereof comprise
a Terpene Profile wherein
the first or second most abundant terpene in the Terpene Profile is alpha
phellandrene.
[0029] In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part (e.g., inflorescence), tissue, or cell thereof comprise
a Terpene Profile wherein
the first or second most abundant terpene in the Terpene Profile is beta
ocimene.
190301 In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part (e.g., inflorescence), tissue, or cell thereof comprise
a Terpene Profile wherein
the first or second most abundant terpene in the Terpene Profile is carene.
[0031] In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part (e.g., inflorescence), tissue, or cell thereof comprise
a Terpene Profile wherein
the first or second most abundant terpene in the Terpene Profile is limonene.
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
100321 In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part (e.g., inflorescence), tissue, or cell thereof comprise
a Terpene Profile wherein
the first or second most abundant terpene in the Terpene Profile is gamma
terpinene.
100331 In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part (e.g., inflorescence), tissue, or cell thereof comprise
a Terpene Profile wherein
the first or second most abundant terpene in the Terpene Profile is alpha
pinene.
10034] In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part (e.g., inflorescence), tissue, or cell thereof comprise
a Terpene Profile wherein
the first or second most abundant terpene in the Terpene Profile is alpha
terpinene.
[00351 In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part (e.g., inflorescence), tissue, or cell thereof comprise
a Terpene Profile wherein
the first or second most abundant terpene in the Terpene Profile is beta
pinene.
10036] In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part (e.g., inflorescence), tissue, or cell thereof comprise
a Terpene Profile wherein
the first or second most abundant terpene in the Terpene Profile is fenchol.
100371 In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part (e.g., inflorescence), tissue, or cell thereof comprise
a Terpene Profile wherein
the first or second most abundant terpene in the Terpene Profile is camphene.
[0038] In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part (e.g., inflorescence), tissue, or cell thereof comprise
a Terpene Profile wherein
the first or second most abundant terpene in the Terpene Profile is alpha
terpineol.
100391 In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part (e.g., inflorescence), tissue, or cell thereof comprise
a Terpene Profile wherein
the first or second most abundant terpene in the Terpene Profile is alpha
humulene.
[0040] In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part (e.g., inflorescence), tissue, or cell thereof comprise
a Terpene Profile wherein
the first or second most abundant terpene in the Terpene Profile is beta
caryophyllene.
6
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
IOW] J In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part (e.g., inflorescence), tissue, or cell thereof comprise
a Terpene Profile wherein
the first or second most abundant terpene in the Terpene Profile is linalool.
100421 In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part (e.g., inflorescence), tissue, or cell thereof comprise
a Terpene Profile wherein
the first or second most abundant terpene in the Terpene Profile is
caryophyllene oxide.
10043] In some embodiments, the cannabis hemp plant, or an asexual clone of
said cannabis hemp
plant, or a plant part (e.g., inflorescence), tissue, or cell thereof comprise
a Terpene Profile in
which myrcene is the first or second most abundant terpene in the Terpene
Profile; wherein the
Terpene Profile is defined as terpinolene, alpha phellandrene, beta ocimene,
carene, limonene,
gamma terpinene, alpha pinene, alpha terpinene, beta pinene, fenchol,
camphene, alpha terpineol,
alpha humulene, beta caryophyllene, linalool, caryophyllene oxide, and
myrcene.
10044] In some embodiments, the present disclosure teaches a method of
producing a cannabis
extract, said method comprising the steps of: contacting the inflorescence of
Specialty Cannabis
hemp with a solvent, thereby producing a cannabis extract.
(00451 In some embodiments, the method of producing a cannabis extract
comprises heating said
extract, thereby decarboxylating at least 70% of the cannabinoid content of
the extract.
100461 In some embodiments, the method of producing a cannabis extract
comprises winterizing
said extract.
100471 In some embodiments, the present disclosure teaches a cannabis extract
from the Specialty
Cannabis hemp plants of the present disclosure.
100481 In some embodiments, the cannabis extract is selected from the group
consisting of kief,
hashish, bubble hash, solvent reduced oils, sludges, e-juice, and tinctures.
100491 In some embodiments, the present disclosure teaches a cannabis extract
comprising greater
than 10% propyl cannabinoid max content, greater than 10% terpene oil content,
and less than 1%
THC max content as measured by HPLC and based on weight of the extract.
[0050] In some embodiments, the present disclosure teaches a method of
breeding cannabis hemp
plants with high propyl cannabinoid content max and low THC max content, said
method
comprising: (i) making a cross between a first cannabis hemp plant of the
Specialty Cannabis
7
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
hemp, and a second cannabis plant to produce an Fl plant (ii) harvesting the
resulting seed; (iii)
growing said seed; and (iv) selecting for high propyl cannabinoid content max
and low THC max
content; wherein the resulting selected cannabis hemp plant comprises at least
1.0% propyl
cannabinoid max content by weight, and no more than 0.3% THC max content by
weight.
I 0051] In some embodiments, the present disclosure teaches a method of
producing cannabis hemp
plants with high propyl cannabinoid content max and low THC max content, said
method
comprising: (i) obtaining a cannabis seed, or cutting from a first cannabis
hemp plant of any one
of the Specialty Cannabis hemp of the present disclosure, (ii) placing said
cannabis seed or cutting
in an environment conducive to plant growth; (iii) allowing said cannabis seed
or cutting to
produce a new cannabis plant; (iv) selecting for high propyl cannabinoid
content max and low
THC max content; wherein the resulting selected cannabis hemp plant is
comprises at least 1.0%
propyl cannabinoid max content by weight, and no more than 0.3% THC max
content by weight.
100521 In some embodiments the present disclosure teaches a cannabis hemp
female inflorescence,
said inflorescence comprising: a) a functional BD allele; b) a propyl
cannabinoid max content of at
least 1.0% by weight; c) a tetrahydrocannabinol (THC max) content of no more
than 0.3% by
weight, wherein the contents of all cannabinoids are measured by high
performance liquid
chromatography (HPLC) and calculated based on dry weight of the inflorescence.
100531 some embodiments the present disclosure teaches a cannabis hemp female
inflorescence,
said inflorescence comprising: a) a functional BD allele; b) a propyl
cannabinoid max content of at
least 1.0% by weight; c) a tetrahydrocannabinol (THC max) content of no more
than 0.3% by
weight, wherein the contents of all cannabinoids are measured by high
performance liquid
chromatography (HPLC) and calculated based on dry weight of the inflorescence,
wherein a
representative sample of seed producing plants with said inflorescence has
been deposited under
NCIMB Nos. 43258, 43259, and 43260.
100541 In some embodiments, the present disclosure teaches a terpene
producing, diploid cannabis
hemp plant cell from a female inflorescence (i) a cannabis hemp plant, (ii) an
asexual clone of the
plant, or (iii) a part of the plant, wherein said cannabis hemp plant, asexual
clone of the plant or
part of the plant produces the female inflorescence, said inflorescence
comprising: a) a functional
BD allele; b) a propyl cannabinoid max content of at least 1.0% by weight; c)
a
tetrahydrocannabinol (THC max) content of no more than 0.3% by weight, wherein
the contents
8
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
of all cannabinoids are measured by high performance liquid chromatography
(HPLC) and
calculated based on dry weight of the inflorescence; wherein and wherein
samples of seed that
produce plants comprising a), b), and c) have been deposited under NCIMB Nos.
43258, 43259,
and 43260.
10055] In some embodiments, the present disclosure teaches a dry, non-viable
(i) cannabis hemp
plant or (ii) part thereof, wherein said cannabis hemp plant or part thereof,
comprises at least a
portion of a female inflorescence, said inflorescence comprising: a) a BD
allele; b) a propyl
cannabinoid max content of at least 1.0% by weight; c) a tetrahydrocannabinol
(THC max) content
of no more than 0.3% by weight, wherein the contents of all cannabinoids are
measured by high
performance liquid chromatography (HPLC) and calculated based on dry weight of
the
inflorescence, wherein samples of seed that produce plants comprising a), b),
and c) have been
deposited under NCIMB Nos. 43258, 43259, and 43260.
100561 In some embodiments, the present disclosure teaches a composition
comprising: a) a propyl
cannabinoid max content of at least 20% by weight; b) a cannabidiol (CBD max)
content of at
least 10% by weight; and c) a tetrahydrocannabinol (THC max) content of no
more than 10% by
weight; wherein the contents of all cannabinoids are measured by high
performance liquid
chromatography (HPLC) and calculated based on weight of the composition.
100571 In some embodiments, the present disclosure teaches a composition
comprising a terpene
oil content greater than about 10% by weight; wherein the terpene oil content
is the additive content
of terpinolene, alpha phellandrene, beta ocimene, carene, limonene, gamma
terpinene, alpha
pinene, alpha terpinene, beta pinene, fenchol, camphene, alpha terpineol,
alpha humulene, beta
caryophyllene, linalool, caryophyllene oxide, and myrcene as measured by GC-
FID and calculated
based on weight of the composition.
(0058j In some embodiments, the present disclosure teaches a composition,
wherein the
composition comprises a terpene oil content greater than about 15% by weight.
100591 In some embodiments, the present disclosure teaches a composition,
wherein the
composition comprises a terpene oil content greater than about 20.0% by
weight.
100601 In some embodiments, the present disclosure teaches a composition,
wherein the
composition comprises a propyl cannabinoid max content of at least 30% by
weight.
9
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
190611 In some embodiments, the present disclosure teaches a composition,
wherein the
composition comprises a propyl cannabinoid max content of at least 40% by
weight.
100621 In some embodiments, the present disclosure teaches a composition,
wherein the
composition comprises a propyl cannabinoid max content of at least 50% by
weight.
190631 In some embodiments, the present disclosure teaches a composition,
wherein the
composition comprises a propyl THC max content of no more than 0.5% by weight.
100641 In some embodiments, the present disclosure teaches a composition,
wherein the
composition comprises a propyl THC max content of no more than 0.3% by weight.
190651 In some embodiments, the present disclosure teaches a composition,
wherein the
composition comprises a propyl THC max content of no more than 0.2% by weight.
190661 In some embodiments, the present disclosure teaches a composition,
wherein the
composition comprises a Terpene Profile in which myrcene is not the dominant
terpene; wherein
the Terpene Profile is defined as terpinolene, alpha phellandrene, beta
ocimene, carene, limonene,
gamma terpinene, alpha pinene, alpha terpinene, beta pinene, fenchol,
camphene, alpha terpineol,
alpha humulene, beta caryophyllene, linalool, caryophyllene oxide, and
myrcene.
[00671 In some embodiments, the present disclosure teaches a composition,
wherein the first or
second most abundant terpene in the Terpene Profile is terpinolene.
[90681 In some embodiments, the present disclosure teaches a composition,
wherein the first or
second most abundant terpene in the Terpene Profile is alpha phellandrene.
100691 In some embodiments, the present disclosure teaches a composition,
wherein the first or
second most abundant terpene in the Terpene Profile is beta ocimene.
190701 In some embodiments, the present disclosure teaches a composition,
wherein the first or
second most abundant terpene in the Terpene Profile is carene.
[00711 In some embodiments, the present disclosure teaches a composition,
wherein the first or
second most abundant terpene in the Terpene Profile is limonene.
190721 In some embodiments, the present disclosure teaches a composition,
wherein the first or
second most abundant terpene in the Terpene Profile is gamma terpinene.
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
100731 In some embodiments, the present disclosure teaches a composition,
wherein the first or
second most abundant terpene in the Terpene Profile is alpha pinene.
10074j In some embodiments, the present disclosure teaches a composition,
wherein the first or
second most abundant terpene in the Terpene Profile is alpha terpinene.
100751 In some embodiments, the present disclosure teaches a composition,
wherein the first or
second most abundant terpene in the Terpene Profile is beta pinene.
10076j In some embodiments, the present disclosure teaches a composition,
wherein the first or
second most abundant terpene in the Terpene Profile is fenchol.
f9077] In some embodiments, the present disclosure teaches a composition,
wherein the first or
second most abundant terpene in the Terpene Profile is camphene.
190781 In some embodiments, the present disclosure teaches a composition,
wherein the first or
second most abundant terpene in the Terpene Profile is alpha terpineol.
0079] In some embodiments, the present disclosure teaches a composition,
wherein the first or
second most abundant terpene in the Terpene Profile is alpha humulene.
190801 In some embodiments, the present disclosure teaches a composition,
wherein the first or
second most abundant terpene in the Terpene Profile is beta caryophyllene.
10081] In some embodiments, the present disclosure teaches a composition,
wherein the first or
second most abundant terpene in the Terpene Profile is linalool.
I0082] In some embodiments, the present disclosure teaches a composition,
wherein the first or
second most abundant terpene in the Terpene Profile is caryophyllene oxide.
11)083 In some embodiments, the present disclosure teaches a composition,
wherein the
composition comprises a Terpene Profile in which myrcene is the first or
second most abundant
terpene in the Terpene Profile; wherein the Terpene Profile is defined as
terpinolene, alpha
phellandrene, beta ocimene, carene, limonene, gamma terpinene, alpha pinene,
alpha terpinene,
beta pinene, fenchol, camphene, alpha terpineol, alpha humulene, beta
caryophyllene, linalool,
caryophyllene oxide, and myrcene.
BRIEF DESCRIPTION OF THE DRAWINGS
11
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
100841 Figure 1A-B. Depicts the current model biosynthetic pathway for several
major
cannabinoids. Figure 1A- Geranyl pyrophosphate (GPP) and olivetolic acid (OA)
are condensed
by the geranyl pyrophosphate olivetolate geranyl transferase (GOT) to form
cannabigerolic acid
(CBGA). Alternatively, GPP and divarinic acid are condensed by GOT to form
cannabigerovarinic
acid (CBGVA). Figure 1B- CBGA or CBGVA is transformed to: (1) THCA/THCVA by
THCA
synthase, (2) CBCA/CBCVA by CBCA synthase, or (3) CBDA/CBDVA by CBDA synthase.
[0085] Figure 2. Depicts a sample questionnaire used for volunteer trials of
Specialty Cannabis
and cannabinoid compositions of the present disclosure. This questionnaire
will be provided to
volunteers with each cannabis blend sample or cannabinoid composition to
measure the effects of
the sample when administered.
[0086] Figure 3. Depicts the breeding scheme for the `03.52.01x09.S1.01' high
propyl
cannabinoid Specialty Cannabis hemp line. Lines THVO1 and CBD05.S1-P24 were
crossed to
produce Fl line V24. V24 was selfed to produce sibling lines V24.S1.N5 and
V24.S1.03. Line
V24.S1.03 was selfed to produce 03.S2.01, which was used in a later cross.
Lines V24.S1.N5 and
V24.S1.03 were crossed to produce Fl line 03.N5.09. 03.N5.09 was then selfed
to produce
09.S1.01. Line 09.S1.01 was then crossed to 03.S2.01 to produce final progeny
line
03.S2.01x09.S1.01. The THC and total propyl cannabinoid content of the progeny
and parental
lines is provided in parenthesis under each named plant as a weight percentage
based on the dry
weight of the inflorescence. This breeding scheme produced novel plants with
THC content below
0.3% and high propyl cannabinoid content.
[0087] Figure 4. Depicts the breeding scheme for the '03.52.16x09. S1.01' high
propyl
cannabinoid Specialty Cannabis hemp line. Lines THVO1 and CBD05.S1-P24 were
crossed to
produce Fl line V24. V24 was selfed to produce sibling lines V24.S1.N5 and
V24.S1.03. Line
V24. S1.03 was selfed to produce 03.S2.16, which was used in a later cross.
Lines V24.S1.N5 and
V24.S1.03 were crossed to produce Fl line 03.N5.09. 03.N5.09 was then selfed
to produce
09.S1.01. Line 09.S1.01 was then crossed to 03.S2.16 to produce final progeny
line
03.S2.16x09.S1.01. The THC and total propyl cannabinoid content of the progeny
and parental
lines is provided in parenthesis under each named plant as a weight percentage
based on the dry
weight of the inflorescence. This breeding scheme produced novel plants with
THC content below
0.3% and high propyl cannabinoid content.
12
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
100881 Figure 5. Depicts the breeding scheme for the 012.09.10x09.S1.01' high
propyl
cannabinoid Specialty Cannabis hemp line. Lines THVO1 and CBD05.S1-P24 were
crossed to
produce Fl line V24. V24 was selfed to produce sibling lines V24.S1.N5 and
V24.S1.03. Lines
V24.S1.N5 and V24.S1.03 were crossed to produce Fl sibling lines 03.N5.09 and
03.N5.12.
03.N5.09 was then selfed to produce 09.S1.01. Line 03.N5.09 was also crossed
with 03.N5.12
to produce line 012.09.10. Line 09.S1.01 was then crossed to 012.09.10 to
produce final progeny
line 012.09.10x09.S1.01. The THC and total propyl cannabinoid content of the
progeny and
parental lines is provided in parenthesis under each named plant as a weight
percentage based on
the dry weight of the inflorescence. This breeding scheme produced novel
plants with THC content
below 0.3% and high propyl cannabinoid content.
[00891 Figure 6. Depicts the breeding scheme for the `V24.S1.P09x09.S1.01 high
propyl
cannabinoid Specialty Cannabis hemp line. Lines THVO1 and CBD05.S1-P24 were
crossed to
produce Fl line V24. V24 was selfed to produce sibling lines V24.S1.P09,
V24.S1.N5, and
V24.S1.03. Lines V24.S1.N5 and V24.S1.03 were crossed to produce Fl line
03.N5.09.
03.N5.09 was then selfed to produce 09.S1.01. Line 09.S1.01 was then crossed
to V24.S1.P09
to produce final progeny V24.S1.P09x09.S1.01. The THC and total propyl
cannabinoid content
of the progeny and parental lines is provided in parenthesis under each named
plant as a weight
percentage based on the dry weight of the inflorescence. This breeding scheme
produced novel
plants with THC content below 0.3% and high propyl cannabinoid content.
(0090i Figure 7. Depicts the breeding scheme for the `V24.52.26x09. S1.01'
high propyl
cannabinoid Specialty Cannabis hemp line. Lines THVO1 and CBD05.S1-P24 were
crossed to
produce Fl line V24. V24 was selfed to produce sibling lines V24.S1.24,
V24.S1.N5, and
V24.S1.03. V24.S1.24 was separately selfed to produce V24.52.26. Lines
V24.S1.N5 and
V24.S1.03 were crossed to produce Fl line 03.N5.09. 03.N5.09 was then selfed
to produce
09.S1.01. Line 09.S1.01 was then crossed to V24.52.26 to produce final progeny
V24.52.26x09.S1.01 line. The THC and total propyl cannabinoid content of the
progeny and
parental lines is provided in parenthesis under each named plant as a weight
percentage based on
the dry weight of the inflorescence. This breeding scheme produced novel
plants with THC content
below 0.3% and high propyl cannabinoid content.
13
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
100911 Figure 8. Depicts the breeding scheme for the `09.S1.01x09. S1.01' high
propyl
cannabinoid Specialty Cannabis hemp line. Lines THVO1 and CBD05.S1-P24 were
crossed to
produce Fl line V24. V24 was selfed to produce sibling lines V24. Sl.N5 and
V24. S1.03. Lines
V24. Sl.N5 and V24. S1.03 were crossed to produce Fl line 03.N5.09. 03.N5.09
was then selfed
to produce 09.S1.01. Line 09.S1.01 was then selfed again to produce final
progeny
09.S1.01x09. S1.01 line. The THC and total propyl cannabinoid content of the
progeny and
parental lines is provided in parenthesis under each named plant as a weight
percentage based on
the dry weight of the inflorescence. This breeding scheme produced novel
plants with THC content
below 0.3% and high propyl cannabinoid content
DETAILED DESCRIPTION OF THE INVENTION
[00921 All publications, patents and patent applications, including any
drawings and appendices,
are herein incorporated by reference to the same extent as if each individual
publication or patent
application was specifically and individually indicated to be incorporated by
reference.
19093I The following description includes information that may be useful in
understanding the
present invention. It is not an admission that any of the information provided
herein is prior art or
relevant to the presently claimed inventions, or that any publication
specifically or implicitly
referenced is prior art.
Definitions
100941 As used herein, the verb "comprise" is used in this description and in
the claims and its
conjugations are used in its non-limiting sense to mean that items following
the word are included,
but items not specifically mentioned are not excluded.
19095] As used herein, the term "about" refers to plus or minus 10% of the
referenced number.
For example, reference to an absolute content of a particular terpene of
"about 1%" means that
that terpene can be present at any amount ranging from 0.9% to 1.1% content by
weight.
100961 The instant specification will often refer to content by weight of
various compounds and
mixtures (e.g., individual volatiles, terpenes and cannabinoids, or defined
sets thereof, such as
terpene oil content, cannabinoid content, propyl cannabinoid content). Persons
having skill in the
art will understand the context under which the weight content is being used,
and will thus
recognize the appropriate frame (i.e. denominator) to use when expressing such
a content. For
14
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
example, weight contents from cannabis inflorescences are reported in terms of
dry weight of the
inflorescence (i.e. by calculating weight of the compound of interest divided
by dry weight of
inflorescence, multiplied by 100). Weight contents of extracts or other
compositions is based on
the weight of the extract or composition, respectively (i.e., by calculating
weight of the compound
of interest divided by weight of the composition, multiplied by 100). In some
instances, the content
of a compound or mixture in an extract or edible will be expressed in terms of
absolute weight
(e.g., a brownie with 500 mg of THC).
[90971 The invention provides cannabis plants. As used herein, the term
"plant" refers to plants
in the genus of Cannabis and plants derived thereof. Such as cannabis plants
produced via asexual
reproduction, tissue culture, and via seed production.
[0098j The invention provides plant parts. As used herein, the term "plant
part" refers to any part
of a plant including but not limited to the embryo, shoot, root, stem, seed,
stipule, leaf, petal,
flower, inflorescence, bud, ovule, bract, trichome, branch, petiole,
internode, bark, pubescence,
tiller, rhizome, frond, blade, ovule, pollen, stamen, and the like. The two
main parts of plants
grown in some sort of media, such as soil or vermiculite, are often referred
to as the "above-
ground" part, also often referred to as the "shoots", and the "below-ground"
part, also often
referred to as the "roots". Plant parts may also include certain extracts such
as kief or hash, which
includes cannabis trichomes or glands. In some embodiments, plant part should
also be interpreted
as referring to individual cells derived from the plant.
(0099j As used herein, the term "plant cell" refers to any totipotent plant
cell from a cannabis
plant. Plant cells of the present disclosure include cells from a cannabis
plant shoot, root, stem,
seed, stipule, leaf, petal, inflorescence, bud, ovule, bract, trichome,
petiole, internode. In some
embodiments, the disclosed plant cell is from a cannabis trichome.
(0100j As used herein, the term dominant refers to a terpene that is the most
abundant in the
Terpene Profile either in absolute content as a percentage by dry weight, or
in relative content as
a percentage of the Terpene Profile.
[01011 The term "a" or "an" refers to one or more of that entity; for example,
"a gene" refers to
one or more genes or at least one gene. As such, the terms "a" (or "an"), "one
or more" and "at
least one" are used interchangeably herein. In addition, reference to "an
element" by the indefinite
article "a" or "an" does not exclude the possibility that more than one of the
elements is present,
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
unless the context clearly requires that there is one and only one of the
elements. Thus, the term a
plant may refer to more than one plants.
101021 As used herein, a "landrace" refers to a local variety of a
domesticated plant species that
has developed largely by natural processes, by adaptation to the natural and
cultural environment
in which it lives. The development of a landrace may also involve some
selection by humans but
it differs from a formal breed that has been selectively bred deliberately to
conform to a particular
formal, purebred standard of traits.
101031 The International Code of Zoological Nomenclature defines rank, in the
nomenclatural
sense, as the level, for nomenclatural purposes, of a taxon in a taxonomic
hierarchy (e.g., all
families are for nomenclatural purposes at the same rank, which lies between
superfamily and
subfamily). While somewhat arbitrary, there are seven main ranks defined by
the international
nomenclature codes: kingdom, phylum/division, class, order, family, genus, and
species. Further
taxonomic hierarchies used in this invention are described below.
101041 The invention provides plant cultivars. As used herein, the term
"cultivar" means a group
of similar plants that by structural features and performance (i.e.,
morphological and physiological
characteristics) can be identified from other varieties within the same
species. Furthermore, the
term "cultivar" variously refers to a variety, strain or race of plant that
has been produced by
horticultural or agronomic techniques and is not normally found in wild
populations. The terms
cultivar, variety, strain and race are often used interchangeably by plant
breeders, agronomists and
farmers.
[0105] The term "variety" as used herein has identical meaning to the
corresponding definition in
the International Convention for the Protection of New Varieties of Plants
(UPOV treaty), of Dec.
2, 1961, as Revised at Geneva on Nov. 10, 1972, on Oct. 23, 1978, and on Mar.
19, 1991. Thus,
"variety" means a plant grouping within a single botanical taxon of the lowest
known rank, which
grouping, irrespective of whether the conditions for the grant of a breeder's
right are fully met, can
be i) defined by the expression of the characteristics resulting from a given
genotype or
combination of genotypes, ii) distinguished from any other plant grouping by
the expression of at
least one of the said characteristics and iii) considered as a unit with
regard to its suitability for
being propagated unchanged.
16
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
10106] The invention provides methods for obtaining plant lines. As used
herein, the term "line"
is used broadly to include, but is not limited to, a group of plants
vegetatively propagated from a
single parent plant, via tissue culture techniques or a group of inbred plants
which are genetically
very similar due to descent from a common parent(s). A plant is said to
"belong" to a particular
line if it (a) is a primary transformant (TO) plant regenerated from material
of that line; (b) has a
pedigree comprised of a TO plant of that line; or (c) is genetically very
similar due to common
ancestry (e.g., via inbreeding or selfing). In this context, the term
"pedigree" denotes the lineage
of a plant, e.g. in terms of the sexual crosses affected such that a gene or a
combination of genes,
in heterozygous (hemizygous) or homozygous condition, imparts a desired trait
to the plant.
101071 As used herein, the term "inbreeding" refers to the production of
offspring via the mating
between relatives. The plants resulting from the inbreeding process are
referred to herein as "inbred
plants" or "inbreds."
[0108] The term LOQ as used herein refers to the limit of quantitation for Gas
Chromatography
(GC) and High Performance Liquid Chromatography (HPLC) measurements.
[0109] The term secondary metabolites as used herein refers to organic
compounds that are not
directly involved in the normal growth, development, or reproduction of an
organism. In other
words, loss of secondary metabolites does not result in immediate death of
said organism.
191101 The term single allele converted plant as used herein refers to those
plants that are
developed by a plant breeding technique called backcrossing wherein
essentially all of the desired
morphological and physiological characteristics of an inbred are recovered in
addition to the single
allele transferred into the inbred via the backcrossing technique.
[01111 The invention provides samples. As used herein, the term "sample"
includes a sample from
a plant, a plant part, a plant cell, an extract, or a composition, or from a
transmission vector, or a
soil, water or air sample.
[0112] The invention provides offspring. As used herein, the term "offspring"
refers to any plant
resulting as progeny from a vegetative or sexual reproduction from one or more
parent plants or
descendants thereof. For instance, an offspring plant may be obtained by
cloning or selfing of a
parent plant or by crossing two parent plants and include selfings as well as
the Fl or F2 or still
further generations. An Fl is a first-generation offspring produced from
parents at least one of
17
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
which is used for the first time as donor of a trait, while offspring of
second generation (F2) or
subsequent generations (F3, F4, etc.) are specimens produced from selfings of
F l's, F2's etc. An
Fl may thus be (and usually is) a hybrid resulting from a cross between two
true breeding parents
(true-breeding is homozygous for a trait), while an F2 may be (and usually is)
an offspring resulting
from self-pollination of said Fl hybrids.
[01131 The invention provides methods for crossing a first plant with a second
plant. As used
herein, the term "cross", "crossing", "cross pollination" or "cross-breeding"
refer to the process
by which the pollen of one flower on one plant is applied (artificially or
naturally) to the ovule
(stigma) of a flower on another plant. Backcrossing is a process in which a
breeder repeatedly
crosses hybrid progeny, for example a first generation hybrid (F1), back to
one of the parents of
the hybrid progeny. Backcrossing can be used to introduce one or more single
locus conversions
from one genetic background into another.
[0114] In some embodiments, the present invention provides methods for
obtaining plant
genotypes comprising recombinant genes. As used herein, the term "genotype"
refers to the
genetic makeup of an individual cell, cell culture, tissue, organism (e.g., a
plant), or group of
organisms.
[0115] In some embodiments, the present invention provides homozygotes. As
used herein, the
term "homozygote" refers to an individual cell or plant having the same
alleles at one or more loci.
[0116] In some embodiments, the present invention provides homozygous plants.
As used herein,
the term "homozygous" refers to the presence of identical alleles at one or
more loci in homologous
chromosomal segments.
19117j In some embodiments, the present invention provides hemizygotes. As
used herein, the
term "hemizygotes" or "hemizygous" refers to a cell, tissue, organism or plant
in which a gene is
present only once in a genotype, as a gene in a haploid cell or organism, a
sex-linked gene in the
heterogametic sex, or a gene in a segment of chromosome in a diploid cell or
organism where its
partner segment has been deleted.
[0118] In some embodiments, the present invention provides heterozygotes. As
used herein, the
terms "heterozygote" and "heterozygous" refer to a diploid or polyploid
individual cell or plant
having different alleles (forms of a given gene) present at least at one
locus. In some embodiments,
18
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
the cell or organism is heterozygous for the gene of interest that is under
control of the synthetic
regulatory element.
101191 The invention provides self-pollination populations. As used herein,
the term "self-
crossing", "self-pollinated" or "self-pollination" means the pollen of one
flower on one plant is
applied (artificially or naturally) to the ovule (stigma) of the same or a
different flower on the same
plant.
101201 The invention provides ovules and pollens of plants. As used herein
when discussing
plants, the term "ovule" refers to the female gametophyte, whereas the term
"pollen" means the
male gametophyte.
[01211 The invention provides methods for obtaining plants comprising
recombinant genes
through transformation. As used herein, the term "transformation" refers to
the transfer of nucleic
acid (i.e., a nucleotide polymer) into a cell. As used herein, the term
"genetic transformation" refers
to the transfer and incorporation of DNA, especially recombinant DNA, into a
cell.
[01221 The invention provides transformants comprising recombinant genes. As
used herein, the
term "transformant" refers to a cell, tissue or organism that has undergone
transformation. The
original transformant is designated as "TO" or "TO." Selfing the TO produces a
first transformed
generation designated as "Fl" or "Ti."
[0123i As used herein, the term "cannabinoid profile" refers to the detectable
(i.e., "non-trace")
cannabinoids present in a sample, such as in cannabis inflorescence material,
or a composition.
Thus, references to plants with novel or diverse cannabinoid profiles in this
document refers to
plants with novel combinations or levels of cannabinoids within a single
sample. The level at which
cannabinoids can be detected will vary slightly depending on the techniques
used, and the
cannabinoid being tested. For the purposes of this disclosure, cannabinoid
levels below 1.0% will
be considered "trace" amounts.
10124] As used herein, the term "propyl cannabinoids" refers to cannabinoids
with propyl (i.e.,
C3) carbon tails. Propyl cannabinoids include, but are not limited to, CBGVA,
THCVA, CBDVA,
CBCVA, and their decarboxylated variants. In contrast, the term "pentyl
cannabinoids" refers to
cannabinoids with pentyl (i.e., C5) carbon tails. Pentyl cannabinoids include,
but are not limited
to CBGA, THCA, CBDA, CBCA, and their decarboxylated variants.
19
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
101251 As used herein, the term "propyl cannabinoid content" refers to the
additive content of the
propyl cannabinoids, as measured by dry weight of the inflorescence, or the
composition
comprising the propyl cannabinoid. The term "propyl cannabinoid max content"
refers to the
additive content of the potential decarboxylated propyl cannabinoids (as
converted by formulas
provided in this disclosure). This term is meant to indicate the quantity of
propyl cannabinoid
content that would be present if all the propyl cannabinoids were
decarboxylated. Unless indicated
otherwise, the terms "propyl cannabinoid content" and "propyl cannabinoid max
content" are used
interchangeably.
10126] As used herein, the term "high propyl cannabinoid content" refers to
non-trace (i.e., > or =
1.0%) propyl cannabinoid max contents.
[0127] As used herein, the term "low THC content" refers to THC contents of no
more than 0.3%
THC.
10128] In some embodiments, the present disclosure refers to BT, BD, or BO
alleles. As used
herein, the term "BT allele" or "BT allele" refers to a gene coding for a THCA
synthase enzyme.
As used herein, the term "BD allele" or "BD allele" refers to a gene coding
for a CBDA synthase
enzyme. As used herein, the term "BO allele" or "Bo allele" refers to a gene
coding for a null THCA
or CBDA synthase enzyme. Thus, a BT allele containing cannabis plant would be
expected to
accumulate THCA/THCVA, and a BD allele containing cannabis plant would be
expected to
accumulate CBDA/CBDVA. Plants with no functional BT alleles, such as plants
with BD/BD or
BD/Bo genotypes can, in many instances, accumulate low quantities of THC. This
THC
accumulation can sometimes go beyond 0.3%, causing the plants to no longer be
categorized as
hemp. Plants of the present disclosure cure this problem, in part by shifting
the flux of THC
synthesis to THCV.
101291 BT, BD, and BO alleles are detectable through direct sequencing (Onofri
et al., 2015
"Sequence heterogeneity of Cannabidiolic- and tetrahydrocannabinolic acid-
synthase in Cannabis
sativa L. and its relationship with chemical phenotype" Phytochemistry Vol 116
pgs 57-68).
Persons having skill in the art can also determine the presence of a BT, BD,
or homozygous BO
alleles by studying the cannabinoid profile of the plant. BT alleles result in
the accumulation of
THCA and/or THCVA, while BD alleles result in the accumulation of CBDA and/or
CBDVA.
Homozygous BO alleles result in plants with only small amounts of THCA and
CBDA, with CBDA
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
typically reaching slightly higher levels than THCA. Thus, for the purposes of
this application,
genotype at the B allele can be assessed by analyzing the cannabinoid profile
of cannabis tissue.
101301 As used herein, the term "functional BT allele" or "functional BD
allele" refers to an allele
that results in the cannabis plant accumulating greater than 1.5% THC max
+THCV max or greater
than 1.5% CBD max + CBDV max, respectively. Cannabinoid accumulation below
this level is
typically attributed to residual activity of otherwise "null" alleles.
10131] Unless otherwise noted, references to cannabinoids in a plant, plant
part, extract, or
composition of the present disclosure should be understood as references to
both the acidic and
decarboxylated versions of the compound (e.g., THCmax as determined by the
conversion
guidelines described in this document, and understood by those skilled in the
art). For example,
references to high THC contents of a cannabis plant in this disclosure should
be understood as
referencing to the combined THC and THCA content.
I 0132] The terms THCmax and THC max are interchangeably used in this
document. This is true
for all other cannabinoids discussed in this document.
101331 As used herein, the term "winterizing" or "winterization" refers to the
process by which
plant lipids and waxes are removed from a cannabis extract. Persons have skill
in the art will
immediately recognize how to winterize an extract. Briefly, winterization is
the dissolving the
cannabis extract into a polar solvent (most commonly ethanol) at sub-zero
temperatures. Doing so
separates the waxes and lipids from the oil, forcing them to collect at the
top of the mixture for
easy filtration/collection. Typically, winterization is conducted by mixing
ethanol and hash oil into
a container and placing it into a sub-zero freezer.
[9134j As used herein, the term "maturity," "harvest maturity," or "floral
maturity" refers to the
developmental stage at which a cannabis plant is ready for harvest. Persons
having skill in the art
will recognize maturity based on the plant's morphologies. Cannabis plants are
considered to be
at harvest maturity when fan leaves begin to yellow, and when inflorescences
begin to take on a
'frosted' appearance, as trichomes develop on calyxes and lower portions of
bracts. If bracts and
inflorescent parts turn overly yellow and/or if the 'frosted' appearance is
visible from afar, this
could indicate the plant is beyond maturity. The color of trichomes can also
be used to determine
maturity. Trichomes from cannabis plants first look small and clear, but
gradually enlarge, and
progressively become 'milkier' and opaque with continued maturation, finally
displaying a
21
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
desiccated appearance and amber color. In the present disclosure, harvest
maturity is defined as
the time period between the enlarged clear trichome developmental stage and
the opaque/milky
trichome developmental stage. Amber trichomes in cannabis plants are, in some
embodiments, an
indication of overly mature trichomes. The present disclosure uses the terms
"maturity," "harvest
maturity," and "floral maturity" interchangeably. Unless otherwise noted, all
cannabinoid and
terpene values of cannabis plants discussed in this document refer to the
level of those compounds
present in a cannabis inflorescence at harvest maturity.
101351 As used herein, the term "Terpene Profile" is defined as the absolute
and relative values of
17 of the most expressed terpenes in the Specialty Cannabis hemp and
compositions of the present
disclosure: terpinolene, alpha phellandrene, beta ocimene, carene, limonene,
gamma terpinene,
alpha pinene, alpha terpinene, beta pinene, fenchol, camphene, alpha
terpineol, alpha humulene,
beta caryophyllene, linalool, caryophyllene oxide, and myrcene. A survey of
the terpene profiles
of several cannabis varieties has found that these terpenes express at high
enough levels so as to
have their own pharmacological effects and also to act in synergy with
cannabinoids.
[01361 As used herein, the term "Terpene Essential Oil" or "Terpene Essential
Oil Content" refers
to the additive contents of all the terpenes in the Terpene Profile, as
measured by weight of the dry
inflorescence or cannabinoid composition.
Cannabis
[0137] Cannabis is an annual, dioecious, flowering herb. Its leaves are
typically palmately
compound or digitate, with serrated leaflets. Cannabis normally has imperfect
flowers, with
staminate "male" and pistillate "female" flowers occurring on separate plants.
It is not unusual,
however, for individual plants to separately bear both male and female flowers
(i.e., have
monoecious plants). Although monoecious plants are often referred to as
"hermaphrodites," true
hermaphrodites (which are less common in cannabis) bear staminate and
pistillate structures on
individual flowers, whereas monoecious plants bear male and female flowers at
different locations
on the same plant.
[01381 The life cycle of cannabis varies with each variety but can be
generally summarized into
germination, vegetative growth, and reproductive stages. Because of heavy
breeding and selection
by humans, most cannabis seeds have lost dormancy mechanisms and do not
require any pre-
treatments or winterization to induce germination (See Clarke, RC et al.
"Cannabis: Evolution and
22
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
Ethnobotany" University of California Press 2013). Seeds placed in viable
growth conditions are
expected to germinate in about 3 to 7 days. The first true leaves of a
cannabis plant contain a single
leaflet, with subsequent leaves developing in opposite formation, with
increasing number of
leaflets. Leaflets can be narrow or broad depending on the morphology of the
plant grown.
Cannabis plants are normally allowed to grow vegetatively for the first 4 to 8
weeks. During this
period, the plant responds to increasing light with faster and faster growth.
Under ideal conditions,
cannabis plants can grow up to 2.5 inches a day, and are capable of reaching
heights of 20 feet or
more. Indoor growth pruning techniques tend to limit cannabis size through
careful pruning of
apical or side shoots.
191391 Cannabis has long been used for drug and industrial purposes, including
fiber (hemp), for
seed and seed oils, for medicinal purposes, and as a recreational drug.
Industrial fiber hemp
products are made from cannabis plants selected to produce an abundance of
fiber. In some
embodiments, hemp varieties of Cannabis have been bred to produce minimal
levels of THC, the
principal psychoactive constituent responsible for the psychoactivity
associated with marijuana.
"Marijuana" varieties of Cannabis on the other hand typically refer to plants
that have been bred
to produce high levels of THC and other secondary metabolites, including other
cannabinoids and
terpenes.
101401 Although marijuana cannabis strains used as a drug and industrial hemp
both derive from
the Cannabis family and contain trace amounts or more of the psychoactive
component
tetrahydrocannabinol (THC), they are distinct strains with unique
phytochemical compositions
and uses. Hemp typically has lower concentrations of THC and higher
concentrations of
cannabidiol (CBD), which decreases or eliminates the psychoactive effects of
the plant.
The legality of industrial hemp varies widely between countries. Some
governments regulate the
concentration of THC and permit only hemp that is bred with an especially low
THC content.
[01411 In 2014, President Obama signed the Agricultural Act of 2014 (a.k.a.
the 2014 Farm Bill),
which included Section 7606, allowing for universities and state departments
of agriculture to
begin cultivating industrial hemp for limited purposes. Specifically, the law
allows universities
and state departments of agriculture to grow or cultivate industrial hemp if:
"(1) the industrial
hemp is grown or cultivated for purposes of research conducted under an
agricultural pilot program
or other agricultural or academic research; and (2) the growing or cultivating
of industrial hemp is
23
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
allowed under the laws of the state in which such institution of higher
education or state department
of agriculture is located and such research occurs." For purposes of the Farm
Bill, industrial hemp
is defined as Cannabis sativa L., having a THC concentration < 0.3%.
101421 The law also requires that the grow sites be certified by¨and
registered with¨their state.
A bipartisan group of U.S. senators introduced the Industrial Hemp Farming Act
of 2015 that
would allow American farmers to produce and cultivate industrial hemp. The
bill would remove
hemp from the controlled substances list as long as it contained no more than
0.3 percent THC.
The U.S. Department of Agriculture, in consultation with the U.S. Drug
Enforcement Agency
(DEA) and the U.S. Food and Drug Administration, released a Statement of
Principles on
Industrial Hemp in the Federal Register on Aug 12, 2016, on the applicable
activities related to
hemp in the 2014 Farm Bill.
101431 Industrial hemp can be further subdivided into the category of fiber
hemp, and resinous
hemp.
101441 Fiber Hemp is used to make a variety of commercial and industrial
products including rope,
clothes, food, paper, textiles, plastics, insulation and biofuel. The bast
fibers can be used to make
textiles that are 100% hemp, but they are commonly blended with other organic
fibers such as flax,
cotton or silk, to make woven fabrics for apparel and furnishings. The inner
two fibers of the plant
are more woody and typically have industrial applications, such as mulch,
animal bedding and
litter. When oxidized (often erroneously referred to as "drying"), hemp oil
from the seeds becomes
solid and can be used in the manufacture of oil-based paints, in creams as a
moisturizing agent, for
cooking, and in plastics. Hemp seeds have been used in bird feed mix as well.
Also, more than
95% of hemp seed sold in the European Union was used in animal and bird feed
according to the
2013 research data. Thus, the hemp seed can be used for animal and bird feed.
101451 Resinous hemp refers to cannabis plants that meet the low THC
requirements of hemp
regulatory programs described above, but which are bred for the production of
non-THC
cannabinoids. The cannabinoids produced from resinous hemp have become a
popular source of
medical and dietary supplement products. The most popular dietary supplement
produced from
resinous hemp is CBD oil and related products.
101461 Cannabis is diploid, having a chromosome complement of 2n=20, although
polyploid
individuals have been artificially produced. The first genome sequence of
Cannabis, which is
24
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
estimated to be 820 Mb in size, was published in 2011 by a team of Canadian
scientists (van Bakel
et al, "The draft genome and transcriptome of Cannabis sativa" Genome Biology
12:R102).
101471 All known strains of Cannabis are wind-pollinated and the fruit is an
achene. Most strains
of Cannabis are short day plants, with the possible exception of C. sativa
subsp. sativa var.
spontanea (= C. ruderalis), which is commonly described as "auto-flowering"
and may be day-
neutral.
101481 Although, some cannabis varieties will flower without the need for
external stimuli, most
varieties have an absolute requirement for inductive photoperiods in the form
of short days or long
nights to induce fertile flowering. The first sign of flowering in cannabis is
the appearance of
undifferentiated flower primordial along the main stem of the nodes. At this
stage, the sex of the
plants are still not distinguishable. As the flower primordia continue to
develop, female (pistillate),
and male (staminate) flowers can be distinguished.
10149] For most cannabinoid producing purposes, only female plants are
desired. The presence of
male flowers is considered undesirable, as pollination is known to reduce the
cannabinoid yield,
and potentially ruin a crop. For this reason, most cannabis is grown
"sinsemilla" (seedless),
through vegetative (i.e., asexual) propagation. In this way, only female
plants are produced and no
space is wasted on male plants. Industrial hemp plants are in some instances
propagated via
feminized seed. Resinous hemp is nearly always grown from feminized seeds to
avoid possible
pollination, which greatly reduces the cannabinoid yield of plants. Thus, in
some embodiments,
the plants and inflorescences of the present disclosure are seedless,
sinsemilla. In some
embodiments, the plants and inflorescences of the present disclosure are
unpollinated.
Cannabis Chemistry- Cannabinoids
101501 Cannabis plants produce a unique family of terpeno-phenolic compounds
called
cannabinoids. Cannabinoids, terpenoids, and other compounds are secreted by
glandular trichomes
that occur most abundantly on the floral calyxes and bracts of female plants.
As a drug it usually
comes in the form of dried flower buds (marijuana), resin (hashish), or
various extracts collectively
known as hashish oil. There are at least 483 identifiable chemical
constituents known to exist in
the cannabis plant (Rudolf Brenneisen, 2007, Chemistry and Analysis of
Phytocannabinoids
(cannabinoids produced by cannabis) and other Cannabis Constituents, In
Marijuana and the
Cannabinoids, ElSohly, ed.; incorporated herein by reference) and at least 85
different
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
cannabinoids have been isolated from the plant (El-Alfy, Abir T, et al., 2010,
"Antidepressant-like
effect of delta-9-tetrahydrocannabinol and other cannabinoids isolated from
Cannabis sativa L",
Pharmacology Biochemistry and Behavior 95 (4): 434-42; incorporated herein by
reference). The
two cannabinoids usually produced in greatest abundance are cannabidiol (CBD)
and/or A9-
tetrahydrocannabinol (THC). THC is psychoactive while CBD is not. See,
ElSohly, ed. (Marijuana
and the Cannabinoids, Humana Press Inc., 321 papers, 2007), which is
incorporated herein by
reference in its entirety, for a detailed description and literature review on
the cannabinoids found
in marijuana.
101511 Cannabinoids accumulate at the highest levels in the trichomes of
cannabis inflorescences.
However, cannabinoids have been detected in nearly all cannabis organs (see
John K. Hemphill et
al, "Cannabinoid Content of Individual Plant Organs From Different
Geographical Strains of
Cannabis Sativa L." Journal of Natural Products, Vol 43, No. 1 Jan-Feb, 1980).
Applicant has
similarly detected terpenes in non-inflorescence parts of cannabis plants.
Thus, in some
embodiments, the plant cells of the present disclosure are terpene and
cannabinoid producing cells.
191521 Cannabinoids are the most studied group of secondary metabolites in
cannabis. Most exist
in two forms, as acids and in neutral (decarboxylated) forms. The acid form is
designated by an
"A" at the end of its acronym (i.e. THCA). The phytocannabinoids are
synthesized in the plant as
acid forms, and while some decarboxylation does occur in the plant, it
increases significantly post-
harvest and the kinetics increase at high temperatures. (Sanchez and Verpoorte
2008). The
biologically active forms for human consumption are the neutral forms.
191531 As discussed above, all cannabinoids in their acid forms (those ending
in "¨A") can be
converted to their non-acidic forms through a process called decarboxylation.
Decarboxylation is
usually achieved by (optionally) thorough drying of the plant material
followed by heating it, often
by either combustion, vaporization, or heating or baking in an oven.
Cannabinoid compositions
can similarly be decarboxylated by being exposed to heat.
191541 In order to find the total amount of cannabinoids in a sample (e.g.,
total amount of active
non-acidic cannabinoid), the total measured content of acid cannabinoid
variants forms should be
adjusted to account for the loss of the carboxyl group. In some embodiments,
this adjustment can
be made by multiplying the molar content of the acidic cannabinoid forms by
the molecular weight
26
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
of the corresponding decarboxylated cannabinoid. Other shorthand conversions
are also available
for quickly converting acidic cannabinoid content to active cannabinoid
content.
101551 For example, in some embodiments, THCA can be converted to active THC
using the
formula: THCA x 0.877 = THC. When using this approach, the maximum THC for the
sample is:
THCmax = (THCA x 0.877) + THC. This method has been validated according to the
principles
of the International Conference on Harmonization. Similarly, CBDA can be
converted to active
CBD and the yield is determined using the yield formula: CBDA x 0.877 = CBD.
Also, the
maximum amount of CBD yielded, i.e. max CBD for the sample is: CBDmax= (CBDA x
0.877)
+ CBD. Additionally, CBGA can be converted to active CBG by multiplying CBGA
by 0.878
(CBGmax=(CBGA x 0.878) + CBG). THCVA and CBDVA can be converted to THCV and
CBDV, respectively by multiplying their acidic contents by 0.8668 (THCVmax=
(THCVA x
0.8668) + THCV; CBDVmax= (CBDVA x 0.8668) + CBDV). CBGVA can be converted to
CBGV by multiplying CBGVA by 0.8676 (CBGVmax= (CBGVA x 0.8676) + CBGV).
191561 Unless otherwise noted, references to cannabinoids in a plant, plant
part, extract, or
composition of the present disclosure includes both the acidic and
decarboxylated versions of the
compound (e.g., THCmax as determined by the conversion guidelines described
above, and
understood by those skilled in the art). References to a cannabinoid content
(however it is
measured) in a claim should be understood as representing theoretical maximums
of
decarboxylated "active" cannabinoid contents, plus converted contents of
acidic versions of the
same cannabinoid, unless otherwise indicated.
101571 The cannabinoids in the Specialty Cannabis plants, plant parts,
extracts and compositions
of the present disclosure include, but are not limited to, A9-
Tetrahydrocannabinol (A9-THC),
A8-Tetrahydrocannabinol (A8-THC), Cannabichromene (CBC), Cannabicyclol (CBL),
Cannabidiol (CBD), Cannabielsoin (CBE), Cannabigerol (CBG), Cannabinidiol
(CBND),
Cannabinol (CBN), Cannabitriol (CBT), and their propyl homologs, including,
but are not
limited to cannabidivarin (CBDV), A9-Tetrahydrocannabivarin (THCV),
cannabichromevarin
(CBCV), and cannabigerovarin (CBGV), and their acidic variants. See Holley et
al. (Constituents
of Cannabis sativa L. XI Cannabidiol and cannabichromene in samples of known
geographical
origin, J. Pharm. Sci. 64:892-894, 1975) and De Zeeuw et al. (Cannabinoids
with a propyl side
27
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
chain in Cannabis, Occurrence and chromatographic behavior, Science 175:778-
779), each of
which is herein incorporated by reference in its entirety for all purposes.
101581 Non-THC cannabinoids include one or more of THCV, CBD, CBDV, CBC, CBCV,
CBN,
CBG, and A 8THC (a.k.a. D8THC) cannabinoids, and their acidic variants.
Notably, non-THC
cannabinoids include propyl THCVA and THCV.
[01591 Brief descriptions and chemical structures for several of the major
cannabinoids are
provided below.
I r
etrahydrocannabinol (THC)
191601 Known as delta-9-tetrahydrocannabinol (A9-THC), THC is the principal
psychoactive
constituent (or cannabinoid) of the cannabis plant. The initially synthesized
and accumulated form
in plant is THC acid (THCA).
101611 THC has mild to moderate analgesic effects, and cannabis can be used to
treat pain by
altering transmitter release on dorsal root ganglion of the spinal cord and in
the periaqueductal
gray. Other effects include relaxation, alteration of visual, auditory, and
olfactory senses, fatigue,
and appetite stimulation. THC has marked antiemetic properties, and may also
reduce aggression
in certain subjects (Hoaken (2003). "Drugs of abuse and the elicitation of
human aggressive
behavior". Addictive Behaviors 28: 1533-1554).
[0162I The pharmacological actions of THC result from its partial agonist
activity at the
cannabinoid receptor CB1, located mainly in the central nervous system, and
the CB2 receptor,
mainly expressed in cells of the immune system (Pertwee, 2006, "The
pharmacology of
cannabinoid receptors and their ligands: An overview". International Journal
of Obesity 30: S13¨
S18.) The psychoactive effects of THC are primarily mediated by its activation
of CB1G-protein
coupled receptors, which result in a decrease in the concentration of the
second messenger
molecule cAMP through inhibition of adenylate cyclase (Elphick et al., 2001,
"The neurobiology
and evolution of cannabinoid signaling". Philosophical Transactions of the
Royal Society B:
Biological Sciences 356 (1407): 381-408.) It is also suggested that THC has an
anticholinesterase
28
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
action, which may implicate it as a potential treatment for Alzheimer's and
Myasthenia (Eubanks
et al., 2006, "A Molecular Link Between the Active Component of Marijuana and
Alzheimer's
Disease Pathology". Molecular Pharmaceutics 3 (6): 773-7.)
10163] In the cannabis plant (which also includes hemp), THC occurs mainly as
tetrahydrocannabinolic acid (THCA, 2-COOH-THC). Geranyl pyrophosphate and
olivetolic acid
react, catalyzed by an enzyme to produce cannabigerolic acid, which is
cyclized by the enzyme
THC acid synthase to give THCA. Over time, or when heated, THCA is
decarboxylated producing
THC. The pathway for THCA biosynthesis is similar to that which produces the
bitter acid
humulone in hops. See Fellermeier et al., (1998, "Prenylation of olivetolate
by a hemp transferase
yields cannabigerolic acid, the precursor of tetrahydrocannabinol". FEBS
Letters 427 (2): 283-5);
de Meijer et al. I, II, III, and IV (I: 2003, Genetics, 163:335-346; II: 2005,
Euphytica, 145:189-
198; III: 2009, Euphytica, 165:293-311; and IV: 2009, Euphytica, 168:95-112.)
101641 Non-limiting examples of THC variants include:
:
1 ,
................................ k. 1
:-....4-ts: 0.i :.--- cp r-"N cm
r sN , 1r;
= õ. , i ,,H : ' : .P1 .
s., ...x, ..,....,.., l=-=,...,
< I si ii:i i SI wi>r =ri 1
" i
................................ ,,. ,
ar =tr' =::=''''''......,'",..,"*N.. a; 0. == ^-,:f.' s,..,-,,..... ,
...,.., .,_ ..,,,,
0 '
i NO .".. '
A9¨ A9¨ A9¨ A9-
Tetrahydrocannabino Tetrahydrocannabino Tetrahydrocannabiva
Tetrahydrocannabior
1 1-C4 rin col
A9-THC-05 A9-THC-C4 A9-THCV-C3 A9-THCO-C3
. .1, j\.=
r.,
' r "=kl , oii g . ,j,, i AsH r
ft ,..., ,,,,, . o$i .I..,:, .1...
i
= = ai , s3 , , ,
.e-V:µ-'''`na '''' kl
õ.:1 =:õ 1 '''.1 '.i ' f.=-=k.y-)- --''Noki wl ) 1 =
,,, ......, ...õ,õõ,....\.....0
-i..1. f s: \ -.,...4 ..i ,zi. , õ, --
,:,Ny... µ4Z:,..''.............'µ , s.,... H_.., R I '"'? ===Ø,
s.r...,
----4. 3 .- ==== t V. 1: '\ '''. .......
i,o''. ss..0 - µ...... `...
A9-Tetrahydro- A9
A9-Tetrahydro-
-Tetrahydro-
A9-Tetrahydro- cannabinolic acid-C4 cannabiorcolic
acid
A9-Tetrahydro- cannabivarinic acid
cannabinolic acid A r B and/or
A ao
cannabinolic acid B A A and/or B
A9-THCA-05 A A9-THCA-C4 A A9-THCOA-C3 A
A9-THCA-05 B A9-THCVA-C3 A
and/or B and/or B
29
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
.=
(=== 1 cm =:="'"% "21
*I;
A.41., ..=====
(¨)-A8-trans- (¨)-A8-trans-
(6aR,10aR)- (6aR,10aR)- (¨)-(6aS',10aR)-A9-
A8- Tetrahydrocannabino Tetrahydrocannabino
Tetrahydrocannabino lic 1
1 acid A (¨)-cis-A9-THC-05
A8-THC-05 A8-THCA-05 A
= =
Cannabidiol (CBD)
101651 CBD is a cannabinoid found in cannabis. Cannabidiol has displayed
sedative effects in
animal tests (Pickens, 1981, "Sedative activity of cannabis in relation to its
delta'-trans-
tetrahydrocannabinol and cannabidiol content". Br. J. Pharmacol. 72 (4): 649-
56). Some research,
however, indicates that CBD can increase alertness, and attenuate the memory-
impairing effect of
THC. (Nicholson et al., June 2004, "Effect of Delta-9-tetrahydrocannabinol and
cannabidiol on
nocturnal sleep and early-morning behavior in young adults" J Clin
Psychopharmacol 24 (3): 305-
13; Morgan et al., 2010, "Impact of cannabidiol on the acute memory and
psychotomimetic effects
of smoked cannabis: naturalistic study, The British Journal of Psychiatry,
197:258-290). It may
decrease the rate of THC clearance from the body, perhaps by interfering with
the metabolism of
THC in the liver. Medically, it has been shown to relieve convulsion,
inflammation, anxiety, and
nausea, as well as inhibit cancer cell growth (Mechoulam, et al., 2007,
"Cannabidiol - recent
advances". Chemistry & Biodiversity 4 (8): 1678-1692.) Recent studies have
shown cannabidiol
to be as effective as atypical antipsychotics in treating schizophrenia
(Zuardi et al., 2006,
"Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug" Braz.
J. Med. Biol. Res. 39
(4): 421-429.). Studies have also shown that it may relieve symptoms of
dystonia (Consroe, 1986,
"Open label evaluation of cannabidiol in dystonic movement disorders". The
International journal
of neuroscience 30 (4): 277-282). CBD reduces growth of aggressive human
breast cancer cells
CA 03085010 2020-06-05
WO 2019/113574
PCT/US2018/064704
in vitro and reduces their invasiveness (McAllister et al., 2007, "Cannabidiol
as a novel inhibitor
of Id-1 gene expression in aggressive breast cancer cells". Mol. Cancer Ther.
6 (11): 2921-7.)
101661 Cannabis produces CBD-carboxylic acid through the same metabolic
pathway as THC,
until the last step, where CBDA synthase performs catalysis instead of THCA
synthase. See Marks
et al. (2009, "Identification of candidate genes affecting A9-
tetrahydrocannabinol biosynthesis in
Cannabis sativa". Journal of Experimental Botany 60 (13): 3715-3726.) and
Meijer et al. I, II, III,
and IV. Non-limiting examples of CBD variants include:
(-4
=.) <
ism µ, c.13 \ t. t
4.'s, /Is \V\ or
Ne=-='s
31
Cannabidiol (¨)-Cannabidiol Canna
Cannabidiol-C4 (¨)-Cannabidivarin Cannabidiorcol
CBD-05 momomethyl ether CBD-C4 CBDV-C3 CBD-Ci
CBDM-05
=
, =,,F N.,
Cannabidiolic acid Cannabidivarinic acid
CBDA-05 CBDVA-C3
OH
HO Cannabigerol (CBG)
[01671 CBG is a non-psychoactive cannabinoid found in the Cannabis genus of
plants.
Cannabigerol is found in higher concentrations in hemp rather than in
varieties of Cannabis
cultivated for high THC content and their corresponding psychoactive
properties. Cannabigerol
has been found to act as a high affinity a2-adrenergic receptor agonist,
moderate affinity 5-HT1A
receptor antagonist, and low affinity CB1 receptor antagonist. It also binds
to the CB2 receptor.
Cannabigerol has been shown to relieve intraocular pressure, which may be of
benefit in the
treatment of glaucoma (Craig et al. 1984, "Intraocular pressure, ocular
toxicity and neurotoxicity
after administration of cannabinol or cannabigerol" Experimental eye research
39 (3):251-259).
Cannabigerol has also been shown to reduce depression in animal models (US
Patent Application
31
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
11/760,364). In particular CBG has been shown to have significant potential
applications in the
treatment of glaucoma, depression, Huntington's disease, MRSA, cachexia, and
cancer (Craig et
al. 1984, "Intraocular pressure, ocular toxicity and neurotoxicity after
administration of cannabinol
or cannabigerol" Experimental eye research 39 (3):251-259; U.S. Pat. No.
8,481,085; Valdeolivas
et al. 2015 "Neuroprotective properties of cannabigerol in Huntington's
disease; studies in R6/2
mice and 30nitropropionate-lesioned mice." Neurotherapeutics Jan 12(1):185-99;
Appendino Get
al., 2008 "Antibacterial cannabinoids from Cannabis sativa: a structure-
activity study" J. Nat Prod.
Aug:71(8):1427-30; Borrelli F et al. 2013 "Beneficial effect of the non-
psychotropic plant
cannabinoid cannabigerol on experimental inflammatory bowel disease" Biochem
Pharmacol
May1:85(9):1306-16; Borrelli F. et al. 2014 "Colon carcinogenesis is inhibited
by the TRPM8
antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid"
Carcinogenesis
Dec:35(12):2787-97) Non-limiting examples of CBG variants include:
. ,..::=41
911 9
= . 9H :
. ,
..j. k ..... .....L. ,..:1, k'm
,
......4,,,,..õ..,k,õ i.....t4.-,..---y-A) (... ws,..... ,
====,..ro oii ,---!!%.----,.A.,..
.)
=-,.... ,,,..--, --r- .....:,..--\,,....--
,,,,,,....
C
._:='= :: H 9 H
, N ..:A, ._=-= N,
Cannabigerol
Cannabigerol Cannabigerovarin
monomethyl ether Cannabinerolic acid A
(E)-CBG-05 (E)-CBGV-C3
(E)-CBGM-05 A (Z)-CBGA-05 A
. oH oi-4 9
..
L,,, ....', ,-. .--, 's:i 9.- '`.::- 'sd.' "-' \
:: 0 -õ,.. ...... s..,.. -...
...-.`,..
Cannabigerolic acid A
Cannabigerolic acid A hyl h
Cannabigerovarinic acid A
monomet eter
(E)-CBGA-05 A (E)-CBGVA-C3 A
(E)-CBGAM-05 A
H
0
Cannabinol (CBN)
101681 CBN is a mildly to non-psychoactive substance cannabinoid found in
Cannabis sativa and
Cannabis indica/afghanica. It is also a metabolite of tetrahydrocannabinol
(THC). CBN acts as a
32
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
weak agonist of the CB1 and CB2 receptors, with lower affinity in comparison
to THC. Non-
limiting examples of CBN variants include
1 , :
:
0ii A.....
6- = ,, Qii ..--"k ot,i f:'k-: .?=3
er-k) 01
t: ,= : 1 ,
, ..0,.. -A, ,,, ,-,-, ..A. ....,::::::,, ...-=;:,..., -.....:::---
.....- ,:,
1Ø--3k,.,:::t1\ ,,,, pv.- ...5.-..f-",..-=". t,Q----
...,::=== ..,...--.. "-v.- ....:#. \
Cannabinol Cannabinol-C4
Cannabivarin Cannabinol-C2 Cannabiorcol
CBN-05 CBN-C4 CBN-C3 CBN-C2 CBN-C2
t
A ,=-S'.i.Y...
1
---:::\ ...= ,...). T ....,,, ...,....,,
I , - : . OH
:(µKi('''''',#.. %-s=-=."µ,..-'-`,
Cannabinol methyl
Cannabinolic acid A
ether
CBNA-05 A
CBNM-05
----
/ 0
HO Cannabichromene (CBC)
191691 CBC bears structural similarity to the other natural cannabinoids,
including
tetrahydrocannabinol, tetrahydrocannabivarin, cannabidiol, and cannabinol,
among others.
Evidence has suggested that it may play a role in the anti-inflammatory and
anti-viral effects of
cannabis, and may contribute to the overall analgesic effects of cannabis. Non-
limiting examples
of CBC variants include:
,....,,,,A,......-.47,
-' -' (l --::õ...,..... - ¨
....õ..õ..,...,..., ..õ.,
..)
....--sk, r
-...õ...0^...,,, ===:),..---. f' Z:
i.,
'`,..::;=== `, il
""' 0 sr s's s 0 Y Y ' Y "C's.....= s.,
,,,,
,...,õO AN 1::C.'''
H
;40.. ,..:, -....- -.....- -... (..e.N),I.i
( )-
( )-Cannabichromene ( )-Cannabichromenic acid
Cannabivarichromene, ( )-
CBC-05 A ( )-
Cannabichromevarin Cannabichromevarinic
acid A
CBCA-05 A CBCV-C3
CBCVA-C3 A
33
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
OH
0
Cannabivarin (CBV)
[0170] Cannabivarin, also known as cannabivarol or CBV, is a non-psychoactive
cannabinoid
found in minor amounts in the hemp plant Cannabis sativa. It is an analog of
cannabinol (CBN)
with the side chain shortened by two methylene bridges (-CH2-). CBV is an
oxidation product of
tetrahydrocannabivarin (THCV, THY).
õõH H
HO Cannabidivarin (CBDV)
101711 CBDV is a non-psychoactive cannabinoid found in Cannabis. It is a
homolog of
cannabidiol (CBD), with the side-chain shortened by two methylene bridges (CH2
units).
Cannabidivarin has been found reduce the number and severity of seizures in
animal models (US
Pat Application 13/075,873). Plants with relatively high levels of CBDV have
been reported in
feral populations of C. indica (= C. sativa ssp. indica var. kafiristanica)
from northwest India, and
in hashish from Nepal.
OH
0 Tetrahydrocannabivarin (THCV, THY)
19172] THCV, or THY is a homologue of tetrahydrocannabinol (THC) having a
propyl (3-carbon)
side chain. This terpeno-phenolic compound is found naturally in Cannabis,
sometimes in
significant amounts. Plants with elevated levels of propyl cannabinoids
(including THCV) have
been found in populations of Cannabis sativa L. ssp. indica (= Cannabis indica
Lam.) from China,
India, Nepal, Thailand, Afghanistan, and Pakistan, as well as southern and
western Africa. THCV
has been shown to be a CB1 receptor antagonist, i.e. it blocks the effects of
THC.
Tetrahydrocannabinol has been shown to increase metabolism, help weight loss
and lower
cholesterol in animal models (US Pat Application 11/667,860)
34
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
HC J3 cm
H-.0 Cannabicyclol (CBL)
10173] Cannabicyclol (CBL) is a non-psychotomimetic cannabinoid found in the
Cannabis
species. CBL is a degradative product like cannabinol. Light converts
cannabichromene to CBL.
Non-limiting examples of CBL variants include:
(0
1
....õ0:,.....
.-- k
A,,..,--'-µ....---......-",..
44.
( )- ( )- ( )-
(1aS',3aR,8bR,8cR)- (1aS',3aR,8bR,8cR)- (1aS',3aR,8bR,8cR)-
Cannabicyclol Cannabicyclolic acid Cannabicyclovarin
CBL-05 A CBLV-C3
CBLA-05 A
OH
,,OH
(R)(R) OH
/ 40
0
Cannabitriol (CBT)
101741 Non-limiting examples of CBT variants include:
. ---
Nat ,,..,. f....,:csT ' cAi ..,%, ... = Qii
; ,RA elikt, ... =
al
:dr,..... Hp44
t. ,t= i,
iLi i ;1: ii i --1µ,0-4-.:0=""=-------= ..............
f=xl,x=,o'''',,,--=¨==¨=, -71:-.0A ,:ok,------,
)- (¨)-(9R,10R)-trans-
(¨)-(9RJOR)-trans- (+)-(9S,10S)- 1
1 )-
(9R,10S/9S,1 10-0-Ethyl-
0R)- (9RJOR/9S,10S)-
Cannabitriol Cannabitriol cannabitriol
Cannabitriol
(¨)-trans-CBT-05 (+)-trans-CBT-05
Cannabitriol-C3
( )-cis-CBT-05 (¨)-trans-CBT-OEt-
( )-trans-CBT-C3
C5
CA 03085010 2020-06-05
WO 2019/113574
PCT/US2018/064704
0, ....-- :11,===,. 3
yAie-s!..- 1 1 .sti Y' =
=
A =
õ,...
=-'`.......4)
310,,T.,,, 1 cii te....,,,::...õ........! =
= .01 : e f. t..:*
:: : i ;: ...= ..c..y .... :, , ..... , .., = ,
......),.... .A. s. .....,s....,
H"-== -t-- 2., ....i : AA. ...:
...::::-..,,,....õ, ',,,.-=;;,-1-'..,..:(..,;.).õ,,t i4..ef ; :..;
i -;=":: =-="::::
-7,0,-,.0:-...,--..,..,.. ; =-es-..;.,,-
,,k.... (-)- fes,t), ..Ø ...,-,...,.....-.,
(6aR,9S,10S,10aR)
8,9-Dihydroxy- - (-)-6a,7,10a-
1 0 -0X0 -A6a(Ma)-
A6a(10a)_ Cannabidiolic acid A 9,10-Dihydroxy-
Trihydroxy-
A9-
tetrahydrocannabin
cannabitriol ester
tetrahydrocannabinol hexahydrocannabi ol
8,9-Di-OH-CBT-05 CBDA-Cs 9-014- no!,
tetrahydrocannabinol
OTHC
CBT-Cs ester Cannabiripsol (-)-Cannabitetrol
Cannabiripsol-Cs
OH
(Y. :
IR Cannabielsoin-type (CBE)
[WI 75i Non-limiting examples of CBE variants include:
Q11
Q34
..-----e
...e .......:.,
i 14:=,\ õ, i = \ e riAõ
; :i, = ...õ, / N::\.>õ....
õ.,..IN;( \}::=:::?'6 r: AsIN't
>iii'. \,...:::'''. = -..`lk. ri i i:
X....N ,01.µ' .....-.A. I :1
==-kk',:kµ...,''',,
....... ''i : il =====...,.. : '-:
0 Z
'k's ek z.., ....,,,, ,....". s ......, \ .Ck's tx'''s
,s:::,,.....,...".., ..4,.. -v-... ....-- ,,,= , 0,-- ..i.- ., -
.. ..- . H L=
0- :. , , ===== ==-.' - =--- H , '43'
P4 i-1 H CY
'(34
(5aS',6S,9R,9aR)- (5aS',6S,9R,9aR)- (5aS',6S,9R,9aR)-
(5aS',6S,9R,9aR)- (5aS',6S,9R,9aR)-
Cannabielsoin C3-Cannabielsoin Cannabielsoic acid A C3-
Cannabielsoic
Cannabielsoic acid B
CBE-Cs CBE-C3 CBEA-Cs A CBEA-Cs B acid B
CBEA-C3 B
i
.......-c
,.' )--t3 e ....Ø : =... ,c,
.\e"" --L. 'S. ==:.:;.' = _ r '.,
=¨i ' fv. i '..-. Nt,;:::',...,
iid \ 1.)''''k,-"*"µ=====''''s ''..... .L A '' , -.....\
...Ly.......5, ..,
µ.."." '" \'
''' ' ''
i.4
Cannabiglendol-C3 Dehydrocannabifuran Cannabifuran
OH-iso-HHCV-C 3 DCBF-Cs CBF-Cs
(0176j More details of cannabinoids synthesis and the properties and uses of
these cannabinoids
are described in Russo (2011, Taming THC: potential cannabis synergy and
phytocannabinoid-
terpenoid entourage effects, British Journal of Pharmacology, 163:1344-1364),
Russo et al. (2006,
36
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
A tale of two cannabinoids: the therapeutic rationale for combining
tetrahydrocannabinol and
cannabidiol, Medical Hypothesis, 2006, 66:234-246), Celia et al. (Impact of
cannabidiol on the
acute memory and psychotomimetic effects of smoked cannabis: naturalistic
study, The British
Journal of Psychiatry, 201, 197:285-290), de Mello Schier et al.,
(Cannabidiol, a cannabis sativa
constituent, as an anxiolytic drug, Rev. Bras. Psiquiatr, 2012, 34(S1):5104-
5117), and Zhornitsky
et al. (Cannabidiol in Humans ¨ the Quest for Therapeutic Targets,
Pharmaceuticals, 2012, 5:529-
552), each of which is herein incorporated by reference in its entirety for
all purposes. Please see
Table 1 for a non-limiting list of medical uses for cannabinoids.
Table 1- Non-limiting list of medical uses for cannabinoids.
MEDICAL CANNABINOM REFERENCES
USES
Dystonia, (a) Consroe, 1986, The International
journal of
Akathisia neuroscience 30 (4): 277-282
1 (Anti CBD (b) Snider et al., 1985, Neurology, (Suppl
1): 201.
convulsant)
Glaucoma (a) Colasanti et al, Exp. Eye Res. 30:251-
259, 1984
2 (lowers CBD (b) Gen. Pharmac. 15:479-484, 1984
intraocular CBG (c) Craig et al. 1984, Experimental eye
research 39
pressure) (3):251-259
Ischemic
disease
(a) U.S. PAT 6,630,507
(Alzheimer ' s,
(b) Snider et al., 1985, "Beneficial and Adverse
Parkinson's,
3 CBD Effects of Cannabidiol in a Parkinson
Patient with
Down
Sinemet-Induced Dystonic Dyskinesia".
Syndrome,
Neurology, (Suppl 1): 201.
HIV,
Dementia)
37
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
MEDICAL CANNABINOM REFERENCES
USES
Good for
patients treated
with oxidant-
4 inducing CBD (a) U.S. PAT 6,630,507
agents for
chemotherapy,
radiation.
(a) US PAT 8,034,843 GW Pharma experiments on
Motion
Shrews
Sickness CBD
(b) Mechoulam, et al., 2007, Chemistry & Biodiversity
(Anti- emetic)
4 (8): 1678-1692.
Pain- Brachial
THC
6 plexus (a) US 20060135599 GW Pharma
THC:CBD
avulsion
Pain and (a) U520080139667
7 inflammation- CBD: THC (b) Mechoulam, et al., 2007, Chemistry &
Biodiversity
Arthritis 4 (8): 1678-1692.
(a) U520080262099
(b) Mechoulam, et al., 2007, Chemistry & Biodiversity
Anti Cancer- CBD: THC
8 4 (8): 1678-1692.
cell movement CBD
(c) McAllister et al., 2007, Mol. Cancer Ther. 6 (11):
2921-7.
38
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
MEDICAL CANNABINOM REFERENCES
USES
(a) US20120004251
(b) US20120165402
(c) Mechoulam, et al., 2007, Chemistry &
Anti Biodiversity 4 (8): 1678-1692.
Convulsant CBDV (d) Carlini etal., J. Clin. Pharmacol.
21:417S-427S,
9
(against CBD 1981
seizures) (e) Karler et al., J. Clin.Pharmacol.
21:437S-448S,
1981
(f) Consroe et al., J. Clin Pharmacol. 21:428S-436S,
1981
Neurological
Pain (MS THC: CBD (a) US20100035978
related)
(a) US20090306221
11 Weight loss THCV
(b) US20080119544
Anti- (a) US20080031977
12 CBG
Depressant (b) US 60/813,814
Irritable Bowel (a) EP 1361864
Syndrome (b) EP 1542657
13 THC:CBD
(Crohn's) (c) U520100286098
Type II (a) U520110082195
14 THCV:CBD
diabetes
Anti-Psychotic (a) US20110038958
THCV:CBD
39
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
MEDICAL CANNABINOM REFERENCES
USES
(b) Zuardi et al., 2006, Braz. J. Med. Biol. Res. 39 (4):
421-429.
16
Cancer Pain THC:CBD (a) US20110230549
Anxiety (a) Mechoulam, et al., 2007, Chemistry &
Biodiversity
Reduction 4 (8): 1678-1692.
17 CBD
(b) Bergamaschi et al., 2003,
Neuropsychopharmacology 36 (6): 1219-1226
Cannabinoid Biosynthetic Pathways
10177] The biosynthetic pathway of cannabinoids has been studied in great
detail. See de Meijer
et al. I, II, III, and IV (I: 2003, Genetics, 163:335-346; II: 2005,
Euphytica, 145:189-198; III: 2009,
Euphytica, 165:293-311; and IV: 2009, Euphytica, 168:95-112), each of which is
herein
incorporated by reference in its entirety for all purposes. According to the
current model, phenolic
precursors such as geranyl pyrophosphate (GPP) and polyketide, olivetolic acid
(OA) are
condensed by geranyl pyrophosphate olivetolate geranyl transferase (GOT) to
form cannabigerolic
acid (CBGA). Alternatively, GPP and divarinic acid can be condensed by GOT to
form
cannabigerovarinic acid (CBGVA). CBGA or CBGVA are considered to be the
"primary
cannabinoids" from which others can be produced.
191781 CBGA/CBGVA is quickly transformed in plants into, for example: (1)
CBCA/CBCVA by
CBCA synthase; (2) THCA/THCVA by THCA synthase; or (3) CBDA/CBDVA by CBDA
synthase. See Figure 1A and B for a visual representation of the current model
of cannabinoid
biosynthesis. The genes coding for THCA synthase and CBDA synthase are found
on the same B
locus. Thus cannabis plants can be categorized into THC-CBD chemotypes based
on the state of
the B locus BT/BT (THC producing, chemotype I), BD/BD (CBD producing,
chemotype III), and
BT/BD (producing both THC and CBD, chemotype II). Additional information on
the genetic
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
regulation of cannabinoids can be found in de Meijer et al. I, II, III, and IV
(I: 2003, Genetics,
163:335-346; II: 2005, Euphytica, 145:189-198; III: 2009, Euphytica, 165:293-
311; and IV: 2009,
Euphytica, 168:95-112). The BT and BD alleles are known, and can be easily
detected using
methods known to those skilled in the art, including Northerns, PCR,
sequencing, or Westerns. A
representative sequence of THCA synthase is available at GenBank ID
AB057805.1. A
representative sequence of the CBDA synthase is available at GenBank ID
AB292682.1.
Cannabis Chemistry- Terpenes and Terpenoids, and other Volatiles
101791 In some embodiments, the specialty plants and compositions of the
present disclosure
comprise novel Terpene Profiles. Terpenes are a large and diverse class of
organic compounds,
produced by a variety of plants. They are often strong smelling and thus may
have had a protective
function. Terpenes are derived biosynthetically from units of isoprene, which
has the molecular
formula C5E18. The basic molecular formulae of terpenes are multiples of (C51-
18)n where n is the
number of linked isoprene units. The isoprene units may be linked together
"head to tail" to form
linear chains or they may be arranged to form rings. Non-limiting examples of
terpenes include
Hemiterpenes, Monoterpenes, Sesquiterpenes, Diterpenes, Sesterterpenes,
Triterpenes,
Sesquarterpenes, Tetraterpenes, Polyterpenes, and Norisoprenoids.
[0180] In addition to cannabinoids, cannabis also produces over 120 different
terpenes (Russo
2011, Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid
entourage
effects, British Journal of Pharmacology, 163:1344-1364). Within the context
and verbiage of this
document the terms `terpenoid' and `terpene' are used interchangeably.
[0181] Cannabinoids are odorless, so terpenoids are responsible for the unique
odor of cannabis,
and each variety has a slightly different profile that can potentially be used
as a tool for
identification of different varieties or geographical origins of samples
(Hillig 2004. "A
chemotaxonomic analysis of terpenoid variation in Cannabis" Biochem System and
Ecology 875-
891). Indeed, recent studies have concluded that terpene production in
cannabis plants is strongly
inherited, and is little influenced by environmental factors. (Casano et al
2011. "Variations in
terpene profiles of different strains of Cannabis sativa" Acta Horticulturae
925:115-121).
Accordingly, the development of novel Terpene Profiles requires the
development of new genetics
though traditional breeding or other techniques for genetic manipulation.
41
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
10182] Terpenes also provide a unique and complex organoleptic profile for
each variety that is
appreciated by both novice users and connoisseurs. Critical differences
between many popular
commercial cannabis strains can be largely attributed to differences in
terpene profiles, which
provide each line with their distinctive aroma and pharmacological effects.
The popular "cookies"
strain of cannabis, is noted by its myrcene and limonene. In addition to many
circulatory and
muscular effects, some terpenes interact with neurological receptors. A few
terpenes produced by
cannabis plants also bind weakly to cannabinoid receptors. Some terpenes can
alter the
permeability of cell membranes and allow in either more or less THC, while
other terpenes can
affect serotonin and dopamine chemistry as neurotransmitters. Terpenoids are
lipophilic, and can
interact with lipid membranes, ion channels, a variety of different receptors
(including both G-
protein coupled odorant and neurotransmitter receptors), and enzymes. Some are
capable of
absorption through human skin and passing the blood brain barrier.
[0183] Generally speaking, terpenes are considered to be pharmacologically
relevant when present
in concentrations of at least 0.05% in plant material (Hazekamp and Fischedick
2010. "Metabolic
fingerprinting of Cannabis sativa L., cannabinoids and terpenoids for
chemotaxonomic and drug
standardization purposes" Phytochemistry 2058-73; Russo 2011, Taming THC:
potential cannabis
synergy and phytocannabinoid-terpenoid entourage effects, British Journal of
Pharmacology,
163:1344-1364). Thus, although there are an estimated 120 different terpenes,
only a few are
produced at high enough levels to be detectable, and fewer still which are
able to reach
organoleptic or pharmacologically relevant levels.
[01841 Terpenoids can be extracted from the plant material by steam
distillation (giving you
essential oil) or vaporization, however the yield varies greatly by plant
tissue, type of extraction,
age of material, and other variables (McPartland and Russo 2001 "Cannabis and
Cannabis
Extracts: Greater Than the Sum of Their Parts?" Hayworth Press). In some
embodiments, the
present disclosure teaches methods for extracting cannabinoids and terpenes.
Other methods for
producing reproducible and quantifiable cannabinoid and terpene measurements
are known to
persons having skill in the art. Typically, the yield of terpenoids in
cannabis inflorescences is less
than 2% by weight on analysis; however, it is thought that they may comprise
up to 10% of the
trichome content. A few of the most recognized terpenes and non-terpene
volatiles in cannabis
are discussed below.
42
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
1//0
/\:/ ' 111 Limonene
19185] D-Limonene, also known as limonene, is a monoterpenoid that is widely
distributed in
nature and often associated with citrus. It has strong anxiolytic properties
in both mice and humans,
apparently increasing serotonin and dopamine in mouse brain. D-limonene has
potent anti-
depressant activity when inhaled. It is also under investigation for a variety
of different cancer
treatments, with some focus on its hepatic metabolite, perillic acid. There is
evidence for activity
in the treatment of dermatophytes and gastro-oesophageal reflux, as well as
having general radical
scavenging properties (Russo 2011, Taming THC: potential cannabis synergy and
phytocannabinoid-terpenoid entourage effects, British Journal of Pharmacology,
163:1344-1364).
Myrcene
[0186] 13-Myrcene, also known as myrcene, is a monoterpenoid also found in
cannabis, and has a
variety of pharmacological effects. It is often associated with a sweet fruit
like taste. It reduces
inflammation, aids sleep, and blocks hepatic carcinogenesis, as well as acting
as an analgesic and
muscle relaxant in mice. When fl-myrcene is combined with A9-THC it could
intensify the sedative
effects of A9-THC, causing the well-known "couch-lock" effect that some
cannabis users
experience (Russo 2011, Taming THC: potential cannabis synergy and
phytocannabinoid-
terpenoid entourage effects, British Journal of Pharmacology, 163:1344-1364).
HO
--,,, ,---'
Linalool
101871 D-Linalool, also known as linalool, is a monoterpenoid with very well-
known anxiolytic
effects. It is often associated with lavender, and frequented used in
aromatherapy for its sedative
impact. It acts as a local anesthetic and helps to prevent scarring from
burns, is anti-nociceptive in
mice, and shows anti-glutamatergic and anticonvulsant activity. Its effects on
glutamate and
GABA neurotransmitter systems are credited with giving it its sedative,
anxiolytic, and
43
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
anticonvulsant activities (Russo 2011, Taming THC: potential cannabis synergy
and
phytocannabinoid-terpenoid entourage effects, British Journal of Pharmacology,
163 : 1344-1364).
z
+). a-pinene
[0188] oc-Pinene is a monoterpene common in nature, also with a plethora of
effects on mammals
and humans. It acts as an acetylcholinesterase inhibitor, which aids memory
and counteracts the
short-term memory loss associated with A9-THC intoxication, is an effective
antibiotic agent, and
shows some activity against MRSA. In addition, a-pinene is a bronchodilator in
humans and has
anti-inflammatory properties via the prostaglandin E-1 pathway (Russo 2011,
Taming THC:
potential cannabis synergy and phytocannabinoid-terpenoid entourage effects,
British Journal of
Pharmacology, 163 : 1344-1364).
H3C H __________
CH3
H2C
13-Caryophyllene
[0189] 13-Caryophyllene is often the most predominant sesquiterpenoid in
cannabis. It is less
volatile than the monoterpenoids, thus it is found in higher concentrations in
material that has been
processed by heat to aid in decarboxylation. It is very interesting in that it
is a selective full agonist
at the CB2 receptor, which makes it the only phytocannabinoid found outside
the cannabis genus.
In addition, it has anti-inflammatory and gastric cytoprotective properties,
and may even have anti-
malarial activity.
44
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
H3C H ________
txCH3
H3C 1
0
õ.1
Caryophyllene oxide
[0190] Caryophyllene oxide is another sesquiterpenoid found in cannabis, which
has antifungal
and anti-platelet aggregation properties. As an aside, it is also the molecule
that drug-sniffing dogs
are trained to find (Russo 2011, Taming THC: potential cannabis synergy and
phytocannabinoid-
terpenoid entourage effects, British Journal of Pharmacology, 163:1344-1364).
HO
Nerolidol
19191 Nerolidol is a sesquiterpene that is often found in citrus peels that
exhibits a range of
interesting properties. It acts as a sedative, inhibits fungal growth, and has
potent anti-malarial and
antileishmanial activity. It also alleviated colon adenomas in rats (Russo
2011, Taming THC:
potential cannabis synergy and phytocannabinoid-terpenoid entourage effects,
British Journal of
Pharmacology, 163:1344-1364). Phytol is a diterpene often found in cannabis
extracts. It is a
degradation product of chlorophyll and tocopherol. It increases GABA
expression and therefore
could be responsible the relaxing effects of green tea and wild lettuce. It
also prevents vitamin-A
induced teratogenesis by blocking the conversion of retinol to its dangerous
metabolite, all-trans-
retinoic acid (Russo 2011, Taming THC: potential cannabis synergy and
phytocannabinoid-
terpenoid entourage effects, British Journal of Pharmacology, 163:1344-1364).
101921 Some of the most commonly found terpenoids in cannabis are summarized
in Table 2, with
their individual organoleptic properties as well as their basic pharmacology.
Table 2- A non-limiting list of the medical effects of some of the most common
terpenes found in
cannabis
CA 03085010 2020-06-05
WO 2019/113574
PCT/US2018/064704
Odor
Terpenoid Description Flavor Description Suggested Pharmacology
a -pinene Herbal, piney Woody, piney, Anti-inflammatory,
bronchodilator,
camphoraceous stimulant
camphene Woody, piney Camphoraceous,cooling, Reduces plasma cholesterol and
minty triglycerides, Antioxidant and
free
radical scavenger
b -pinene Herbal, Fresh, piney, woody Strong antimicrobial
cooling, piney
myrcene Spicy, Woody, vegetative, citrus Anti-inflammatory, sedative,
herbaceous antibiotic, analgesic
a - Terpenic, citrus Terpenic, citrus, lime Antinociceptive
phellandrene
carene Citrus, sweet None given CNS depressant, anti---
inflammatory
a -terpinene Woody, citrus, Terpenic, woody, piney Antioxidant
medicinal
46
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
Odor
Terpenoid Description Flavor Description Suggested Pharmacology
limonene Citrus, fresh Sweet, orange, citrus
Anxiolytic, antidepressant,
immunostimulant
b -ocimene Floral, green Green, tropical, woody Possible anti---
bacterial
g-terpinene Terpenic, Terpenic, citrus, lime-like Antioxidant
woody
terpinolene Herbal, woody Sweet, fresh, piney, citrus Comforting, calming,
anti-oxidant,
antifungal
linalool Floral, citrus Citrus, orange, lemon,
Sedative, anxiolytic,
floral immunostimulant
fenchol Camphor, Fresh, piney Possible stimulant
piney
a -terpineol Floral, piney None given Sedative, AChE inhibitor,
antioxidant
47
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
Odor
Terpenoid Description Flavor Description Suggested Pharmacology
b - Spicy, woody Spicy, clove, rosemary Selective agonist of CB2
receptor,
caryophyllene anti-inflammatory, antimalarial
a -humulene Woody None given Anti-inflammatory
caryophyllene Woody, sweet None given Antifungal, stimulant
oxide
Analysis of Cannabinoids and Terpenes
101931 As reported herein, the absolute cannabinoid and terpene contents of a
plant are calculated
based on weight of cannabinoid or terpene present in a sample divided by the
dried weight of the
dried trimmed inflorescence. Dried inflorescences refer to harvested
inflorescence tissue dried to
¨ 10% moisture level. Where specifically indicated, terpene and cannabinoid
contents are further
adjusted to account for any remaining moisture content, by removing the weight
of any remaining
moisture from the measured weight of the inflorescence. Moisture content of a
flower can be
determined by a variety of analytical methods. Persons having skill in the art
will be familiar with
methods for measuring moisture content. In some embodiments, the present
disclosure teaches the
use of FTIR analysis for calculating moisture content of inflorescences. In
other embodiments, the
present disclosure teaches the use of additional drying steps in desiccant
chambers to calculate
remaining moisture contents.
0194] The term trimmed inflorescence as used herein refers to inflorescences
with sun (sugar)
leaves cut off such that only the calyx and reproductive buds remain. Trimming
can be performed
manually, through careful manicuring of harvested tissue, or via automated
mechanical methods.
101951 In some embodiments, the present disclosure also teaches methods of pre-
screening grown
seeds for specific cannabinoid contents. For example, the types of
cannabinoids produced by a
48
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
cannabis inflorescence can also be determined in the field via thin layer
chromatography (TLC)
analysis (see "Cannabis Inflorescence & Leaf QC" from The American Herbal
Pharmacopeia
2013).
101961 The present disclosure will often refer to Specialty Cannabis
comprising a selected
cannabinoid or terpene content. In some instances, the present disclosure will
refer to Specialty
Cannabis that produces inflorescences comprising a selected cannabinoid or
terpene content. It
will be understood that both of these statements are interchangeable, and that
references to the
cannabinoid or terpene contents of a Specialty Cannabis refer to the contents
of the inflorescences
those plants produce.
Specialty Cannabis (hemp)
101971 In some embodiments, the present disclosure provides Specialty Cannabis
with novel
cannabinoid profiles. In some embodiments, the Specialty Cannabis of the
present disclosure
qualifies as industrial hemp. The presently disclosed inventions are based in
part on the instant
inventors' discovery that resinous hemp plants could be bred to produce high
(non-trace) quantities
of propyl cannabinoids, while also accumulating no more than 0.3% THC. The
novelty of the
presently disclosed invention is discussed in more detail below.
10198] Traditional resinous hemp plants are BD/BD lines that produce CBD,
while accumulating
only trace quantities of THC. These traditional hemp plants, while a good
source of CBD, fail to
accumulate any appreciable quantities of non-CBD cannabinoids, including no
propyl
cannabinoids. For example, to the applicant's best knowledge, there are
currently no resinous
hemp plants that produce non-trace quantities of propyl cannabinoids, while
also accumulating no
more than 0.3% THC, as required under U.S. law. As a result, traditional
resinous hemp plants
provide only CBD-based medicine that fails to exploit the medicinal benefits
of any other
cannabinoids, including propyl cannabinoids.
191991 Another risk associated with the cultivation of traditional resinous
hemp, is that traditional
hemp crops can sometimes accumulate higher than 0.3% THC, if allowed to go
beyond harvest
maturity. Even hemp plants that exhibit Bo/BD genotypes, with no functional
THCA synthase, still
accumulate small amounts of THC. This accumulation may be due to improper
conversion by
CBDA synthase enzymes, or though residual activity in Bo "null" THCA synthase
alleles.
49
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
102001 As a consequence, most¨if not all¨traditional resinous hemp lines have
the potential to
exceed the 0.3% legal THC content limits if not harvested at precisely the
right time. Even a single
day delay in the harvest of a traditional resinous hemp crop can result in the
plant no longer
qualifying as hemp, potentially requiring the destruction of the entire crop,
and also resulting in
possible legal consequences for the growing farmer.
[02011 GW Pharmaceuticals has developed and patented a cannabis variety that
does not produce
any THC (US 9,035,130), and could thus address the harvest maturity concerns
of traditional
hemp. This plant however, has been bred to comprise a "cannabinoid knockout
factor" that blocks
cannabinoid biosynthesis entirely. Thus, the plant patented by GW
pharmaceuticals would only be
helpful for fiber production, and would not serve the same purpose as the
Specialty Cannabis hemp
lines of the present disclosure, which also accumulate high levels of
cannabinoids, including CBD,
CBG, and propyl cannabinoids.
[0202] The Specialty Cannabis plants of the present disclosure address the
limitations of
traditional resinous hemp lines. Without wishing to be bound by any theory,
the present inventors
believe that the presently disclosed Specialty Cannabis plant comprise one or
more alleles
redirecting cannabinoid flux to propyl (C3) cannabinoids. This genetic feature
prevents the
accumulation of THC, thus ensuring that the Specialty Cannabis plants of the
present disclosure
qualify as hemp under U.S. and foreign law. This is particularly important for
large crops, where
harvest can several days, or weeks to complete. The Specialty Cannabis hemp
lines of the present
disclosure solve this problem, reducing production costs, and ensuring that
the grower will remain
within the law. The presently disclosed Specialty Cannabis lines are also
beneficial to consumers,
who now gain access to additional non-THC cannabinoids in their hemp products.
[0203] In some embodiments, the Specialty Cannabis plants of the present
disclosure represent a
new category of cannabis plants in which high (non-trace) levels of propyl
cannabinoids
accumulate with no more than 0.3% THC. In some embodiments, the Specialty
Cannabis plants
of the present disclosure accumulate no detectable THC content (e.g., less
than 0.01% by weight,
as measured by HPLC). Thus, in some embodiments, the Specialty Cannabis plants
of the present
disclosure solve the problems of previously existing hemp lines.
[02041 In some embodiments, the Specialty Cannabis of the present disclosure
produce
inflorescences comprising about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%,
12%, 13%,
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%,
29%, 30%,
31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%,
46%, 47%,
48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60% total
cannabinoids
by weight of the dried inflorescence, and all ranges therebetween. Thus, in
some embodiments,
the Specialty Cannabis of the present disclosure comprise 1-5%, 1-10%, 1-40%,
1-30%, or 1-25%
cannabinoid content by weight.
[0205] In some embodiments, the Specialty Cannabis of the present disclosure
produce
inflorescences comprising more than about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%,
10%, 11%,
12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%,
27%, 28%,
29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%,
44%, 45%,
46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%
total
cannabinoids by weight of the dried inflorescence while accumulating no more
than 0.3% or 0.2%
THC content by weight.
192061 In some embodiments, the Specialty Cannabis of the present disclosure
produce
inflorescences comprising about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%,
12%, 13%,
14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%,
29%, 30%,
31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, or 40% propyl cannabinoids by
weight, and
all ranges therebetween. Thus, in some embodiments, the Specialty Cannabis of
the present
disclosure comprise 2%-10%, 3%-30%, or 3%-25% propyl cannabinoids content by
weight of the
dried inflorescence.
102071 In some embodiments, the Specialty Cannabis of the present disclosure
produce
inflorescences comprising more than about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%,
10%, 11%,
12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%,
27%, 28%,
29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, or 40% propyl
cannabinoids by
weight of the dried inflorescence while accumulating no more than 0.3% or 0.2%
THC content by
weight.
[0208] In some embodiments, the Specialty Cannabis of the present disclosure
qualify as industrial
hemp under relevant U.S. and European regulations. That is, in some
embodiments, the Specialty
Cannabis of the present disclosure accumulate no more than 0.3%, or less than
0.2% THC content.
51
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
[02091 In some embodiments, the Specialty Cannabis of the present disclosure
produce
inflorescences comprising about 0.00%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%,
0.06%, 0.07%,
0.08%, 0.09%, 0.10%, 0.11%, 0.12%, 0.13%, 0.14%, 0.15%, 0.16%, 0.17%, 0.18%,
0.19%,
0.20%, 0.21%, 0.22%, 0.23%, 0.24%, 0.25%, 0.26%, 0.27%, 0.28%, 0.29%, or 0.30%
THC by
weight of the dried inflorescence, and all ranges therebetween. Thus, in some
embodiments, the
Specialty Cannabis of the present disclosure comprise 0.00%-0.10%, 0.00%-
0.20%, or 0.00%-
0.30% THC content by weight of the dried inflorescence.
WWI In some embodiments, the Specialty Cannabis of the present disclosure
produce
inflorescences comprising no more than about 0.00%, 0.01%, 0.02%, 0.03%,
0.04%, 0.05%,
0.06%, 0.07%, 0.08%, 0.09%, 0.10%, 0.11%, 0.12%, 0.13%, 0.14%, 0.15%, 0.16%,
0.17%,
0.18%, 0.19%, 0.20%, 0.21%, 0.22%, 0.23%, 0.24%, 0.25%, 0.26%, 0.27%, 0.28%,
0.29%, or
0.30% THC by weight of the dried inflorescence, while accumulating at least 1%
non-THC
cannabinoid content by weight.
192111 In some embodiments, the Specialty Cannabis of the present disclosure
produce
inflorescences comprising no more than about 0.00%, 0.01%, 0.02%, 0.03%,
0.04%, 0.05%,
0.06%, 0.07%, 0.08%, 0.09%, 0.10%, 0.11%, 0.12%, 0.13%, 0.14%, 0.15%, 0.16%,
0.17%,
0.18%, 0.19%, 0.20%, 0.21%, 0.22%, 0.23%, 0.24%, 0.25%, 0.26%, 0.27%, 0.28%,
0.29%, or
0.30% THC by weight of the dried inflorescence, at any stage in the plant's
growth. That is, in
some embodiments, the Specialty Cannabis hemp lines of the present disclosure
never accumulate
greater than 0.3%, or greater than 0.2% THC, even if allowed to develop past
harvest maturity.
102121 In some embodiments, the Specialty Cannabis of the present disclosure
produce
inflorescences comprising about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%,
12%, 13%,
14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%,
29%, 30%,
31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, or 40% CBD by weight of the dried
inflorescence, and all ranges therebetween. Thus, in some embodiments, the
Specialty Cannabis
of the present disclosure comprise 3%-40%, 3%-30%, or 3%-25% CBD content by
weight of the
dried inflorescence.
1.92131 In some embodiments, the Specialty Cannabis of the present disclosure
produce
inflorescences comprising more than about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%,
10%, 11%,
12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%,
27%, 28%,
52
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, or 40% CBD by weight of
the
dried inflorescence while accumulating no more than 0.3% or 0.2% THC content
by weight.
102141 In some embodiments, the Specialty Cannabis of the present disclosure
accumulates CBC.
Thus, in some embodiments, the Specialty Cannabis of the present disclosure
produce
inflorescences comprising about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%,
12%, 13%,
14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%,
29%, 30%,
31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, or 40% CBC by weight of the dried
inflorescence, and all ranges therebetween. Thus, in some embodiments, the
Specialty Cannabis
of the present disclosure comprise 3%-40%, 3%-30%, or 3%-25% CBC content by
weight of the
dried inflorescence.
[0215] In some embodiments, the Specialty Cannabis of the present disclosure
produce
inflorescences comprising more than about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%,
10%, 11%,
12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%,
27%, 28%,
29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, or 40% CBC by weight of
the
dried inflorescence while accumulating no more than 0.3% or 0.2% THC content
by weight.
10216.1 In some embodiments, the Specialty Cannabis of the present disclosure
produce
inflorescences comprising about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%,
12%, 13%,
14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%,
29%, 30%,
31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, or 40% THCV by weight of the
dried
inflorescence, and all ranges therebetween. Thus, in some embodiments, the
Specialty Cannabis
of the present disclosure comprise 3%-40%, 3%-30%, or 3%-25% THCV content by
weight of the
dried inflorescence.
102171 In some embodiments, the Specialty Cannabis of the present disclosure
produce
inflorescences comprising more than about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%,
10%, 11%,
12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%,
27%, 28%,
29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, or 40% THCV by weight
of the
dried inflorescence of the dried inflorescence while accumulating no more than
0.3% or 0.2% THC
content by weight.
[0218] In some embodiments, the Specialty Cannabis of the present disclosure
produce
inflorescences comprising about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%,
12%, 13%,
53
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%,
29%, 30%,
31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, or 40% CBDV by weight of the
dried
inflorescence, and all ranges therebetween. Thus, in some embodiments, the
Specialty Cannabis
of the present disclosure comprise 3%-40%, 3%-30%, or 3%-25% CBDV content by
weight of the
dried inflorescence.
[0219] In some embodiments, the Specialty Cannabis of the present disclosure
produce
inflorescences comprising more than about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%,
10%, 11%,
12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%,
27%, 28%,
29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, or 40% CBDV by weight
of the
dried inflorescence while accumulating no more than 0.3% or 0.2% THC content
by weight.
[0220] In some embodiments, the Specialty Cannabis of the present disclosure
accumulates
CBCV. Thus, in some embodiments, the Specialty Cannabis of the present
disclosure produce
inflorescences comprising about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%,
12%, 13%,
14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%,
29%, 30%,
31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, or 40% CBCV by weight of the
dried
inflorescence, and all ranges therebetween. Thus, in some embodiments, the
Specialty Cannabis
of the present disclosure comprise 3%-40%, 3%-30%, or 3%-25% CBCV content by
weight of the
dried inflorescence.
[0221] In some embodiments, the Specialty Cannabis of the present disclosure
produce
inflorescences comprising more than about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%,
10%, 11%,
12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%,
27%, 28%,
29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, or 40% CBCV by weight
of the
dried inflorescence while accumulating no more than 0.3% or 0.2% THC content
by weight.
102221 Another important aspect of cannabis breeding is the Terpene Profile of
a plant. In some
embodiments, the present invention teaches the preference for cannabis plant
material with novel
Terpene Profiles. In some embodiments, the Specialty Cannabis of the present
disclosure produce
inflorescences comprising organoleptically pleasing Terpene Profiles.
02231 In some embodiments, the Specialty Cannabis of the present invention has
an absolute
content of any one of the 17 terpenes in the Terpene Profile as set forth in
Table 3 that is 0%,
0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.11%,
0.12%, 0.13%,
54
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
0.14%, 0.15%, 0.16%, 0.17%, 0.18%, 0.19%, 0.2%, 0.21%, 0.22%, 0.23%, 0.24%,
0.25%, 0.26%,
0.27%, 0.28%, 0.29%, 0.3%, 0.31%, 0.32%, 0.33%, 0.34%, 0.35%, 0.36%, 0.37%,
0.38%, 0.39%,
0.4%, 0.41%, 0.42%, 0.43%, 0.44%, 0.45%, 0.46%, 0.47%, 0.48%, 0.49%, 0.5%,
0.51%, 0.52%,
0.53%, 0.54%, 0.55%, 0.56%, 0.57%, 0.58%, 0.59%, 0.6%, 0.61%, 0.62%, 0.63%,
0.64%, 0.65%,
0.66%, 0.67%, 0.68%, 0.69%, 0.7%, 0.71%, 0.72%, 0.73%, 0.74%, 0.75%, 0.76%,
0.77%, 0.78%,
0.79%, 0.8%, 0.81%, 0.82%, 0.83%, 0.84%, 0.85%, 0.86%, 0.87%, 0.88%, 0.89%,
0.9%, 0.91%,
0.92%, 0.93%, 0.94%, 0.95%, 0.96%, 0.97%, 0.98%, 0.99%, 1%, 1.01%, 1.02%,
1.03%, 1.04%,
1.05%, 1.06%, 1.07%, 1.08%, 1.09%, 1.1%, 1.11%, 1.12%, 1.13%, 1.14%, 1.15%,
1.16%, 1.17%,
1.18%, 1.19%, 1.2%, 1.21%, 1.22%, 1.23%, 1.24%, 1.25%, 1.26%, 1.27%, 1.28%,
1.29%, 1.3%,
1.31%, 1.32%, 1.33%, 1.34%, 1.35%, 1.36%, 1.37%, 1.38%, 1.39%, 1.4%, 1.41%,
1.42%, 1.43%,
1.44%, 1.45%, 1.46%, 1.47%, 1.48%, 1.49%, 1.5%, 1.51%, 1.52%, 1.53%, 1.54%,
1.55%, 1.56%,
1.57%, 1.58%, 1.59%, 1.6%, 1.61%, 1.62%, 1.63%, 1.64%, 1.65%, 1.66%, 1.67%,
1.68%, 1.69%,
1.7%, 1.71%, 1.72%, 1.73%, 1.74%, 1.75%, 1.76%, 1.77%, 1.78%, 1.79%, 1.8%,
1.81%, 1.82%,
1.83%, 1.84%, 1.85%, 1.86%, 1.87%, 1.88%, 1.89%, 1.9%, 1.91%, 1.92%, 1.93%,
1.94%, 1.95%,
1.96%, 1.97%, 1.98%, 1.99%, 2%, 2.01%, 2.02%, 2.03%, 2.04%, 2.05%, 2.06%,
2.07%, 2.08%,
2.09%, 2.1%, 2.11%, 2.12%, 2.13%, 2.14%, 2.15%, 2.16%, 2.17%, 2.18%, 2.19%,
2.2%, 2.21%,
2.22%, 2.23%, 2.24%, 2.25%, 2.26%, 2.27%, 2.28%, 2.29%, 2.3%, 2.31%, 2.32%,
2.33%, 2.34%,
2.35%, 2.36%, 2.37%, 2.38%, 2.39%, 2.4%, 2.41%, 2.42%, 2.43%, 2.44%, 2.45%,
2.46%, 2.47%,
2.48%, 2.49%, 2.5%, 2.51%, 2.52%, 2.53%, 2.54%, 2.55%, 2.56%, 2.57%, 2.58%,
2.59%, 2.6%,
2.61%, 2.62%, 2.63%, 2.64%, 2.65%, 2.66%, 2.67%, 2.68%, 2.69%, 2.7%, 2.71%,
2.72%, 2.73%,
2.74%, 2.75%, 2.76%, 2.77%, 2.78%, 2.79%, 2.8%, 2.81%, 2.82%, 2.83%, 2.84%,
2.85%, 2.86%,
2.87%, 2.88%, 2.89%, 2.9%, 2.91%, 2.92%, 2.93%, 2.94%, 2.95%, 2.96%, 2.97%,
2.98%, 2.99%,
3%, 3.2%, 3.4%, 3.6%, 3.8%, 4%, 4.2%, 4.3%, 4.4%, 4.6%, 4.8%, 5%, 5.2%, 5.4%,
5.6%, 5.8%,
6%, 6.2%, 6.4%, 6.6%, 6.8%, 7%, 7.2%, 7.4%, 7.6%, 7.8%, 8%, or greater based
on dry weight
of inflorescence, including all ranges therebetween. Thus in some embodiments
the absolute
content of any one of the terpenes is between about 0.05% and about 0.85%.
This paragraph is
intended to be read as applying to any specific terpene(s) in a Terpene
Profile, such that the name
of any one or two or more of these terpenes as specifically referred to
elsewhere herein (e.g.,
linalool) can replace the phrase "any one of the 17 terpenes in the Terpene
Profile."
[02241 In some embodiments, the Specialty Cannabis of the present invention
has an absolute
content of any one of the 17 terpenes in the Terpene Profile that is greater
than 0%, 0.01%, 0.02%,
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.11%, 0.12%, 0.13%,
0.14%, 0.15%,
0.16%, 0.17%, 0.18%, 0.19%, 0.2%, 0.21%, 0.22%, 0.23%, 0.24%, 0.25%, 0.26%,
0.27%, 0.28%,
0.29%, 0.3%, 0.31%, 0.32%, 0.33%, 0.34%, 0.35%, 0.36%, 0.37%, 0.38%, 0.39%,
0.4%, 0.41%,
0.42%, 0.43%, 0.44%, 0.45%, 0.46%, 0.47%, 0.48%, 0.49%, 0.5%, 0.51%, 0.52%,
0.53%, 0.54%,
0.55%, 0.56%, 0.57%, 0.58%, 0.59%, 0.6%, 0.61%, 0.62%, 0.63%, 0.64%, 0.65%,
0.66%, 0.67%,
0.68%, 0.69%, 0.7%, 0.71%, 0.72%, 0.73%, 0.74%, 0.75%, 0.76%, 0.77%, 0.78%,
0.79%, 0.8%,
0.81%, 0.82%, 0.83%, 0.84%, 0.85%, 0.86%, 0.87%, 0.88%, 0.89%, 0.9%, 0.91%,
0.92%, 0.93%,
0.94%, 0.95%, 0.96%, 0.97%, 0.98%, 0.99%, 1%, 1.01%, 1.02%, 1.03%, 1.04%,
1.05%, 1.06%,
1.07%, 1.08%, 1.09%, 1.1%, 1.11%, 1.12%, 1.13%, 1.14%, 1.15%, 1.16%, 1.17%,
1.18%, 1.19%,
1.2%, 1.21%, 1.22%, 1.23%, 1.24%, 1.25%, 1.26%, 1.27%, 1.28%, 1.29%, 1.3%,
1.31%, 1.32%,
1.33%, 1.34%, 1.35%, 1.36%, 1.37%, 1.38%, 1.39%, 1.4%, 1.41%, 1.42%, 1.43%,
1.44%, 1.45%,
1.46%, 1.47%, 1.48%, 1.49%, 1.5%, 1.51%, 1.52%, 1.53%, 1.54%, 1.55%, 1.56%,
1.57%, 1.58%,
1.59%, 1.6%, 1.61%, 1.62%, 1.63%, 1.64%, 1.65%, 1.66%, 1.67%, 1.68%, 1.69%,
1.7%, 1.71%,
1.72%, 1.73%, 1.74%, 1.75%, 1.76%, 1.77%, 1.78%, 1.79%, 1.8%, 1.81%, 1.82%,
1.83%, 1.84%,
1.85%, 1.86%, 1.87%, 1.88%, 1.89%, 1.9%, 1.91%, 1.92%, 1.93%, 1.94%, 1.95%,
1.96%, 1.97%,
1.98%, 1.99%, 2%, 2.01%, 2.02%, 2.03%, 2.04%, 2.05%, 2.06%, 2.07%, 2.08%,
2.09%, 2.1%,
2.11%, 2.12%, 2.13%, 2.14%, 2.15%, 2.16%, 2.17%, 2.18%, 2.19%, 2.2%, 2.21%,
2.22%, 2.23%,
2.24%, 2.25%, 2.26%, 2.27%, 2.28%, 2.29%, 2.3%, 2.31%, 2.32%, 2.33%, 2.34%,
2.35%, 2.36%,
2.37%, 2.38%, 2.39%, 2.4%, 2.41%, 2.42%, 2.43%, 2.44%, 2.45%, 2.46%, 2.47%,
2.48%, 2.49%,
2.5%, 2.51%, 2.52%, 2.53%, 2.54%, 2.55%, 2.56%, 2.57%, 2.58%, 2.59%, 2.6%,
2.61%, 2.62%,
2.63%, 2.64%, 2.65%, 2.66%, 2.67%, 2.68%, 2.69%, 2.7%, 2.71%, 2.72%, 2.73%,
2.74%, 2.75%,
2.76%, 2.77%, 2.78%, 2.79%, 2.8%, 2.81%, 2.82%, 2.83%, 2.84%, 2.85%, 2.86%,
2.87%, 2.88%,
2.89%, 2.9%, 2.91%, 2.92%, 2.93%, 2.94%, 2.95%, 2.96%, 2.97%, 2.98%, 2.99%,
3%, 3.2%,
3.4%, 3.6%, 3.8%, 4%, 4.2%, 4.3%, 4.4%, 4.6%, 4.8%, 5%, 5.2%, 5.4%, 5.6%,
5.8%, 6%, 6.2%,
6.4%, 6.6%, 6.8%, 7%, 7.2%, 7.4%, 7.6%, 7.8%, or 8% based on dry weight of
inflorescence.
This paragraph is intended to be read as applying to any specific terpene(s)
in a Terpene Profile,
such that the name of any one or two or more of these terpenes as specifically
referred to elsewhere
herein (e.g., linalool) can replace the phrase "any one of the 17 terpenes in
the Terpene Profile."
102251 A limonene dominant terpene is used to refer to Terpene Profiles in
which limonene is the
most abundant terpene in the Terpene Profile (i.e., limonene relative or
absolute content is >
content of any single one of the 16 other terpenes in the Terpene Profile).
Reference to other
56
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
dominant terpenes is similarly based on said terpene being the most abundant
within the Terpene
Profile.
102261 In some embodiments, the Specialty Cannabis of the present invention
has 0.1%, 0.2%,
0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%,
1.6%, 1.7%,
1.8%, 1.9%, 2%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3%,
3.1%, 3.2%, 3.3%,
3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%,
4.7%, 4.8%,
4.9%, 5%, 5.1%, 5.2%, 5.3%, 5.4%, 5.5%, 5.6%, 5.7%, 5.8%, 5.9%, 6%, 6.1%,
6.2%, 6.3%, 6.4%,
6.5%, 6.6%, 6.7%, 6.8%, 6.9%, 7%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5%, 7.6%, 7.7%,
7.8%, 7.9%, 8%
terpene essential oil content by dry weight, including all ranges
therebetween. Thus in some
embodiments the essential oil content of the Specialty Cannabis varieties of
the present invention
is between about 0.5% and about 8% by dry weight. In other embodiments the
essential oil contents
of the Specialty Cannabis varieties of the present invention is between about
1.0% and about 5%
by dry weight.
192271 In some embodiments, the Specialty Cannabis of the present invention
has greater than
0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.1%, 1.2%, 1.3%,
1.4%, 1.5%,
1.6%, 1.7%, 1.8%, 1.9%, 2%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%,
2.9%, 3%, 3.1%,
3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4%, 4.1%, 4.2%, 4.3%, 4.4%,
4.5%, 4.6%,
4.7%, 4.8%, 4.9%, 5%, 5.1%, 5.2%, 5.3%, 5.4%, 5.5%, 5.6%, 5.7%, 5.8%, 5.9%,
6%, 6.1%, 6.2%,
6.3%, 6.4%, 6.5%, 6.6%, 6.7%, 6.8%, 6.9%, 7%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5%,
7.6%, 7.7%,
7.8%, 7.9%, or 8% terpene essential oil content by weight of the dried
inflorescence.
[92281 In some embodiments, the terpene content of the Specialty Cannabis of
the present
disclosure is described in relative terms as a percentage composition of the
total Terpene Profile.
Thus for example a Specialty Cannabis with 1.2% absolute terpinolene content
and 1.2% limonene
content and no other terpenes in the Terpene Profile would said to have 50%
terpinolene and 50%
limonene relative content.
192291 In some embodiments, the Specialty Cannabis of the present invention
has a relative
content of any one of the 17 terpenes in the Terpene Profile that is greater
than or less than 1%,
2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%,
19%,
20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%,
35%, 36%,
37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%,
52%, 53%,
57
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%,
69%, 70%,
71%, 72%, 73%, 74%, 75%, 76%, 77%, 79%, 79%, 80%, 81%, 82%, 83%, 84%, 85%,
86%, 87%,
88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, including
any
ranges therebetween. Thus in some embodiments the relative content of any one
of the terpenes is
between 0% and 100%. This paragraph is intended to be read as applying to any
specific terpene(s)
in a Terpene Profile, such that the name of any of one or two or more these
terpenes as specifically
referred to elsewhere herein (e.g., linalool) can replace the phrase "any one
of the 17 terpenes in
the Terpene Profile."
10230] In some embodiments, the Specialty Cannabis of the present disclosure
produce female
inflorescences. In some embodiments, the Specialty Cannabis of the present
disclosure have been
feminized to produce female seed. In some embodiments, the supporting seed
deposits referenced
in the present disclosure are feminized. Persons having skill in the art will
be familiar with
techniques to feminize cannabis seeds, including breeding through treatment
with silver
thiosulfate, colloidal silver, hormones, and rodelization method.
[02311 Another important breeding phenotype is flower color. The accumulation
of anthocyanins,
carotenoids, or other color-producing compounds in leaves and flowers of
cannabis can have an
effect on consumer visual appeal and flavor. Iconic examples of the appeal of
color are the popular
"Purple Kush", "Purple Haze", and "Purple Trainwreck" varieties that express
anthocyanins in
their late maturation stages to produce dark purple leaves. Color selections
can also be based on
(but not limited to) unique coloration of stem, leaf, inflorescence, calyx,
stamen, trichome bodies
and finished products including extracts and hash.
I92321 Yield is another important factor in breeding. Cannabis yield is
measured by pounds (lbs),
grams (g) or kilograms (Kg) of dried (e.g., -10% moisture) trimmed flowers.
Yield can be
expressed in terms of yield per plant, yield per watt of light, and yield per
square meter of growing
area among others. Cannabis yield is also dependent on the growing
environment. For example,
yields for a particular cannabis strain will vary between outdoor growth long
season, outdoor
growth short season, or indoor growth. Yield may also be affected by growing
conditions such as
type of lighting, soil, fertilizer use, size of growing pot, etc.
102331 In some embodiments, the Specialty Cannabis of the present disclosure
produce . 1 g, .2g,
.3g, .4g, .5g, .6g, .7g, .8g, .9g, 1.0g, 1.1g, 1.2g, 1.3g, 1.4g, 1.5g, 1.6g,
1.7g, 1.8g, 1.9g, 2.0g, 2.1g,
58
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
2.2g, 2.3g, 2.4g, 2.5g, 2.6g, 2.7g, 2.8g, 2.9g, 3.0g, 3.1g, 3.2g, 3.3g, 3.4g,
3.5g, 3.6g, 3.7g, 3.8g,
3.9g, 4.0g, 4.1g, 4.2g, 4.3g, 4.4g, 4.5g, 4.6g, 4.7g, 4.8g, 4.9g, or 5.0g of
dried flowers per watt of
light, including all ranges therebetween. In some embodiments, the Specialty
Cannabis of the
present invention produces 10g, 15g, 20g, 25g, 30g, 35g, 40g, 45g, 50g, 55g,
60g, 65g, 70g, 75g,
80g, 85g, 90g, 95g, 100g, 105g, 110g, 115g, 120g, 125g, 130g, 135g, 140g,
145g, 150g, 155g,
160g, 165g, 170g, 175g, 180g, 185g, 190g, 195g, 200g, 210g, 220g, 230g, 240g,
250g, 260g, 270g,
280g, 290g, 300g, 310g, 320g, 330g, 340g, 350g, 360g, 370g, 380g, 390g, 400g,
410g, 420g, 430g,
440g, 450g, 460g, 470g, 480g, 490g, 500g, 550g, 600g, 650g, 700g, 750g, 800g,
850g, 900g, 950g,
1000g, 2000g, 3000g, or 5000g of dried flowers per plant, including all ranges
therebetween.
102341 Other desirable yield phenotypes that can be used in the breeding
programs of the present
disclosure include:
102351 High Yield Natural Light Production Long Season - Selection based on
yield performance
for early ripening varieties during long seasons.
102361 High Yield Natural Light Production Short Season - Selection based on
yield performance
of late ripening varieties during long season and/or yield of plants that
ripen in winter months and
at low light levels.
[0237] High Yield Indoor Production - Selection based solely on plant yield
performance in
artificial lighting (e.g., HID). Another important phenotype that is important
for cannabis
production is structural features for easy harvesting.
102381 Structure for Manual Trim/Market - Selections are based on the relative
ratio by weight of
finished flower. This usually is directly related to dense trichome morphology
with very few sun
leaves.
[0239] Structure for Automated Trimming - Selection based on flower morphology
that is more
kola (continuous long bud) with many sun leaves protruding from large
inflorescences. Overall
flower size is typically large, but trichomes are less densely packed and
overall inflorescence is
less dense than what is traditionally selected for manual trim.
[0240] Root Structure - Positive root selection is marked by overall root
vigor and adventitious
root growth, ease of transplant, rate of root development on clonal
propagations, and root shooting
59
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
from tissue culture samples. Root selections can also be based on resistance
to soil and hydroponic
pathogens including Pythium.
10241j Vigor - Selection for plant vigor are marked by tremendous grow rates
and robust
stem/stalk infrastructure. Often times, selection display morphologies that
are very much enlarged
compared to sibling progeny.
[02421 Fungal Resistance - Selections based on plant that exhibit immunity or
partial immunity to
fungal diseases and pathogens including but not limited to powdery mildew,
botrytis, downy
mildew among others.
10213] Harvesting by Combine ¨ Selections based on plant ideotypes that are
better suited for
large-scale, outdoor, field production and harvesting. Examples of applicable
traits include stem
lodging resistance, stems suitable for machine cutting, resistance to
prevalent pests in field
production (e.g., corn borers), suitable height for machine combining, etc.
10244] For a non-limiting list of cannabinoid phenotypes, please see Marijuana
Botany, An
Advanced study: The Propagation and Breeding of Distinctive Cannabis by Robert
Connell Clarke.
[0245] The present invention also relates to variants, mutants and
modifications of the seeds, plant
parts and/or whole plants of the cannabis plants of the present invention.
Variants, mutants and
trivial modifications of the seeds, plants, plant parts, plant cells of the
present invention can be
generated by methods well known and available to one skilled in the art,
including but not limited
to, mutagenesis (e.g., chemical mutagenesis, radiation mutagenesis, transposon
mutagenesis,
insertional mutagenesis, signature tagged mutagenesis, site-directed
mutagenesis, and natural
mutagenesis), knock-outs/knock-ins, antisense and RNA interference. For more
information of
mutagenesis in plants, such as agents, protocols, see Acquaah et al.
(Principles of plant genetics
and breeding, Wiley-Blackwell, 2007, ISBN 1405136464, 9781405136464, which is
herein
incorporated by reference in its entity).
10246] The present invention also relates to a mutagenized population of the
cannabis plants of
the present invention, and methods of using such populations. In some
embodiments, the
mutagenized population can be used in screening for new cannabis lines that
comprise one or more
or all of the morphological, physiological, biological, and/or chemical
characteristics of cannabis
plants of the present invention. In some embodiments, the new cannabis plants
obtained from the
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
screening process comprise one or more or all of the morphological,
physiological, biological,
and/or chemical characteristics of cannabis plants of the present invention,
and one or more
additional or different new morphological, physiological, biological, and/or
chemical
characteristic.
10217] The mutagenized population of the present invention can be used in
Targeting Induced
Local Lesions in Genomes (TILLING) screening method, which combines a standard
and efficient
technique of mutagenesis with a chemical mutagen (e.g., Ethyl methanesulfonate
(EMS)) with a
sensitive DNA screening-technique that identifies single base mutations (also
called point
mutations) in a target gene. Detailed description on methods and compositions
on TILLING can
be found in Till et al. (Discovery of induced point mutations in maize genes
by TILLING, BMC
Plant Biology 2004, 4:12), Weil et al., (TILLING in Grass Species, Plant
Physiology January 2009
vol. 149 no. 1 158-164), Comai, L. and S. Henikoff ("TILLING: practical single-
nucleotide
mutation discovery." Plant J 45(4): 684-94), McCallum et al., (Nature
Biotechnology, 18: 455-
457, 2000), McCallum et al., (Plant Physiology, 123: 439-442, 2000), Colbert
et al., (Plant Physiol.
126(2): 480-484, 2001), U.S. Patent. No. 5,994,075, U.S. Patent Application
Publication No.
2004/0053236A1, and International Patent Application Publication Nos. WO
2005/055704 and
WO 2005/048692, each of which is hereby incorporated by reference for all
purposes.
Cannabis breeding methods
[0248] In some embodiments, the plants of the present invention can be used to
produce new plant
varieties. In some embodiments, the plants are used to develop new, unique and
superior varieties
or hybrids with desired phenotypes.
[02491 In some embodiments, selection methods, e.g., molecular marker assisted
selection, can be
combined with breeding methods to accelerate the process. Additional breeding
methods have
been known to one of ordinary skill in the art, e.g., methods discussed in
Chahal and Gosal
(Principles and procedures of plant breeding: biotechnological and
conventional approaches, CRC
Press, 2002, ISBN 084931321X, 9780849313219), Taji et al. (In vitro plant
breeding, Routledge,
2002, ISBN 156022908X, 9781560229087), Richards (Plant breeding systems,
Taylor & Francis
US, 1997, ISBN 0412574500, 9780412574504), Hayes (Methods of Plant Breeding,
Publisher:
READ BOOKS, 2007, ISBN1406737062, 9781406737066), each of which is
incorporated by
reference in its entirety for all purposes. Cannabis genome has been sequenced
recently (van Bakel
61
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
et al., The draft genome and transcriptome of Cannabis sativa, Genome Biology,
12(10):R102,
2011). Molecular makers for cannabis plants are described in Datwyler et al.
(Genetic variation
in hemp and marijuana (Cannabis sativa L.) according to amplified fragment
length
polymorphisms, J Forensic Sci. 2006 Mar;51(2):371-5.), Pinarkara et al., (RAPD
analysis of seized
marijuana (Cannabis sativa L.) in Turkey, Electronic Journal of Biotechnology,
12(1), 2009),
Hakki et al., (Inter simple sequence repeats separate efficiently hemp from
marijuana (Cannabis
sativa L.), Electronic Journal of Biotechnology, 10(4), 2007), Datwyler et
al., (Genetic Variation
in Hemp and Marijuana (Cannabis sativa L.) According to Amplified Fragment
Length
Polymorphisms, J Forensic Sci, March 2006, 51(2):371-375), Gilmore et al.
(Isolation of
microsatellite markers in Cannabis sativa L. (marijuana), Molecular Ecology
Notes, 3(1):105-107,
March 2003), Pacifico et al., (Genetics and marker-assisted selection of
chemotype in Cannabis
sativa L.), Molecular Breeding (2006) 17:257-268), and Mendoza et al.,
(Genetic individualization
of Cannabis sativa by a short tandem repeat multiplex system, Anal Bioanal
Chem (2009)
393:719-726), each of which is herein incorporated by reference in its
entirety for all purposes.
102501 In some embodiments, molecular markers are designed and made, based on
the genome of
the plants of the present application. In some embodiments, the molecular
markers are selected
from Isozyme Electrophoresis, Restriction Fragment Length Polymorphisms
(RFLPs), Randomly
Amplified Polymorphic DNAs (RAPDs), Arbitrarily Primed Polymerase Chain
Reaction (AP-
PCR), DNA Amplification Fingerprinting (DAF), Sequence Characterized Amplified
Regions
(SCARs). Amplified Fragment Length Polymorphisms (AFLPs), and Simple Sequence
Repeats
(SSRs) which are also referred to as Microsatellites, etc. Methods of
developing molecular markers
and their applications are described by Avise (Molecular markers, natural
history, and evolution,
Publisher: Sinauer Associates, 2004, ISBN 0878930418, 9780878930418),
Srivastava et al.
(Plant biotechnology and molecular markers, Publisher: Springer, 2004,
ISBN1402019114,
9781402019111), and Vienne (Molecular markers in plant genetics and
biotechnology, Publisher:
Science Publishers, 2003), each of which is incorporated by reference in its
entirety for all
purposes.
192511 The molecular markers can be used in molecular marker assisted
breeding. For example,
the molecular markers can be utilized to monitor the transfer of the genetic
material. In some
embodiments, the transferred genetic material is a gene of interest, such as
genes that contribute
62
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
to one or more favorable agronomic phenotypes when expressed in a plant cell,
a plant part, or a
plant.
102521 Details of existing cannabis plants varieties and breeding methods are
described in Potter
et al. (2011, World Wide Weed: Global Trends in Cannabis Cultivation and Its
Control), Holland
(2010, The Pot Book: A Complete Guide to Cannabis, Inner Traditions / Bear &
Co,
ISBN1594778981, 9781594778988), Green 1(2009, The Cannabis Grow Bible: The
Definitive
Guide to Growing Marijuana for Recreational and Medical Use, Green Candy
Press, 2009, ISBN
1931160589, 9781931160582), Green 11 (2005, The Cannabis Breeder's Bible: The
Definitive
Guide to Marijuana Genetics, Cannabis Botany and Creating Strains for the Seed
Market, Green
Candy Press, 1931160279, 9781931160278), Starks (1990, Marijuana Chemistry:
Genetics,
Processing & Potency, ISBN 0914171399, 9780914171393), Clarke (1981, Marijuana
Botany, an
Advanced Study: The Propagation and Breeding of Distinctive Cannabis, Ronin
Publishing, ISBN
091417178X, 9780914171782), Short (2004, Cultivating Exceptional Cannabis: An
Expert
Breeder Shares His Secrets, ISBN 1936807122, 9781936807123), Cervantes (2004,
Marijuana
Horticulture: The Indoor/Outdoor Medical Grower's Bible, Van Patten
Publishing, ISBN
187882323X, 9781878823236), Franck et al. (1990, Marijuana Grower's Guide, Red
Eye Press,
ISBN 0929349016, 9780929349015), Grotenhermen and Russo (2002, Cannabis and
Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential, Psychology
Press, ISBN
0789015080, 9780789015082), Rosenthal (2007, The Big Book of Buds: More
Marijuana
Varieties from the World's Great Seed Breeders, ISBN 1936807068,
9781936807062), Clarke, RC
(Cannabis: Evolution and Ethnobotany 2013 (In press)), King, J (Cannabible
Vols 1-3, 2001-
2006), and four volumes of Rosenthal's Big Book of Buds series (2001, 2004,
2007, and 2011),
each of which is herein incorporated by reference in its entirety for all
purposes.
192531 Classical breeding methods can be included in the present invention to
introduce one or
more recombinant expression cassettes of the present invention into other
plant varieties, or other
close-related species that are compatible to be crossed with the transgenic
plant of the present
invention.
102541 In some embodiments, said method comprises (i) crossing any one of the
plants of the
present invention comprising the expression cassette as a donor to a recipient
plant line to create a
63
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
Fl population; (ii) selecting offspring that have expression cassette.
Optionally, the offspring can
be further selected by testing the expression of the gene of interest.
102551 In some embodiments, complete chromosomes of the donor plant are
transferred. For
example, the transgenic plant with the expression cassette can serve as a male
or female parent in
a cross pollination to produce offspring plants, wherein by receiving the
transgene from the donor
plant, the offspring plants have the expression cassette.
102561 In a method for producing plants having the expression cassette,
protoplast fusion can also
be used for the transfer of the transgene from a donor plant to a recipient
plant. Protoplast fusion
is an induced or spontaneous union, such as a somatic hybridization, between
two or more
protoplasts (cells in which the cell walls are removed by enzymatic treatment)
to produce a single
bi- or multi-nucleate cell. The fused cell that may even be obtained with
plant species that cannot
be interbred in nature is tissue cultured into a hybrid plant exhibiting the
desirable combination of
traits. More specifically, a first protoplast can be obtained from a plant
having the expression
cassette. A second protoplast can be obtained from a second plant line,
optionally from another
plant species or variety, preferably from the same plant species or variety,
that comprises
commercially desirable characteristics, such as, but not limited to disease
resistance, insect
resistance, valuable grain characteristics (e.g., increased seed weight and/or
seed size) etc. The
protoplasts are then fused using traditional protoplast fusion procedures,
which are known in the
art to produce the cross.
(0257j Alternatively, embryo rescue may be employed in the transfer of the
expression cassette
from a donor plant to a recipient plant. Embryo rescue can be used as a
procedure to isolate
embryos from crosses wherein plants fail to produce viable seed. In this
process, the fertilized
ovary or immature seed of a plant is tissue cultured to create new plants (see
Pierik, 1999, In vitro
culture of higher plants, Springer, ISBN 079235267x, 9780792352679, which is
incorporated
herein by reference in its entirety).
192581 In some embodiments, the recipient plant is an elite line having one or
more certain desired
traits. Examples of desired traits include but are not limited to those that
result in increased biomass
production, production of specific chemicals, increased seed production,
improved plant material
quality, increased seed oil content, etc. Additional examples of desired
traits includes pest
resistance, vigor, development time (time to harvest), enhanced nutrient
content, novel growth
64
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
patterns, aromas or colors, salt, heat, drought and cold tolerance, and the
like. Desired traits also
include selectable marker genes (e.g., genes encoding herbicide or antibiotic
resistance used only
to facilitate detection or selection of transformed cells), hormone
biosynthesis genes leading to the
production of a plant hormone (e.g., auxins, gibberellins, cytokinins,
abscisic acid and ethylene
that are used only for selection), or reporter genes (e.g. luciferase, P-
glucuronidase,
chloramphenicol acetyl transferase (CAT, etc.). The recipient plant can also
be a plant with
preferred chemical compositions, e.g., compositions preferred for medical use
or industrial
applications.
10259] Classical breeding methods can be used to produce new varieties of
cannabis according to
the present invention. Newly developed Fl hybrids can be reproduced via
asexual reproduction.
[0260] Open-Pollinated Populations. The improvement of open-pollinated
populations of such
crops as rye, many maizes and sugar beets, herbage grasses, legumes such as
alfalfa and clover,
and tropical tree crops such as cacao, coconuts, oil palm and some rubber,
depends essentially
upon changing gene-frequencies towards fixation of favorable alleles while
maintaining a high
(but far from maximal) degree of heterozygosity. Uniformity in such
populations is impossible
and trueness-to-type in an open-pollinated variety is a statistical feature of
the population as a
whole, not a characteristic of individual plants. Thus, the heterogeneity of
open-pollinated
populations contrasts with the homogeneity (or virtually so) of inbred lines,
clones and hybrids.
[0261] Population improvement methods fall naturally into two groups, those
based on purely
phenotypic selection, normally called mass selection, and those based on
selection with progeny
testing. Interpopulation improvement utilizes the concept of open breeding
populations; allowing
genes to flow from one population to another. Plants in one population
(cultivar, strain, ecotype,
or any germplasm source) are crossed either naturally (e.g., by wind) or by
hand or by bees
(commonly Apis mellifera L. or Megachile rotundata F.) with plants from other
populations.
Selection is applied to improve one (or sometimes both) population(s) by
isolating plants with
desirable traits from both sources.
[02621 There are basically two primary methods of open-pollinated population
improvement.
First, there is the situation in which a population is changed en masse by a
chosen selection
procedure. The outcome is an improved population that is indefinitely
propagatable by random-
mating within itself in isolation. Second, the synthetic variety attains the
same end result as
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
population improvement but is not itself propagatable as such; it has to be
reconstructed from
parental lines or clones. These plant breeding procedures for improving open-
pollinated
populations are well known to those skilled in the art and comprehensive
reviews of breeding
procedures routinely used for improving cross-pollinated plants are provided
in numerous texts
and articles, including: Allard, Principles of Plant Breeding, John Wiley &
Sons, Inc. (1960);
Simmonds, Principles of Crop Improvement, Longman Group Limited (1979);
Hallauer and
Miranda, Quantitative Genetics in Maize Breeding, Iowa State University Press
(1981); and,
Jensen, Plant Breeding Methodology, John Wiley & Sons, Inc. (1988).
10263] Mass Selection. In mass selection, desirable individual plants are
chosen, harvested, and
the seed composited without progeny testing to produce the following
generation. Since selection
is based on the maternal parent only, and there is no control over
pollination, mass selection
amounts to a form of random mating with selection. As stated herein, the
purpose of mass selection
is to increase the proportion of superior genotypes in the population.
102641 Synthetics. A synthetic variety is produced by crossing inter se a
number of genotypes
selected for good combining ability in all possible hybrid combinations, with
subsequent
maintenance of the variety by open pollination. Whether parents are (more or
less inbred) seed-
propagated lines, as in some sugar beet and beans (Vicia) or clones, as in
herbage grasses, clovers
and alfalfa, makes no difference in principle. Parents are selected on general
combining ability,
sometimes by test crosses or toperosses, more generally by polycrosses.
Parental seed lines may
be deliberately inbred (e.g. by selfing or sib crossing). However, even if the
parents are not
deliberately inbred, selection within lines during line maintenance will
ensure that some inbreeding
occurs. Clonal parents will, of course, remain unchanged and highly
heterozygous.
[0265] Whether a synthetic can go straight from the parental seed production
plot to the farmer or
must first undergo one or two cycles of multiplication depends on seed
production and the scale
of demand for seed. In practice, grasses and clovers are generally multiplied
once or twice and
are thus considerably removed from the original synthetic.
[02661 While mass selection is sometimes used, progeny testing is generally
preferred for
polycrosses, because of their operational simplicity and obvious relevance to
the objective, namely
exploitation of general combining ability in a synthetic.
66
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
102671 The numbers of parental lines or clones that enter a synthetic vary
widely. In practice,
numbers of parental lines range from 10 to several hundred, with 100-200 being
the average.
Broad based synthetics formed from 100 or more clones would be expected to be
more stable
during seed multiplication than narrow based synthetics.
10268] Pedigreed varieties. A pedigreed variety is a superior genotype
developed from selection
of individual plants out of a segregating population followed by propagation
and seed increase of
self-pollinated offspring and careful testing of the genotype over several
generations. This is an
open pollinated method that works well with naturally self-pollinating
species. This method can
be used in combination with mass selection in variety development. Variations
in pedigree and
mass selection in combination are the most common methods for generating
varieties in self-
pollinated crops.
102691 Hybrids. A hybrid is an individual plant resulting from a cross between
parents of differing
genotypes. Commercial hybrids are now used extensively in many crops,
including corn (maize),
sorghum, sugar beet, sunflower and broccoli. Hybrids can be formed in a number
of different ways,
including by crossing two parents directly (single cross hybrids), by crossing
a single cross hybrid
with another parent (three-way or triple cross hybrids), or by crossing two
different hybrids (four-
way or double cross hybrids).
102701 Strictly speaking, most individuals in an out breeding (i.e., open-
pollinated) population are
hybrids, but the term is usually reserved for cases in which the parents are
individuals whose
genomes are sufficiently distinct for them to be recognized as different
species or subspecies.
Hybrids may be fertile or sterile depending on qualitative and/or quantitative
differences in the
genomes of the two parents. Heterosis, or hybrid vigor, is usually associated
with increased
heterozygosity that results in increased vigor of growth, survival, and
fertility of hybrids as
compared with the parental lines that were used to form the hybrid. Maximum
heterosis is usually
achieved by crossing two genetically different, highly inbred lines.
Plant Transformation
[0271] Specialty Cannabis plants of the present invention can be further
modified by introducing
into the plants one or more transgenes which when expressed lead to desired
phenotypes. The
most common method for the introduction of new genetic material into a plant
genome involves
67
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
the use of living cells of the bacterial pathogen Agrobacterium tumefaciens to
literally inject a
piece of DNA, called transfer or T-DNA, into individual plant cells (usually
following wounding
of the tissue) where it is targeted to the plant nucleus for chromosomal
integration. There are
numerous patents governing Agrobacterium mediated transformation and
particular DNA delivery
plasmids designed specifically for use with Agrobacterium---for example,
US4536475,
EP0265556, EP0270822, W08504899, W08603516, US5591616, EP0604662, EP0672752,
W08603776, W09209696, W09419930, W09967357, US4399216, W08303259, US5731179,
EP068730, W09516031, US 5693512, US 6051757 and EP904362A1. Agrobacterium-
mediated
plant transformation involves as a first step the placement of DNA fragments
cloned on plasmids
into living Agrobacterium cells, which are then subsequently used for
transformation into
individual plant cells. Agrobacterium-mediated plant transformation is thus an
indirect plant
transformation method. Methods of Agrobacterium-mediated plant transformation
that involve
using vectors with no T-DNA are also well known to those skilled in the art
and can have
applicability in the present invention. See, for example, U.S. Patent No.
7,250,554, which utilizes
P-DNA instead of T-DNA in the transformation vector.
[02721 Direct plant transformation methods using DNA have also been reported.
The first of these
to be reported historically is electroporation, which utilizes an electrical
current applied to a
solution containing plant cells (M. E. Fromm et al., Nature, 319, 791 (1986);
H. Jones et al., Plant
Mol. Biol., 13, 501 (1989) and H. Yang et al., Plant Cell Reports, 7, 421
(1988). Another direct
method, called "biolistic bombardment", uses ultrafine particles, usually
tungsten or gold, that are
coated with DNA and then sprayed onto the surface of a plant tissue with
sufficient force to cause
the particles to penetrate plant cells, including the thick cell wall,
membrane and nuclear envelope,
but without killing at least some of them (US 5,204,253, US 5,015,580). A
third direct method
uses fibrous forms of metal or ceramic consisting of sharp, porous or hollow
needle-like
projections that literally impale the cells, and also the nuclear envelope of
cells. Both silicon
carbide and aluminum borate whiskers have been used for plant transformation
(Mizuno et al.,
2004; Petolino et al., 2000; U553 02523 US Application 20040197909) and also
for bacterial and
animal transformation (Kaepler et al., 1992; Raloff, 1990; Wang, 1995). There
are other methods
reported, and undoubtedly, additional methods will be developed. However, the
efficiencies of
each of these indirect or direct methods in introducing foreign DNA into plant
cells are invariably
extremely low, making it necessary to use some method for selection of only
those cells that have
68
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
been transformed, and further, allowing growth and regeneration into plants of
only those cells
that have been transformed.
102731 For efficient plant transformation, a selection method must be employed
such that whole
plants are regenerated from a single transformed cell and every cell of the
transformed plant carries
the DNA of interest. These methods can employ positive selection, whereby a
foreign gene is
supplied to a plant cell that allows it to utilize a substrate present in the
medium that it otherwise
could not use, such as mannose or xylose (for example, refer US 5,767,378; US
5994629). More
typically, however, negative selection is used because it is more efficient,
utilizing selective agents
such as herbicides or antibiotics that either kill or inhibit the growth of
nontransformed plant cells
and reducing the possibility of chimeras. Resistance genes that are effective
against negative
selective agents are provided on the introduced foreign DNA used for the plant
transformation.
For example, one of the most popular selective agents used is the antibiotic
kanamycin, together
with the resistance gene neomycin phosphotransferase (nptII), which confers
resistance to
kanamycin and related antibiotics (see, for example, Messing & Vierra, Gene
19: 259-268 (1982);
Bevan et al., Nature 304:184-187 (1983)). However, many different antibiotics
and antibiotic
resistance genes can be used for transformation purposes (refer US 5034322, US
6174724 and US
6255560). In addition, several herbicides and herbicide resistance genes have
been used for
transformation purposes, including the bar gene, which confers resistance to
the herbicide
phosphinothricin (White et al., Nucl Acids Res 18: 1062 (1990), Spencer et
al., Theor Appl Genet
79: 625-631(1990), US 4795855, US 5378824 and US 6107549). In addition, the
dhfr gene, which
confers resistance to the anticancer agent methotrexate, has been used for
selection (Bourouis et
al., EMBO J. 2(7): 1099-1104 (1983).
[02741 Genes can be introduced in a site directed fashion using homologous
recombination.
Homologous recombination permits site specific modifications in endogenous
genes and thus
inherited or acquired mutations may be corrected, and/or novel alterations may
be engineered into
the genome. Homologous recombination and site-directed integration in plants
are discussed in,
for example, U.S. Patent Nos. 5,451,513, 5,501,967 and 5,527,695.
102751 Methods of producing transgenic plants are well known to those of
ordinary skill in the art.
Transgenic plants can now be produced by a variety of different transformation
methods including,
but not limited to, electroporation; microinjection; microprojectile
bombardment, also known as
69
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
particle acceleration or biolistic bombardment; viral-mediated transformation;
and
Agrobacterium-mediated transformation. See, for example, U.S. Patent Nos.
5,405,765;
5,472,869; 5,538,877; 5,538,880; 5,550,318; 5,641,664; 5,736,369 and
5,736,369; and
International Patent Application Publication Nos. WO/2002/038779 and
WO/2009/117555; Lu et
al., (Plant Cell Reports, 2008, 27:273-278); Watson et al., Recombinant DNA,
Scientific American
Books (1992); Hinchee et al., Bio/Tech. 6:915-922 (1988); McCabe et al.,
Bio/Tech. 6:923-926
(1988); Toriyama et al., Bio/Tech. 6:1072-1074 (1988); Fromm et al., Bio/Tech.
8:833-839
(1990); Mullins et al., Bio/Tech. 8:833-839 (1990); Hiei et al., Plant
Molecular Biology 35:205-
218 (1997); Ishida et al., Nature Biotechnology 14:745-750 (1996); Zhang et
al., Molecular
Biotechnology 8:223-231 (1997); Ku et al., Nature Biotechnology 17:76-80
(1999); and, Raineri
et al., Bio/Tech. 8:33-38 (1990)), each of which is expressly incorporated
herein by reference in
their entirety. Other references teaching the transformation of cannabis
plants and the production
of callus tissue include Raharjo et al 2006, "Callus Induction and
Phytochemical Characterization
of Cannabis sativa Cell Suspension Cultures", Indo. J. Chem 6(1) 70-74; and
"The biotechnology
of Cannabis sativa" by Sam R. Zwenger, electronically published April, 2009.
[02761 Microprojectile bombardment is also known as particle acceleration,
biolistic
bombardment, and the gene gun (Biolistic Gene Gun). The gene gun is used to
shoot pellets that
are coated with genes (e.g., for desired traits) into plant seeds or plant
tissues in order to get the
plant cells to then express the new genes. The gene gun uses an actual
explosive (.22 caliber blank)
to propel the material. Compressed air or steam may also be used as the
propellant. The Biolistic
Gene Gun was invented in 1983-1984 at Cornell University by John Sanford,
Edward Wolf, and
Nelson Allen. It and its registered trademark are now owned by E. I. du Pont
de Nemours and
Company. Most species of plants have been transformed using this method.
192771 Agrobacterium tumefaciens is a naturally occurring bacterium that is
capable of inserting
its DNA (genetic information) into plants, resulting in a type of injury to
the plant known as crown
gall. Most species of plants can now be transformed using this method,
including cucurbitaceous
species. A transgenic plant formed using Agrobacterium transformation methods
typically
contains a single gene on one chromosome, although multiple copies are
possible. Such transgenic
plants can be referred to as being hemizygous for the added gene. A more
accurate name for such
a plant is an independent segregant, because each transformed plant represents
a unique T-DNA
integration event (U.S. Patent No. 6,156,953). A transgene locus is generally
characterized by the
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
presence and/or absence of the transgene. A heterozygous genotype in which one
allele
corresponds to the absence of the transgene is also designated hemizygous
(U.S. Patent No.
6,008,437).
102781 General transformation methods, and specific methods for transforming
certain plant
species (e.g., maize) are described in U.S. Patent Nos. 4940838, 5464763,
5149645, 5501967,
6265638, 4693976, 5635381, 5731179, 5693512, 6162965, 5693512, 5981840,
6420630,
6919494, 6329571, 6215051, 6369298, 5169770, 5376543, 5416011, 5569834,
5824877,
5959179, 5563055, and 5968830, each of which is incorporated herein by
reference in its entirety
for all purposes.
[02791 Non-limiting examples of methods for transforming cannabis plants and
cannabis tissue
culture methods are described in Zweger (The Biotechnology of Cannabis sativa,
April 2009);
MacKinnon (Genetic transformation of Cannabis sativa Linn: a multipurpose
fiber crop, doctoral
thesis, University of Dundee, Scotland, 2003), MacKinnon et al. (Progress
towards transformation
of fiber hemp, Scottish Crop Research, 2000), and US 20120311744, each of
which is herein
incorporated by reference in its entirety for all purposes. The transformation
can be physical,
chemical and/or biological.
[0280] In some embodiments, the present disclosure teaches the genetic
modification of Specialty
Cannabis. In some embodiments, the Specialty Cannabis of the present
disclosure comprise one
or more transgenes, or DNA edits. Thus in some embodiments, the present
disclosure teaches
transformation of plants (e.g., via agrobacterium, gene gun, or other delivery
mechanism). In other
embodiments, the present disclosure teaches gene editing with CRISPR, as
disclosed in US Patent
Nos 8,697,359, 9,790,490, and US Application No 15/482,603.
Specialty Cannabinoid Compositions
(0281 In some embodiments, the present disclosure teaches cannabinoid
compositions
comprising high propyl cannabinoid contents with little to no THC. In some
embodiments, the
compositions of the present disclosure are completely derived from cannabis
extractions (i.e., all
components are derived from the cannabis plant). In other embodiments, the
present disclosure
teaches cannabinoid compositions in which only the active cannabinoid and
terpene components
must be derived from the cannabis plant. In yet other embodiments, the present
disclosure teaches
71
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
cannabinoid compositions in which one or more components are derived from
sources other than
the cannabis plant (e.g., from other organisms, or chemically synthesized).
102821 For example, the cannabinoid compositions of the present disclosure
can, in some
embodiments, comprise cannabinoids produced via standard chemical,
biochemical, or
biocatalytic methods. Persons having skill in the art will be familiar with
various synthesis
methods, including those of U.S. 9,359,625 and Taura et al. 1996, The Journal
of Biological
Chemistry, Vol. 271, No. 21, p. 17411-17416.
[02831 In some embodiments, the compositions of the present disclosure are
treated to convert
THC to CBD to reduce or eliminate THC content. Persons having skill in the art
will be familiar
with the various methods for converting THC to CBD, including those discussed
in US Patent No.
9,259,449.
[02841 In some embodiments, the compositions of the present disclosure mimic
the cannabinoid
and Terpene Profiles of the Specialty Cannabis plants disclosed herein. That
is, in some
embodiments, the cannabinoid compositions comprise a cannabinoid component
with little to no
THC, and a terpene component. Thus, in some embodiments, the cannabinoid
compositions of the
present disclosure comprise no more than 0.3% THC with greater than 1% propyl
cannabinoid
contents, and at least 1% terpene oil content, as measured by the weight of
the composition.
Extractions methods designed to preserve cannabinoid and Terpene Profiles are
disclosed in other
sections of this application.
(0285j In other embodiments, the compositions of the present disclosure
comprise more
concentrated cannabinoid and terpene content than the Specialty Cannabis hemp
plants. Thus, in
some embodiments, the cannabinoid compositions comprise a CBDV content of
greater than 20%,
a terpene oil content of greater than 10%, and a THC content of less than 10%,
as measured by
weight of the composition.
[0286] In some embodiments, the present disclosure teaches methods of
supplementing cannabis
extracts with one or more cannabinoid or terpene to account for any losses of
the compounds
during the extraction process. In yet other embodiments, the present
disclosure teaches the
formulation of cannabis compositions from individual components (i.e., by
mixing individual
cannabinoid and terpene components obtained from the same or different
sources).
72
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
[02871 In some embodiments, the cannabinoid compositions of the present
disclosure are designed
to mimic the organoleptic experience produced by the Specialty Cannabis.
102881 In some embodiments, the cannabinoid compositions of the present
disclosure comprise
about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%,
17%, 18%,
19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%,
34%, 35%,
36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%,
51%, 52%,
53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%,
68%, 69%,
70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%,
85%, 86%,
87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% total
cannabinoids
by weight of the composition, and all ranges therebetween. Thus, in some
embodiments, the
cannabinoid compositions of the present disclosure comprise 1-5%, 1-10%, 1-
40%, 1-30%, or 1-
60% cannabinoid content by weight of the composition.
[0289] In some embodiments, the cannabinoid compositions of the present
disclosure comprise
more than about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%,
15%, 16%,
17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%,
32%, 33%,
34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%,
49%, 50%,
51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%,
66%, 67%,
68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%,
83%, 84%,
85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%,
total
cannabinoids by weight of the composition.
[0290] In some embodiments, the cannabinoid compositions of the present
disclosure comprise
about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%,
17%, 18%,
19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%,
34%, 35%,
36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%,
51%, 52%,
53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%,
68%, 69%,
70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%,
85%, 86%,
87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% propyl
cannabinoids
by weight of the composition, and all ranges therebetween. Thus, in some
embodiments, the
Cannabinoid compositions of the present disclosure comprise 2%-10%, 3%-30%, or
3%-60%
propyl cannabinoids content by weight of the composition.
73
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
I0291] In some embodiments, the cannabinoid compositions of the present
disclosure comprise
more than about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%,
15%, 16%,
17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%,
32%, 33%,
34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%,
49%, 50%,
51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%,
66%, 67%,
68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%,
83%, 84%,
85%, 86%, 87%, 88%, 89%, 90% 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%
propyl
cannabinoids by weight of the composition while accumulating no more than 10%,
9%, 8%, 7%,
6%, 5%, 4%, 3%, 2%, 1%, 0.3% or 0.2% THC content by weight of the composition.
102921 In some embodiments, the cannabinoid compositions of the present
disclosure comprise
about 0.00%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%,
0.10%, 0.11%,
0.12%, 0.13%, 0.14%, 0.15%, 0.16%, 0.17%, 0.18%, 0.19%, 0.20%, 0.21%, 0.22%,
0.23%,
0.24%, 0.25%, 0.26%, 0.27%, 0.28%, 0.29%, 0.30%, 1%, 2%, 3%, 4%, 5%, 6%, 7%,
8%, 9%, or
10% THC by weight of the composition, and all ranges therebetween. Thus, in
some embodiments,
the cannabinoid compositions of the present disclosure comprise 0.00%-0.10%,
0.00%-0.20%,
0.00%-0.30%, 0.00%-3.00%, or 0.00%-9.00% THC content by weight of the
composition.
[0293] In some embodiments, the cannabinoid compositions of the present
disclosure comprise
less than about 0.00%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%,
0.09%,
0.10%, 0.11%, 0.12%, 0.13%, 0.14%, 0.15%, 0.16%, 0.17%, 0.18%, 0.19%, 0.20%,
0.21%,
0.22%, 0.23%, 0.24%, 0.25%, 0.26%, 0.27%, 0.28%, 0.29%, 0.30% 1%, 2%, 3%, 4%,
5%, 6%,
7%, 8%, 9%, or 10% THC by weight of the composition, while accumulating at
least 20% non-
THC cannabinoid content by weight of the composition.
[0294] In some embodiments, the cannabinoid compositions of the present
disclosure comprise
about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%,
17%, 18%,
19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%,
34%, 35%,
36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%,
51%, 52%,
53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%,
68%, 69%,
70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%,
85%, 86%,
87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% CBD by
weight of
the composition, and all ranges therebetween. Thus, in some embodiments, the
cannabinoid
74
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
compositions of the present disclosure comprise 3%-40%, 3%-30%, or 3%-65% CBD
content by
weight of the composition.
102951 In some embodiments, the cannabinoid compositions of the present
disclosure comprise
more than about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%,
15%, 16%,
17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%,
32%, 33%,
34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%,
49%, 50%,
51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%,
66%, 67%,
68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%,
83%, 84%,
85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, or 98%, CBD
by
weight of the composition while accumulating no more than 10%, 9%, 8%, 7%, 6%,
5%, 4%, 3%,
2%, 1%, 0.3% or 0.2% THC content by weight of the composition.
I0296] In some embodiments, the cannabinoid compositions of the present
disclosure comprise
about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%,
17%, 18%,
19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%,
34%, 35%,
36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%,
51%, 52%,
53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%,
68%, 69%,
70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%,
85%, 86%,
87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% CBC by
weight of
the composition, and all ranges therebetween. Thus, in some embodiments, the
cannabinoid
compositions of the present disclosure comprise 3%-40%, 3%-30%, or 3%-65% CBC
content by
weight of the composition.
[92971 In some embodiments, the cannabinoid compositions of the present
disclosure comprise
more than about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%,
15%, 16%,
17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%,
32%, 33%,
34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%,
49%, 50%,
51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%,
66%, 67%,
68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%,
83%, 84%,
85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, or 98% CBC by
weight
of the composition while accumulating no more than 10%, 9%, 8%, 7%, 6%, 5%,
4%, 3%, 2%,
1%, 0.3% or 0.2% THC content by weight of the composition.
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
[02981 In some embodiments, the cannabinoid composition of the present
disclosure comprise
about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%,
17%, 18%,
19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%,
34%, 35%,
36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%,
51%, 52%,
53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%,
68%, 69%,
70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%,
85%, 86%,
87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% THCV by
weight of
the composition, and all ranges therebetween. Thus, in some embodiments, the
cannabinoid
compositions of the present disclosure comprise 3%-40%, 3%-30%, or 3%-65% THCV
content
by weight of the composition.
[02991 In some embodiments, the cannabinoid compositions of the present
disclosure comprise
more than about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%,
15%, 16%,
17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%,
32%, 33%,
34%, 35%, 36%, 37%, 38%, 39%, or 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%,
49%,
50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%,
65%, 66%,
67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%,
82%, 83%,
84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, or 98%
THCV
by weight of the composition while accumulating no more than 10%, 9%, 8%, 7%,
6%, 5%, 4%,
3%, 2%, 1%, 0.3% or 0.2% THC content by weight of the composition.
I0300i In some embodiments, the cannabinoid compositions of the present
disclosure produce
comprise about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%,
15%, 16%,
17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%,
32%, 33%,
34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%,
49%, 50%,
51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%,
66%, 67%,
68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%,
83%, 84%,
85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%
CBDV
by weight of the composition, and all ranges therebetween. Thus, in some
embodiments, the
cannabinoid compositions of the present disclosure comprise 3%-40%, 3%-30%, or
3%-25%
CBDV content by weight of the composition.
76
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
I0301j In some embodiments, the cannabinoid compositions of the present
disclosure comprise
more than about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%,
15%, 16%,
17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%,
32%, 33%,
34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%,
49%, 50%,
51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%,
66%, 67%,
68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%,
83%, 84%,
85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, or 98% CBDV
by
weight of the composition while accumulating no more than 10%, 9%, 8%, 7%, 6%,
5%, 4%, 3%,
2%, 1%, 0.3% or 0.2% THC content by weight of the composition.
193021 In some embodiments, the cannabinoid compositions of the present
disclosure comprise
about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%,
17%, 18%,
19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%,
34%, 35%,
36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%,
51%, 52%,
53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%,
68%, 69%,
70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%,
85%, 86%,
87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% CBCV by
weight of
the composition, and all ranges therebetween. Thus, in some embodiments, the
cannabinoid
compositions of the present disclosure comprise 3%-40%, 3%-30%, or 3%-65% CBCV
content
by weight of the composition.
103031 Thus, in some embodiments, the cannabinoid compositions of the present
disclosure
comprise more than about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%,
13%, 14%,
15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%,
30%, 31%,
32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%,
47%, 48%,
49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%,
64%, 65%,
66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%,
81%, 82%,
83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, or
98%
CBCV by weight of the composition while accumulating no more than 10%, 9%, 8%,
7%, 6%,
5%, 4%, 3%, 2%, 1%, 0.3% or 0.2% THC content by weight of the composition.
[0304] In some embodiments, the cannabinoid compositions of the present
disclosure produce
comprise organoleptically pleasing Terpene Profiles.
77
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
[03051 In some embodiments, the cannabinoid compositions of the present
invention has an
absolute content of any one of the 17 terpenes in the Terpene Profile that is
0%, 0.01%, 0.02%,
0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.11%, 0.12%, 0.13%,
0.14%, 0.15%,
0.16%, 0.17%, 0.18%, 0.19%, 0.2%, 0.21%, 0.22%, 0.23%, 0.24%, 0.25%, 0.26%,
0.27%, 0.28%,
0.29%, 0.3%, 0.31%, 0.32%, 0.33%, 0.34%, 0.35%, 0.36%, 0.37%, 0.38%, 0.39%,
0.4%, 0.41%,
0.42%, 0.43%, 0.44%, 0.45%, 0.46%, 0.47%, 0.48%, 0.49%, 0.5%, 0.51%, 0.52%,
0.53%, 0.54%,
0.55%, 0.56%, 0.57%, 0.58%, 0.59%, 0.6%, 0.61%, 0.62%, 0.63%, 0.64%, 0.65%,
0.66%, 0.67%,
0.68%, 0.69%, 0.7%, 0.71%, 0.72%, 0.73%, 0.74%, 0.75%, 0.76%, 0.77%, 0.78%,
0.79%, 0.8%,
0.81%, 0.82%, 0.83%, 0.84%, 0.85%, 0.86%, 0.87%, 0.88%, 0.89%, 0.9%, 0.91%,
0.92%, 0.93%,
0.94%, 0.95%, 0.96%, 0.97%, 0.98%, 0.99%, 1%, 1.01%, 1.02%, 1.03%, 1.04%,
1.05%, 1.06%,
1.07%, 1.08%, 1.09%, 1.1%, 1.11%, 1.12%, 1.13%, 1.14%, 1.15%, 1.16%, 1.17%,
1.18%, 1.19%,
1.2%, 1.21%, 1.22%, 1.23%, 1.24%, 1.25%, 1.26%, 1.27%, 1.28%, 1.29%, 1.3%,
1.31%, 1.32%,
1.33%, 1.34%, 1.35%, 1.36%, 1.37%, 1.38%, 1.39%, 1.4%, 1.41%, 1.42%, 1.43%,
1.44%, 1.45%,
1.46%, 1.47%, 1.48%, 1.49%, 1.5%, 1.51%, 1.52%, 1.53%, 1.54%, 1.55%, 1.56%,
1.57%, 1.58%,
1.59%, 1.6%, 1.61%, 1.62%, 1.63%, 1.64%, 1.65%, 1.66%, 1.67%, 1.68%, 1.69%,
1.7%, 1.71%,
1.72%, 1.73%, 1.74%, 1.75%, 1.76%, 1.77%, 1.78%, 1.79%, 1.8%, 1.81%, 1.82%,
1.83%, 1.84%,
1.85%, 1.86%, 1.87%, 1.88%, 1.89%, 1.9%, 1.91%, 1.92%, 1.93%, 1.94%, 1.95%,
1.96%, 1.97%,
1.98%, 1.99%, 2%, 2.01%, 2.02%, 2.03%, 2.04%, 2.05%, 2.06%, 2.07%, 2.08%,
2.09%, 2.1%,
2.11%, 2.12%, 2.13%, 2.14%, 2.15%, 2.16%, 2.17%, 2.18%, 2.19%, 2.2%, 2.21%,
2.22%, 2.23%,
2.24%, 2.25%, 2.26%, 2.27%, 2.28%, 2.29%, 2.3%, 2.31%, 2.32%, 2.33%, 2.34%,
2.35%, 2.36%,
2.37%, 2.38%, 2.39%, 2.4%, 2.41%, 2.42%, 2.43%, 2.44%, 2.45%, 2.46%, 2.47%,
2.48%, 2.49%,
2.5%, 2.51%, 2.52%, 2.53%, 2.54%, 2.55%, 2.56%, 2.57%, 2.58%, 2.59%, 2.6%,
2.61%, 2.62%,
2.63%, 2.64%, 2.65%, 2.66%, 2.67%, 2.68%, 2.69%, 2.7%, 2.71%, 2.72%, 2.73%,
2.74%, 2.75%,
2.76%, 2.77%, 2.78%, 2.79%, 2.8%, 2.81%, 2.82%, 2.83%, 2.84%, 2.85%, 2.86%,
2.87%, 2.88%,
2.89%, 2.9%, 2.91%, 2.92%, 2.93%, 2.94%, 2.95%, 2.96%, 2.97%, 2.98%, 2.99%,
3%, 3.2%,
3.4%, 3.6%, 3.8%, 4%, 4.2%, 4.3%, 4.4%, 4.6%, 4.8%, 5%, 5.2%, 5.4%, 5.6%,
5.8%, 6%, 6.2%,
6.4%, 6.6%, 6.8%, 7%, 7.2%, 7.4%, 7.6%, 7.8%, 8%, 9%, 10%, 11%, 12%, 13%, 14%,
15%, 16%,
17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%,
32%, 33%,
34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%,
49%, 50%,
51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60% or greater based on the
weight of
cannabinoid composition, including all ranges therebetween. Thus in some
embodiments the
78
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
absolute content of any one of the terpenes is between about 0.05% and about
5%. This paragraph
is intended to be read as applying to any specific terpene(s) in a Terpene
Profile, such that the
name of any one or two or more of these terpenes as specifically referred to
elsewhere herein (e.g.,
linalool) can replace the phrase "any one of the 17 terpenes in the Terpene
Profile."
[0306] In some embodiments, the cannabinoid compositions of the present
invention has an
absolute content of any one of the 17 terpenes in the Terpene Profile that is
greater than 0%, 0.01%,
0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.11%, 0.12%,
0.13%, 0.14%,
0.15%, 0.16%, 0.17%, 0.18%, 0.19%, 0.2%, 0.21%, 0.22%, 0.23%, 0.24%, 0.25%,
0.26%, 0.27%,
0.28%, 0.29%, 0.3%, 0.31%, 0.32%, 0.33%, 0.34%, 0.35%, 0.36%, 0.37%, 0.38%,
0.39%, 0.4%,
0.41%, 0.42%, 0.43%, 0.44%, 0.45%, 0.46%, 0.47%, 0.48%, 0.49%, 0.5%, 0.51%,
0.52%, 0.53%,
0.54%, 0.55%, 0.56%, 0.57%, 0.58%, 0.59%, 0.6%, 0.61%, 0.62%, 0.63%, 0.64%,
0.65%, 0.66%,
0.67%, 0.68%, 0.69%, 0.7%, 0.71%, 0.72%, 0.73%, 0.74%, 0.75%, 0.76%, 0.77%,
0.78%, 0.79%,
0.8%, 0.81%, 0.82%, 0.83%, 0.84%, 0.85%, 0.86%, 0.87%, 0.88%, 0.89%, 0.9%,
0.91%, 0.92%,
0.93%, 0.94%, 0.95%, 0.96%, 0.97%, 0.98%, 0.99%, 1%, 1.01%, 1.02%, 1.03%,
1.04%, 1.05%,
1.06%, 1.07%, 1.08%, 1.09%, 1.1%, 1.11%, 1.12%, 1.13%, 1.14%, 1.15%, 1.16%,
1.17%, 1.18%,
1.19%, 1.2%, 1.21%, 1.22%, 1.23%, 1.24%, 1.25%, 1.26%, 1.27%, 1.28%, 1.29%,
1.3%, 1.31%,
1.32%, 1.33%, 1.34%, 1.35%, 1.36%, 1.37%, 1.38%, 1.39%, 1.4%, 1.41%, 1.42%,
1.43%, 1.44%,
1.45%, 1.46%, 1.47%, 1.48%, 1.49%, 1.5%, 1.51%, 1.52%, 1.53%, 1.54%, 1.55%,
1.56%, 1.57%,
1.58%, 1.59%, 1.6%, 1.61%, 1.62%, 1.63%, 1.64%, 1.65%, 1.66%, 1.67%, 1.68%,
1.69%, 1.7%,
1.71%, 1.72%, 1.73%, 1.74%, 1.75%, 1.76%, 1.77%, 1.78%, 1.79%, 1.8%, 1.81%,
1.82%, 1.83%,
1.84%, 1.85%, 1.86%, 1.87%, 1.88%, 1.89%, 1.9%, 1.91%, 1.92%, 1.93%, 1.94%,
1.95%, 1.96%,
1.97%, 1.98%, 1.99%, 2%, 2.01%, 2.02%, 2.03%, 2.04%, 2.05%, 2.06%, 2.07%,
2.08%, 2.09%,
2.1%, 2.11%, 2.12%, 2.13%, 2.14%, 2.15%, 2.16%, 2.17%, 2.18%, 2.19%, 2.2%,
2.21%, 2.22%,
2.23%, 2.24%, 2.25%, 2.26%, 2.27%, 2.28%, 2.29%, 2.3%, 2.31%, 2.32%, 2.33%,
2.34%, 2.35%,
2.36%, 2.37%, 2.38%, 2.39%, 2.4%, 2.41%, 2.42%, 2.43%, 2.44%, 2.45%, 2.46%,
2.47%, 2.48%,
2.49%, 2.5%, 2.51%, 2.52%, 2.53%, 2.54%, 2.55%, 2.56%, 2.57%, 2.58%, 2.59%,
2.6%, 2.61%,
2.62%, 2.63%, 2.64%, 2.65%, 2.66%, 2.67%, 2.68%, 2.69%, 2.7%, 2.71%, 2.72%,
2.73%, 2.74%,
2.75%, 2.76%, 2.77%, 2.78%, 2.79%, 2.8%, 2.81%, 2.82%, 2.83%, 2.84%, 2.85%,
2.86%, 2.87%,
2.88%, 2.89%, 2.9%, 2.91%, 2.92%, 2.93%, 2.94%, 2.95%, 2.96%, 2.97%, 2.98%,
2.99%, 3%,
3.2%, 3.4%, 3.6%, 3.8%, 4%, 4.2%, 4.3%, 4.4%, 4.6%, 4.8%, 5%, 5.2%, 5.4%,
5.6%, 5.8%, 6%,
6.2%, 6.4%, 6.6%, 6.8%, 7%, 7.2%, 7.4%, 7.6%, 7.8%, 8%, 9%, 10%, 11%, 12%,
13%, 14%,
79
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%,
30%, 31%,
32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%,
47%, 48%,
49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60% based on weight
of
cannabinoid composition. This paragraph is intended to be read as applying to
any specific
terpene(s) in a Terpene Profile, such that the name of any one or two or more
of these terpenes as
specifically referred to elsewhere herein (e.g., linalool) can replace the
phrase "any one of the 17
terpenes in the Terpene Profile."
19307] In some embodiments, the cannabinoid compositions of the present
invention has 0.1%,
0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.1%, 1.2%, 1.3%, 1.4%,
1.5%, 1.6%,
1.7%, 1.8%, 1.9%, 2%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%,
3%, 3.1%, 3.2%,
3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%,
4.6%, 4.7%,
4.8%, 4.9%, 5%, 5.1%, 5.2%, 5.3%, 5.4%, 5.5%, 5.6%, 5.7%, 5.8%, 5.9%, 6%,
6.1%, 6.2%, 6.3%,
6.4%, 6.5%, 6.6%, 6.7%, 6.8%, 6.9%, 7%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5%, 7.6%,
7.7%, 7.8%,
7.9%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%,
23%,
24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%,
39%, 40%,
41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%,
56%, 57%,
58%, 59%, 60% terpene essential oil content by weight of the composition,
including all ranges
therebetween. Thus in some embodiments the essential oil content of the
cannabinoid
compositions of the present invention is between about 0.5% and about 30% by
weight of the
composition. In other embodiments the essential oil contents of the
cannabinoid compositions of
the present invention is between about 1.0% and about 25% by weight of the
composition.
[008j In some embodiments, the cannabinoid compositions of the present
invention has greater
than 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.1%, 1.2%,
1.3%, 1.4%, 1.5%,
1.6%, 1.7%, 1.8%, 1.9%, 2%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%,
2.9%, 3%, 3.1%,
3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4%, 4.1%, 4.2%, 4.3%, 4.4%,
4.5%, 4.6%,
4.7%, 4.8%, 4.9%, 5%, 5.1%, 5.2%, 5.3%, 5.4%, 5.5%, 5.6%, 5.7%, 5.8%, 5.9%,
6%, 6.1%, 6.2%,
6.3%, 6.4%, 6.5%, 6.6%, 6.7%, 6.8%, 6.9%, 7%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5%,
7.6%, 7.7%,
7.8%, 7.9%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%,
21%, 22%,
23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%,
38%, 39%,
40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%,
55%, 56%,
57%, 58%, 59%, or 60% terpene essential oil content by weight of the
composition.
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
[03091 In some embodiments, the terpene content of the cannabinoid
compositions of the present
disclosure is described in relative terms as a percentage composition of the
total Terpene Profile.
Thus for example a cannabinoid compositions with 1.2% absolute terpinolene
content and 1.2%
limonene content and no other terpenes in the Terpene Profile would said to
have 50% terpinolene
and 50% limonene relative content.
[0310] In some embodiments, the cannabinoid compositions of the present
invention has a relative
content of any one of the 17 terpenes in the Terpene Profile that is greater
than or less than 1%,
2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%,
19%,
20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%,
35%, 36%,
37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%,
52%, 53%,
54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%,
69%, 70%,
71%, 72%, 73%, 74%, 75%, 76%, 77%, 79%, 79%, 80%, 81%, 82%, 83%, 84%, 85%,
86%, 87%,
88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, including
any
ranges therebetween. Thus in some embodiments the relative content of any one
of the terpenes is
between 0% and 100%. This paragraph is intended to be read as applying to any
specific terpene(s)
in a Terpene Profile, such that the name of any of one or two or more these
terpenes as specifically
referred to elsewhere herein (e.g., linalool) can replace the phrase "any one
of the 17 terpenes in
the Terpene Profile."
[0311] In some embodiments, additional components are optionally added to the
cannabinoid
compositions of the present disclosure to improve the taste and/or physical
properties of the
composition (such as stability, viscosity, appearance of smoke as it is
inhaled, etc.). Such
additional components include, but are not limited to, sweeteners, natural
flavorants, artificial
flavorants, colorants, antioxidants, preservatives, chelating agents,
viscomodulators, tonicifiers,
odorants, opacifiers, suspending agents, binders, thickeners, carriers and
mixtures thereof,
including, but not limited to, xanthum gum, carboxymethylcellulose,
carboxyethylcellulose,
hydroxypropylcellulose, methylcellulose, microcrystalline cellulose, starches,
dextrins,
maltodextrins, other polyols (including sugar alcohols, such as sorbitol,
lactitol or mannitol),
carbohydrates (e.g., lactose), propylene glycol alginate, gellan gum, guar,
pectin, tragacanth gum,
gum acacia, locust bean gum, gum arabic, mannitol, sucralose, silicon dioxide,
stearic acid,
hydroxypropyl methylcellulose, mono-, di- and triglycerides (acyl glycerols),
ether and sugar
81
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
acetates or other acid esters such as dimethyl acetate, ethyl acetate,
isopropyl acetate, ethylhexyl
acetate, butyl acetate, triethyl citrate, dimethyl butyrate and the like.
103121 In some embodiments, the cannabinoid compositions of the present
disclosure comprise
one or more medium chain length triglycerides (MCTs). MCTs are triglycerides
whose fatty acids
have an aliphatic tail of 6-12 carbon atoms. In certain embodiments, the MCT
is one or more of
caproic acid, caprylic acid, capric acid, lauric acid and mixtures thereof.
Suitable sources of MCTs
are known to those skilled in the art and include, for example, coconut oil
and palm kernel oil.
103131 In some embodiments, the cannabinoid compositions of the present
disclosure comprise
one or more polyesterdiols. The polyesterdiol may be a linear two to ten units
polymer (also
referred to as (ester)2-10 glycol), that is derived from natural or non-
natural sources such as
vegetables, fruits, bacteria, yeast, algae, or manufactured by chemical
processes.
103141 For example, in some embodiments, the polyesterdiol is 1) a
polypropylene glycol such as:
dipropylene glycol; tripropylene glycol, including tetra-, penta-, hexa-,
hepta-, octa-, nona- and
decapropylene glycol and other derivatives thereof; 2) a polybutylene glycol
such as: dibutylene
glycol, tributylene glycol, including tetra-, penta-, hexa-, hepta-, octa-,
nona- and decabutylene
glycol, and other derivatives thereof; 3) also including 2-10 unit polymers of
rare organic ester
types such as pentylene, octylene, terpentylene, nonylene, linalylene,
isoamylene, isobutylene,
geranylene, bornylene, benzylene and allylene, caprylylene, such as, for
example, polyisobutylene
glycol such as diisobutylene glycol; and 4) triethylene glycol, including
tetra-, penta-, hexa-, hepta-
, octa-, nona- and decaethylene glycols and other derivatives thereof such as
acid or sugar
conjugates, and esters or ether or alcohol derivatives.
[03151 In some embodiments, the cannabinoid compositions of the present
disclosure comprise a
linear polyesterdiol selected from the group consisting of: (ethylene)3-10
glycol; (propylene)2-10
glycol; (butylene)2-10 glycol; (pentylene)2-10 glycol; (octylene)2-10 glycol;
(terpentylene)2-10
glycol; (nonylene)2-10 glycol; (linalylene)2-10 glycol; (isoamylene)2-10
glycol; (isobutylene)2-
glycol; (geranylene)2-10 glycol; (bornylene)2-10 glycol; (benzylene)2-10
glycol; (allylene)2-
10 glycol; and (caprylylene)2-10 glycol; acid or sugar conjugates thereof, and
ester or ether or
alcohol derivatives thereof.
[03161 In some embodiments, the cannabinoid compositions of the present
disclosure comprises
a carrier selected from the group consisting of: triethylene glycol;
tetraethyleneglycol,
82
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
pentaethylenglycol, hexaethyleneglycol,
heptaethyleneglycol, octaethyleneglycol,
nonaethylenglycol; decaethylene glycol; dipropylene glycol; tripropylene
glycol; tetrapropylene
glycol, pentapropylene glycol, hexapropylene glycol, heptapropylene glycol,
octapropylene
glycol, nonapropylene glycol; decapropylene glycol; dibutylene glycol,
tributylene glycol;
tetrabutylene glycol, pentabutylene glycol, hexabutylene glycol, heptabutylene
glycol,
octabutylene glycol, nonabutylene glycol, decabutylene glycol and
diisobutylene glycol.
[0317] In some embodiments, the carrier is selected from the group consisting
of borneol,
camphor, 1,8-Cineole, citral, geraniol, indomethacin, limonene, linalool,
linalyl acetate, 0-
myrcene, myrcenol, 1-menthol, menthone, neomenthol, nerol, nerolidol, a-
pinene, peppermint oil,
pulegone, phytol, terpineol, terpinen-4-ol, thymohydroquinone, thymol, and
thymoquinone
[0318j In some embodiments, the compositions of the present disclosure
comprise one or more of
propylene glycol, glycerine, vegetable glycerine, and/or water.
Cannabis Extracts
[03191 In some embodiments, the present disclosure provides for extracts from
Specialty Cannabis
plants. Cannabis extracts or products or the present disclosure include:
[03201 Kief- refers to trichomes collected from cannabis. The trichomes of
cannabis are the areas
of cannabinoid and terpene accumulation. Kief can be gathered from containers
where cannabis
flowers have been handled. It can be obtained from mechanical separation of
the trichomes from
inflorescence tissue through methods such as grinding flowers, or collecting
and sifting through
dust after manicuring or handling cannabis. Kief can be pressed into hashish
for convenience or
storage.
193211 Hash- sometimes known as hashish, is often composed of preparations of
cannabis
trichomes. Hash pressed from kief is often solid.
193221 Bubble Hash- sometimes called bubble melt hash can take on paste-like
properties with
varying hardness and pliability. Bubble hash is usually made via water
separation in which
cannabis material is placed in a cold water bath and stirred for a long time
(around 1 hour). Once
the mixture settles it can be sifted to collect the hash.
[0323i Solvent reduced oils- also sometimes known as hash oil, honey oil, or
full melt hash among
other names. This type of cannabis oil is made by soaking plant material in a
chemical solvent.
83
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
After separating plant material, the solvent can be boiled or evaporated off,
leaving the oil behind.
Butane Hash Oil is produced by passing butane over cannabis and then letting
the butane
evaporate. Budder or Wax is produced through isopropyl extraction of cannabis.
The resulting
substance is a wax like golden brown paste. Another common extraction solvent
for creating
cannabis oil is CO2. Persons having skill in the art will be familiar with CO2
extraction techniques
and devices, including those disclosed in US 20160279183, US 2015/01505455, US
9,730,911,
and US 2018/0000857. Other guidance on CO2 extractions of cannabinoids and
terpenes can be
found in Perrotin-Brunel et al. "Solubility of non-psychoactive cannabinoids
in supercritical
carbon dioxide and comparison with psychoactive cannabinoids" The Journal of
Supercritical
Fluids, 55(2010) 603-608; Rovetto and Aieta, "Supercritical carbon dioxide
extraction of
cannabinoids from Cannabis sativa L." The Journal of Supercritical Fluids 129
(2017) 16-27;
Porto and Natolino. "Separation of aroma compounds from industrial hemp
inflorescences
(Cannabis sativa L.) by supercritical CO2 extraction and on-line
fractionation" Industrial Crops
and Products 58 (2014) 99-103; US Pat. No. 6,403,126; US Pat No. 7,700,368;
and
U520030050334.
[03241 Tinctures- are alcoholic extracts of cannabis. These are usually made
by mixing cannabis
material with high proof ethanol and separating out plant material.
103251 E-juice- are cannabis extracts dissolved in either propylene glycol,
vegetable glycerin, or
a combination of both. Some E-juice formulations will also include
polyethylene glycol and
flavorings. E-juice tends to be less viscous than solvent reduced oils and is
commonly consumed
on e-cigarettes or pen vaporizers.
193261 Rick Simpson Oil (ethanol extractions)- are extracts produced by
contacting cannabis with
ethanol and later evaporating the vast majority of ethanol away to create a
cannabinoid paste. In
some embodiments, the extract produced from contacting the cannabis with
ethanol is heated so
as to decarboxylate the extract.
193271 In some embodiments, the Specialty Cannabis of the present invention is
extracted via
methods that preserve the cannabinoid and terpenes. In other embodiments, said
methods can be
used with any cannabis plants. The extracts of the present invention are
designed to produce
products for human or animal consumption via inhalation (via combustion,
vaporization and
nebulization), buccal absorption within the mouth, oral administration, and
topical application
84
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
delivery methods. The present invention teaches an optimized method at which
we extract
compounds of interest, by extracting at the point when the drying harvested
plant has reached 15%
water weight, which minimizes the loss of terpenes and plant volatiles of
interest. Stems are
typically still 'cool' and 'rubbery' from evaporation taking place. This
timeframe (or if frozen at
this point in process) allow extractor to minimize terpene loss to
evaporation. There is a direct
correlation between cool/slow/dry and preservation of essential oils. Thus,
there is a direct
correlation to EO loss in flowers that dry too fast, or too hot conditions or
simply dry out too much
(<10% H20).
I 0328] The chemical extraction of Specialty Cannabis can be accomplished
employing polar and
non-polar solvents in various phases at varying pressures and temperatures to
selectively or
comprehensively extract terpenes, cannabinoids and other compounds of flavor,
fragrance or
pharmacological value for use individually or combination in the formulation
of our products. The
extractions can be shaped and formed into single or multiple dose packages,
e.g., dabs, pellets and
loads. The solvents employed for selective extraction of our cultivars may
include water, carbon
dioxide, 1,1,1,2-tetrafluoroethane, butane, propane, ethanol, isopropyl
alcohol, hexane, and
limonene, in combination or series. We can also extract compounds of interest
mechanically by
sieving the plant parts that produce those compounds. Measuring the plant
part, i.e. trichome gland
head, to be sieved via optical or electron microscopy can aid the selection of
the optimal sieve pore
size, ranging from 30 to 130 microns, to capture the plant part of interest.
The chemical and
mechanical extraction methods of the present invention can be used to produce
products that
combine chemical extractions with plant parts containing compounds of
interest. The extracts of
the present invention may also be combined with pure compounds of interest to
the extractions,
e.g. cannabinoids or terpenes to further enhance or modify the resulting
formulation's fragrance,
flavor or pharmacology.
[03291 In some embodiments, the extractions are supplemented with terpenes or
cannabinoids to
adjust for any loss of those compounds during extraction processes. In some
embodiments, the
cannabis extracts of the present invention mimic the chemistry of the cannabis
flower material. In
some embodiments, the cannabis extracts of the present invention will about
the same cannabinoid
and Terpene Profile of the dried flowers of the Specialty Cannabis of the
present invention.
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
103301 Extracts of the present invention can be used for vaporization,
production of e-juice or
tincture for e-cigarettes, or for the production of other consumable products
such as edibles or
topical spreads.
Use of Specialty Cannabis and Cannabinoid Compositions in Edibles
I0331] Cannabis edibles such as candy, brownies, and other foods are a popular
method of
consuming cannabis for medicinal and recreational purposes. In some
embodiments, the Specialty
Cannabis of the present disclosure and/or the cannabinoid compositions of the
present disclosure
can be used to make cannabis edibles. Most cannabis edible recipes begin with
the extraction of
cannabinoids and terpenes, which are then used as an ingredient in various
edible recipes.
[03321 In one embodiment, the cannabis extract used to make edibles out of the
Specialty Cannabis
of the present invention is cannabis butter. Cannabis butter is made by
melting butter in a container
with cannabis and letting it simmer for about half an hour, or until the
butter turns green. The butter
is then chilled and used in normal recipes. Other extraction methods for
edibles include extraction
into cooking oil, milk, cream, flour (grinding cannabis and blending with
flour for baking). Lipid
rich extraction mediums/edibles are believed to facilitate absorption of
cannabinoids into the blood
stream. THC absorbed by the body is converted by the liver into 11-hydroxy-
THC. This
modification increases the ability of the THC molecule to bind to the CB1
receptor and also
facilitates crossing of the brain blood barrier thereby increasing the potency
and duration of its
effects. For additional information on various edibles that can be produced
with the Specialty
Cannabis of the present invention, please see (Sarah Conrique "The Vegan
Stoner Cookbook: 100
easy Vegan Recipes to Much" ISBN 1607744643; "Official High Times Cannabis
Cookbook"
ASIN BOOH137YI8U; Bliss Cameron "Marijuana Cooking: Good Medicine Made Easy"
ISBN
1931160325; Tim Pilcher "The Cannabis Cookbook: Over 35 Tasty Recipes for
Meals, Munchies,
and More" ISBN 0762430907).
[03331 Thus, in some embodiments, the present disclosure teaches edibles
produced from the
Specialty Cannabis and/or cannabinoid compositions disclosed herein.
[0334] This invention is further illustrated by the following examples, which
should not be
construed as limiting. The contents of all references, patents and published
patent applications
cited throughout this application, as well as the Figures and the Sequence
Listing, are incorporated
herein by reference.
86
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
EXAMPLES
Example 1. Chemical Analysis of Cannabinoids and Terpenes.
103351 Chemical analyses of the parental and progeny Specialty Cannabis
varieties of the present
disclosure, and of the cannabinoid compositions of the present disclosure,
were each carried out
using standard chemical separation and detection techniques well known to
those skilled in the
arts. Qualitative identification of cannabinoids and terpenes was carried out
by GCMS, while
quantitative analysis was done by GC-FID and/or HPLC-PDA (Photo Diode Array).
Initial field
analyses of cannabinoids was performed using thin layer chromatography as
described in
("Cannabis Inflorescence & Leaf QC" from The American Herbal Pharmacopeia
2013). The in-
house assays for cannabinoids included orthogonal methods of GC-FID and HPLC
for the highest
level of accuracy.
03361 Plant inflorescence samples were prepared by grinding ¨5 g of dried
cannabis flower
material in a coffee grinder. From this homogenized material, 1000 20 mg was
placed in a 50mL
falcon tube with ¨1 g of 2mm beads and 15 mL of working solution. Each sample
was placed in
the bead beater (1600 MiniG from Spex Sample Prep) and homogenized on high for
6 minutes.
Then approximately 2mL of each sample were transferred to 2mL centrifuge vials
and centrifuged
at 10000 g for 5 minutes. For samples suspected of having higher or lower
concentrations of
analytes the mass to volume ratio of the extraction could be adjusted. The
neat sample was placed
in a GC vial for terpene analysis without dilution. The supernatant was also
diluted with working
solution for GC and HPLC analysis. A 1:96 dilution provided the appropriate
concentration for
analysis of cannabinoids present at concentrations above 2.3%, while a 1:6
dilution allowed for
analysis of cannabinoids below this level.
i. Terpenoids by gas chromatography-flame ionization detector (GC-F1D)
I9337] Terpenes were quantified by a method developed on a GC-FID instrument
from Perkin
Elmer (Waltham, MA). It is recognized among analytical scientists that terpene
measurements
conducted via HPLC are unreliable, as HPLC is not effective at measuring
volatiles, such as
terpenes. This method separates and quantifies 17 different terpenoids
commonly found in
cannabis plant tissue. The terpenoids are each quantified by their own
individual calibration curves
generated with analytical reference standards (Sigma Aldrich) and all use n-
nonane as the internal
standard.
87
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
10338] The instrumentation includes a Clarus 680 gas chromatograph (GC)
equipped with an
autosampler, an Elite-5 column (Perkin Elmer (Waltham, MA), 30 m length, 0.25
mm internal
diameter, 0.25 lam thickness film diameter) and a flame ionization detector
(FID). Instrument
control and data acquisition and analyses was accomplished by TotalChrom
software version
1.2.3.4 (Perkin Elmer, Waltham, MA).
(9339i Calibration curves were generated by injecting each standard in
triplicate and the RSDs
provided the measure of precision while the absolute accuracy was determined
by comparing the
concentrations of the standards predicted by the calibration curve to their
"known" values
determined by dilution ratios. AOAC International standards for accuracy and
precision were used
as quality guidelines for every calibration. Check standards were run at the
start, middle, and end
of every analysis, and recalibration was performed when they varied more than
+1- 5% of their
initial average response. Levels that failed the acceptance criteria and
analytes were not quantified
at those levels until recalibration of the instrument corrected the
deficiency. Most of the curves
were linear to nearly two orders of magnitude and based on the sample mass
extracted (500 mg)
and the two possible extraction volumes (3x3 mL or 3x5mL), this provided
quantitation of terpene
levels from 0.01-0.9% or 0.02-1.5% (typical) in the plant matrix.
Cannabinoids by GC-FID
10340i Cannabinoids were quantified by an analytical method developed and run
on a Perkin
Elmer (Waltham, MA) GC-FID instrument as well. This method was developed to
separate six
neutral cannabinoids, CBD, CBG, CBN, THC, A8-THC, and CBC. The cannabinoids
are each
quantified by their own individual calibration curves generated with
analytical reference standards
(Restek) and all use tricosane as the internal standard. The retention time of
THCV was
determined by analyzing THVO1 (vide infra) by GCMS, however since analytical
standards were
not available it was "quantified" by referencing the calibration curve for
THC.
10341] There was no need to consider chromatographic separation of acidic
forms of the
cannabinoids due to their immediate conversion to neutral form in the heated
injector of the
instrument, although a thorough study of the conversion efficiency of THCA was
performed and
is discussed in section iv. (orthogonal analyses of all samples).
0342] The instrumentation includes a Clarus 680 gas chromatograph (GC)
equipped with an
autosampler, an Elite-1 column (Perkin Elmer (Waltham, MA), 30 m length, 0.25
mm internal
88
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
diameter, 0.25 pm thickness film diameter) and a flame ionization detector
(FID). Instrument
control and data acquisition and analyses was accomplished by TotalChrom
software version
1.2.3.4 (Perkin Elmer, Waltham, MA).
I9343] Calibration curves were generated by injecting each standard in
triplicate and the RSDs
provided the measure of precision while the absolute accuracy was determined
by comparing the
concentrations of the standards predicted by the calibration curve to their
"known" values
determined by dilution ratios. AOAC International standards for accuracy and
precision were used
as quality guidelines for every calibration. Check standards were run at the
start, middle, and end
of every analysis, and recalibration was performed when they varied more than
+/- 5% of their
initial average response. Levels that failed the acceptance criteria and
analytes were not quantified
at those levels until recalibration of the instrument corrected the
deficiency.
10344] Due to the very linear nature of the FID detector, the GC-FID
cannabinoid assay generally
provided satisfactory results over nearly two orders of magnitude (up to 1.0
mg/mL), however in
order to use the same calibration solutions and "validation" procedures for
both GC and HPLC the
range was reduced to that of the HPLC method. Based on the sample mass
extracted (500 mg)
and a 3x3mL extraction (low oil samples), a 1:3 dilution provided quantitation
of cannabinoid
levels from 0.09-1.35% and the 1:40 dilution from 1.15-18% in the plant
matrix. A 3x5mL
extraction (high oil samples, typical), a 1:3 dilution provided quantitation
of cannabinoid levels
from 0.14-2.25% and the 1:40 dilution from 1.9-30% in the plant matrix.
Cannabinoids by high performance liquid chromatography ¨ photo diode array
detector (HPLC-PDA)
03451 An HPLC-PDA (also known as HPLC-DAD, or simply HPLC) assay was developed
as an
orthogonal method to GC-FID for cannabinoid analyses. This method quantifies
six neutral
cannabinoids (CBD, CBG, CBN, THC, A8-THC, and CBC) as well as the acid
cannabinoids
THCA, CBDA and CBGA amongst other acidic cannabinoids, based on calibration
curves
generated with analytical standards and an internal reference standard
(ibuprofen).
193461 All HPLC analyses were performed using a Agilent 1290 System (Agilent
Technologies,
Santa Clara, CA). The HPLC system comprised G4212A diode array detector, a
G1316C
temperature controlled column compartment, a G4226A autosampler, and a G4204A
quaternary
pump. Separation of the cannabinoids was achieved on a Poroshell 120 EC- C18
column (2.7
89
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
150mm x 2.1mm i.d., PN 693775-902) with a Poroshell 120 EC-C18 guard column
(2.7 p,, 5mm
x 2.1mm i.d., PN 821725-911) in place (Agilent Technologies, Santa Clara, CA).
Instrument
control, data acquisition and integration was achieved with OpenLab CDS
ChemStation Rev
C.01.06 software (Agilent Technologies, Santa Clara, CA).
I 0317] Calibration was achieved by performing a five-point calibration curve
(0.016 ¨ 0.25mg/mL
for each analyte) followed by linear regression analysis. This analysis was
performed with
Microsoft Excel (Redmond, WA) software. The calibration curves were generated
by injecting
each standard in triplicate and the RSDs provided the measure of precision
while the absolute
accuracy was determined by comparing the concentrations of the standards
predicted by the
calibration curve to their "known" values determined by dilution ratios. AOAC
International
standards for accuracy and precision were used as quality guidelines for every
calibration. Check
standards were run at the start, middle, and end of every analysis, and
recalibration was performed
when they varied more than +/- 5% of their initial average response.
iv. Orthogonal analyses of all samples
[03481 The cannabinoid content was quantified by both GC-FID and EIPLC. The
main difference
between GC and EIPLC is that GC involves thermal stress and mainly resolves
analytes by boiling
points while EIPLC does not involve heat and mainly resolves analytes by
polarity. There are
several reasons that this orthogonal approach to analyses is desirable for
highly accurate and
reproducible results in determining chemotype. The first reason is related to
the difference between
the cannabinoids produced naturally by the plant (the acidic cannabinoids) and
those that are
bioactive (the neutral cannabinoids). Cannabis biosynthesizes all the
cannabinoids in their
relatively unstable acidic forms, and these forms are generally not bioactive
in the traditional sense.
The application of heat (flame, vaporizer, oven, etc.) causes a loss of the
carboxylic acid group
and generates the neutral forms of the cannabinoids, which are generally the
bioactive forms that
are sought after, however this process is highly variable and not
quantitative. If one wants to know
the native phytochemical profile of the plant then EIPLC should be used since
this assay does not
involve heat. If one wants to know the possible available amount of bioactive
cannabinoids, then
GC should be used since conversion to these forms in the injector of the GC is
an inherent part of
the analytical method.
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
103491 The second reason is also related to the difference between the acidic
and neutral
cannabinoids, but has to do with the availability of analytical standards to
calibrate the instruments.
While all of the neutral cannabinoids (THC, CBG, CBC, CBD, and CBN) are
available as
analytical standards, THCA is the only acidic cannabinoid available as an
analytical standard and
the instruments were only calibrated for quantification using actual
analytical standards.
Technically the HPLC assay could characterize the naturally occurring
chemotypes, but the acidic
analytes are not available as standards, so this quantification is approximate
and considered for
information only. The acidic analytes are all quantified by reference to the
calibration curve for
THCA, and this is not an unreasonable assumption as many of them have
approximately the same
spectral properties. The GC assay is calibrated with analytical standards, but
these are the neutral
cannabinoids and their formation from the naturally occurring acidic
cannabinoids in the GC
injector is not quantitative, which complicates exact characterization of the
naturally occurring
chemotype.
103501 The final reason is simply to have an internal crosscheck of our
results by using orthogonal
testing methods. Each type of assay (GC and HPLC) has its strengths and
weaknesses, and by
using both methods, one can compare results and ensure that both the
identification and
quantitation of the components are accurate. A caveat to this, as mentioned
above, is that the
conversion of the acidic forms to the neutral forms is not quantitative due to
thermal degradation.
Under the highly optimized conditions of a GC injector, we have found
conversion can vary
between 75-85% (for analytical THCA standards), while cannabis samples
generally have a
conversion of 70-80%. Similar conversion rates are also described in
literature for highly
optimized analytical instruments (Dussy et al. 2004). Because of this
incomplete conversion our
GC results are consistently 20-30% lower than the HPLC results for cannabis
samples. This same
conversion efficiency can be applied to estimate the maximum availability of
THC based on
THCA content when smoking or vaporizing cannabis.
v. Method "validation"
R13511 Method validation is important in establishing that a method is fit for
its intended purpose,
providing assurance that the results that are reported are precise, accurate,
and reflective of the
sample. Very few labs in the cannabis industry attempt to validate their
assays and this fact,
combined with inappropriate sampling have resulted in erroneous data for
several varieties. In
91
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
order to validate the analytical methods employed for this project, an
abbreviated protocol similar
to Single Laboratory Validation (SLV) was carried out. Assay "validation" was
carried out by
spiking blank matrix with the analytes at low, med, and high concentrations
and carrying out the
assay procedure in replicate (n=5). While some analytes provided better
results than others the
analyte RSDs, recoveries, and precisions at these concentrations satisfied
AOAC guidance (based
on mg/mL). In general, the RSDs for the terpenes at the low, medium, and high
concentrations
(varied by terpene but generally 0.016, 0.125, and 1.0 mg/mL) were less than
5%, 4%, and 3%
respectively. The absolute bias for these analytes was generally less than
10%, 4%, and 2%. In
general the RSDs for the cannabinoids by both GC and HPLC at the low, medium,
and high
concentrations (0.016, 0.61, and 0.250 mg/mL) were less than 2%, 2%, and 1%
respectively. The
absolute bias for these analytes was generally less than 10%, 2%, and 2%. The
assays all provided
satisfactory S/N ratios at the lowest level and this was initially taken as
the LOQ. After subsequent
re-calibrations (n=3 at each level), the LOQ was taken as the lowest level of
the calibration curve
that provided acceptable accuracy (<10% error) determined by comparing the
known
concentration levels (determined by dilution ratios) to the predicted levels
(obtained from the
signal and calibration curve).
[0352] The error between the known and measured values establishes the
accuracy of the method
and verifies that real samples do not present any matrix effects that
influence the resulting
measurements. The precision, or closeness of individual measurements, of the
method is also
determined by carrying out all analyses in replicate (n=5). Guidance for
acceptable values was
taken from publications provided by the AOAC.
I9353 I The in-house validation revealed that the above-described chemical
analysis methods were
accurate and reliable, and the use of orthogonal methods of analyses provided
an internal check on
the assays as well as an understanding of the use of GC to analyze thermally
unstable molecules.
Using multiple dilution ratios kept samples in the linear ranges of the
assays, and method validation
verified that precise and accurate results were obtained. Similar methods for
analyzing
cannabinoids and terpenes are also discussed I Giese et al. "Development and
Validation of a
Reliable and Robust Method for the Analysis of Cannabinoids and Terpenes in
Cannabis" Journal
of AOAC International Vol. 98 No. 6, 2015, incorporated herein by reference.
See also US Patent
Application No. 15/539,344, which is hereby incorporated by reference.
92
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
Example 2. Volunteer trials using high propyl cannabinoid hemp. (PROPHETIC).
[93541 In order to demonstrate the added utility of the high propyl
cannabinoid Specialty Cannabis
hemp varieties of the present invention, volunteer comparison trials will
conducted. During these
trials, volunteers will be provided with cannabis blends with varying terpene
and cannabinoid
profiles to determine the effect of Specialty Cannabis with higher propyl
content.
[03551 The volunteer trial for higher propyl content hemp will be conducted
over 2 weeks.
Volunteers will be split into six groups (1-6). Each volunteer in the group
will be given two
samples (a control and a comparator blend). In this trial, the control
comparator blends will be
prepared to contain nearly identical levels of a non-propyl cannabinoids (e.g.
THC, and/or CBD),
but each week the comparator will be formulated so as to include different
levels of THCV and/or
CBDV added (e.g., either 2%, 5%, or 7.5% CBDV added in).
103561 Thirty volunteers will be recruited and asked to fill out surveys
inquiring about the
experience of smoking/vaporizing each sample. Surveys will also ask volunteers
questions related
to their physiological response to the sample. An example of the type of
questionnaire that will be
used is shown in Figure 2.
Example 3. Volunteer trials using high propyl cannabinoid compositions.
(PROPHETIC).
10357] Volunteer comparison trials will be conducted to determine the effect
of increased propyl
cannabinoid content in cannabis compositions with no more than 0.3% THC
contents. Volunteer
trials will be conducted in similar fashion to those of Example 2.
103581 Briefly, each volunteer in the group will be given two composition
samples (a control and
a comparator blend). The samples will be provided in single-use e-cigarettes
or in tinctures
designed to be vaporized or administered to the mucosa/swallowed,
respectively. In this trial, the
control comparator compositions will be prepared to contain nearly identical
levels of a non-
propyl cannabinoid (e.g. THC, and/or CBD), but each week the comparator will
be formulated so
as to include different levels of a propyl cannabinoid added (e.g., either 2%,
5%, or 7.5% CBDV
added in).
[0359] Thirty volunteers will be recruited and asked to fill out surveys
inquiring about the
experience of smoking each sample. Surveys will also ask volunteers questions
related to their
93
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
physiological response to the sample. An example of the type of questionnaire
that will be used is
shown in Figure 2.
Example 4. Analysis of Parental Varieties
103601 One objective of the inventions of the present disclosure was to
develop cannabis varieties
accumulating high levels of propyl cannabinoids with no more than 0.3% or 0.2%
THC content.
This goal was achieved through a multi-pronged cannabis breeding program that
utilized existing
public and proprietary cannabis lines to produce novel cannabis germplasms
exhibiting high levels
of propyl cannabinoids, with no more than 0.3% or 0.2% THC content across
varied genetic and
phenotypic backgrounds.
[0361.1 As an initial step, the cannabinoid profiles of each parental line was
determined using
HPLC as described in Example 1. The resulting measurements of the initial
parental lines are
summarized in Table 3. All of the initial parental lines exhibited either only
trace amounts of
propyl cannabinoid content, or accumulated greater than 0.3% THC content.
Table 3 also reports
the cannabinoid contents of several intermediate filial generations generated
during each breeding
scheme that were used as parents for the final progeny lines.
94
Table 3 Cannabinoid Contents of Parental and Partial Intermediate Filial
Lines.
3
0
4 .5
7t'
t
THVO1
0.92% 0.72%
0.08%0.00%0.27%0.08%0.00%0.23%0.04%0.00%0.00%0.04%0.00%0.00%0.00%0.00%1.03%0.34
%
CBD05.S1-P24
0.53% 15.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
0.58%0.08%0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.47% 0.00%
V24
2.66% 7.37%
0.43%0.00%0.43%0.76%0.00%0.00%0.00%0.00%0.00%0.09%0.00%0.00%0.00%0.00%2.33%1.12
%
V24.S1.N5
4.05% 0.00%
0.60%0.00%3.47%0.00%0.00%0.14%0.00%0.00%0.00%0.08%0.00%0.00%0.00%0.00%3.70%3.08
%
V24.S1.03
0.17% 4.97%
0.14%0.00%0.14%2.65%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.15%2.41
%
V24.S1.P09X09.S1.01 2.71% 8.16%
0.49%0.00%2.12%4.03%0.00%0.19%0.14%0.07%0.00%0.09%0.00%0.00%0.00%0.00%2.57%5.41
%
03.S2.01
0.21% 5.45%
0.09%0.00%0.22%4.10%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.18%3.74
%
03.S2.16X09.S1.01 0.25% 6.35%
0.33%0.00%0.17%3.18%0.00%0.00%0.09%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.22%2.90
%
09.S1.01X09.S1.01 6.44% 14.09% 1.00%0.00% 1.41% 1.72% 0.00% 0.16%0.12%
0.07%0.00% 0.00%0.00% 0.00% 0.00% 0.00%5.81%2.71%
*All Max values were calculated based on theoretical maximum formulas
disclosed in this application. N/A indicates that the
cannabinoid was not tested. Total Max Propyl Cannabinoids reflects the
additive content of decarboxylated equivalents of THCVA,
THCV, CBDVA, CBDV, CBGVA, and CBGV as defined in earlier sections of this
document. 1-d
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
Example 5. Breeding of Specialty Cannabis
193621 One objective of the inventions of the present disclosure was to
develop cannabis varieties
accumulating high levels of propyl cannabinoids with no more than 0.3% or 0.2%
THC content.
In some embodiments, the Specialty Cannabis varieties of the present invention
were additionally
selected for their ability to produce terpenes that are appealing to patients
and that may also provide
a pharmacological activity that modifies, enhances or ameliorates the effects
of the cannabinoids.
Thus, a secondary objective of the breeding programs of the present disclosure
was to produce
plants with high terpene oil content and diverse Terpene Profiles.
103631 In order to achieve these objectives, the parental cannabis varieties
of Example 4 were
incorporated into a multi-pronged cannabis breeding program to develop
Specialty Cannabis plants
and varieties. Figures 3-8 depict the breeding schemes for six exemplary
independently produced
high propyl hemp varieties of the present disclosure.
10364j The breeding schemes of Figures 3-8 were designed to increase propyl
cannabinoid
production in hemp cannabis lines. These schemes resulted in novel cannabis
hemp varieties
exhibiting 10-100X propyl cannabinoid contents of the parental lines. In some
instances, the
resulting progeny also exhibited high oil contents and varied terpene
phenotypes.
103651 The present disclosure envisions further crosses from those described
in Figures 3-8. In
one representative version of this breeding regime the resultant Fl progeny
from the crosses of
any one of Figures 3-8, or Tables 5-18 can be selfed to bulk up F2 seed. In
some embodiments,
the F2 seed will be used for biological deposit.
10366] F2 seed can further be grown to produce F2 progeny. Selection for
desirable phenotypes
and/or genotypes can be conducted within the Fl, F2, or subsequent progeny
since the selections
can be maintained (i.e., fixed) via asexual reproduction. Alternatively, the
F2 progeny can be
crossed among themselves to produce a bulked F3 population from which desired
progeny can be
selected and/or further generations of crossing can be conducted. Again,
selected F2 progeny can
be maintained (i.e., fixed) via asexual reproduction. In another embodiment,
the resultant Fl
progeny can by backcrossed to high propyl cannabinoid parent or a hemp variety
to further
reinforce the traits of other parent. In some embodiments, the cannabinoid and
terpene
components of Specialty Cannabis hemp lines of the present disclosure can be
maintained by
extracting the cannabinoid and terpene contents. In some embodiments, the
resulting extract will
96
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
mimic the cannabinoid and terpene contents of the plant/inflorescence. In some
embodiments,
extracts of the present disclosure can be stored indefinitely.
103671 According to the present invention, the lines can also be further
selected for a specific
content of certain other cannabinoids and/or of certain terpenes/terpenoids,
and/or for additional
phenotypic and genotypic characteristics. Desirable phenotypic characteristics
include but are not
limited to larger plant size (i.e., greater bulk or biomass), higher
production of flower buds, larger
flowers, more trichomes, shorter plant stature, ability to tolerate lower
and/or higher growing
temperatures, greater germination percentage, greater seedling vigor, more
efficient water usage,
disease resistance, pest resistance, and other desirable agronomic and
production traits. For an
overview of diseases and pests of importance to cannabis production see Clarke
et al. (2000) Hemp
Diseases and Pests: Management and Biological Control. An Advanced Treatise
(CABI
Publishing).
103681 The progeny resulting from any selection stage of either the crosses
described in Figures
3-8, or any of the described selfing, sib crosses, or backcrossing versions of
the breeding regimes
of the present invention can be asexually reproduced so as to fix and maintain
the desirable content,
propyl cannabinoid content, low THC content, the aroma and flavor(s) typical
of the desired class,
and the other desirable phenotypic and/or genotypic characteristics. The
resultant selected lines
will be designated as Specialty Cannabis Varieties.
[0369] The resultant Specialty Cannabis plants of the present invention also
generally have more
terpene essential oil content per plant than contemporary hemp varieties. More
terpene essential
oil per plant means less plant matter is required per
treatment/administration, thereby also further
minimizing any health risks for medical and recreational cannabis
smokers/consumers. This would
also further increase production efficiency.
Example 6. Chemical Analysis of Specialty Cannabis
19370] The new Specialty Cannabis varieties created through crosses as
described in Example 5
were subjected to cannabinoid and terpene chemical analysis as described in
Example 1. The
resulting breeding schemes of Example 5 produced six separate lines of high
propyl cannabinoid
Specialty Cannabis hemp germplasm (03.52.01X09.S1.01,"03.S2.16X09.S1.01,'
'012.09.10X09.S1.01,' `V24.S1.P09X09.S1.01,' `V24.52.26X09.S1.01,'
and
'09.S1.01X09.S1.01'). The level of cannabinoids of several plants within each
of the high propyl
97
CA 03085010 2020-06-05
WO 2019/113574
PCT/US2018/064704
cannabinoid lines was measured by HPLC, and is presented across Tables 5-10.
Terpenes for
several plants within each of the high propyl cannabinoid lines were measured
using GC-FID, and
are presented as absolute content measurements based on the percent content by
weight of dry
inflorescences in Tables 11-13. A summary table of representative plants from
each of the high
propyl cannabinoid hemp lines is presented in Table 4.
Table 4. Representative Plants from the High propyl Cannabinoid Specialty
Cannabis Hemp
Lines of the Present Disclosure
Propyl
High Propyl Line Cannabinoid THC max Genotype
Dominant
Terpenes
Max
'03.S2.01X09.S1.01' Bo/BD or
4.44% 0.00% BD/BD
(NCIMB 43258)
'03.S2.16X09.S1.01' Bo/BD or
3.86% 0.00% BD/BD
(NCIMB 43259)
'012.09.10X09.S1.01'
4.74% 0.00% Bo/BD or
(NCIMB 43260) BD/BD
IV24.S1.P09X09.S1.01' 3.97% 0.00% BT/BD, Bo/BD
or BD/BD
IV24.S2.26X09.S1.01' 4.83% 0.00% BT/BD, Bo/BD
or BD/BD
'09.S1.01X09.S1.01' 5.60% 0.00% Bo/BD or
BD/BD
98
Table 5 Cannabinoid Contents of Plants from the ' 03.S2.01x09.S1.01' Line
c.) c..7 c-)
c= E-1
Q"
03 S201.09S101.06-0.044362824 0.00%3 .78% 0.00%0.00% 0.00%5.12%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%7.75% 0.00%4.44%
03 S201.09S101.01-0.043227316 0.00%3.75% 0.00%0.00% 0.00%4.99%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%7.61% 0.00%4.32%
03 S201.09S101.12-0.042837256 0.00%3 .27% 0.00%0.00% 0.00%4.94%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%7.15% 0.00%4.28%
03 S201.09S101.35-0.041173 0.00%3.23% 0.00%0.00% 0.00%4.75%0.00% 0.00%0.00%
0.00% 0.00%0.00% 0.00%0.00% 0.00% 0.00% 6.95% 0.00%4.12%
03 S201.09S101.48-0.035876852 0.00%3.62% 0.00%0.00% 0.00%4.14%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%6.77% 0.00%3.59%
03 S201.09S101.30-0.037783812 0.00%3.40% 0.00%0.00% 0.00%4.36%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%6.76% 0.00%3.78%
03 S201.09S101.19-0.033770528 0.00%3.33% 0.00%0.00% 0.00%3.90%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%6.29% 0.00%3.38%
03 S201.09S101.41-0.036110888 0.00%2.94% 0.00%0.00% 0.00%4.17%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%6.19% 0.00%3.61%
03 S201.09S101.44-0.036856336 0.00%2.84% 0.00%0.00% 0.00%4.25%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%6.17% 0.00%3.69%
03 S201.09S101.37-0.037411088 0.00%2.69% 0.00%0.00% 0.00%4.32%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%6.10% 0.00%3.74%
03 S201.09S101.22-0.034039236 0.00%2.98% 0.00%0.00% 0.00%3.93%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%6.02% 0.00%3.40%
03 S201.09S101.04-0.035807508 0.00%2.71% 0.00%0.00% 0.00%4.13%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%5.96% 0.00%3.58%
03 S201.09S101.16-0.038607272 0.00%2.35% 0.00%0.00% 0.00%4.45%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%5.92% 0.00%3.86%
03 S201.09S101.15-0.031906908 0.00%3.05% 0.00%0.00% 0.00%3.68%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%5.87% 0.00%3.19%
03 S201.09S101.03-0.035088064 0.00%2.65% 0.00%0.00% 0.00%4.05%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%5.83% 0.00%3.51%
03 S201.09S101.42-0.032791044 0.00%2.70% 0.00%0.00% 0.00%3.78%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%5.65% 0.00%3 .28%
03 S201.09S101.46-0.033406472 0.00%2.60% 0.00%0.00% 0.00%3.85%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%5.62% 0.00%3 .34%
03 S201.09S101.25-0.03449864 0.00%2.42% 0.00%0.00% 0.00%3.98%0.00% 0.00%0.00%
0.00% 0.00%0.00% 0.00%0.00% 0.00% 0.00% 5.57% 0.00%3.45%
ci)
03 S201.09S101.05-0.031412832 0.00%2.77% 0.00%0.00% 0.00%3.62%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%5.57% 0.00%3.14%
oe
03 S201.09S101.08-0.032236292 0.00%2.65% 0.00%0.00% 0.00%3.72%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%5.55% 0.00%3 .22%
03 S201.09S101.36-0.03198492 0.00%2.65% 0.00%0.00% 0.00%3.69%0.00% 0.00%0.00%
0.00% 0.00%0.00% 0.00%0.00% 0.00% 0.00% 5.52% 0.00%3.20%
03 S201.09S101.26-0.031014104 0.00%2.76% 0.00%0.00% 0.00%3.58%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%5.52% 0.00%3.10%
C-) C-) C.) A c..7
C-) .. C=
0 3 S201.09S101.16-0.03614556 0.07%
1.95%0.00%0.08%0.20%3.98%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%5.46
%0.06%3.61%
03 S201.09S101.23-0.03302508 0.00%2.46% 0.00%0.00% 0.00%3.81%0.00% 0.00%0.00%
0.00% 0.00%0.00% 0.00%0.00% 0.00% 0.00% 5.46% 0.00%3.30%
03 S201.09S101.27-0.033103092 0.00%2.45% 0.00%0.00% 0.00%3.82%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%5.46% 0.00%3 .31%
03 S201.09S101.07-0.034307944 0.00%2.29% 0.00%0.00% 0.00%3.96%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%5.44% 0.00%3 .43%
03 S201.09S101.10-0.030606708 0.00%2.70% 0.00%0.00% 0.00%3.53%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%5.43% 0.00%3 .06%
03 S201.09S101.17-0.03129148 0.00%2.54% 0.00%0.00% 0.00%3.61%0.00% 0.00%0.00%
0.00% 0.00%0.00% 0.00%0.00% 0.00% 0.00% 5.36% 0.00%3.13%
03 S201.09S101.45-0.029479868 0.00%2.70% 0.00%0.00% 0.00%3.40%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%5.32% 0.00%2.95%
03 S201.09S101.28-0.031915576 0.00%2.37% 0.00%0.00% 0.00%3.68%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%5.27% 0.00%3.19%
L.
03 S201.09S101.02-0.029809252 0.00%2.47% 0.00%0.00% 0.00%3.44%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%5.14% 0.00%2.98%
03 S201.09S101.20-0.029349848 0.00%2.51% 0.00%0.00% 0.00%3.39%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%5.14% 0.00%2.93%
03 S201.09S101.34-0.027893624 0.00%2.49% 0.00%0.00% 0.00%3.22%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%4.97% 0.00%2.79%
0
03 S201.09S101.40-0.029003128 0.00%2.34% 0.00%0.00% 0.00%3.35%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%4.96% 0.00%2.90%
03 S201.09S101.09-0.029939272 0.00%2.23% 0.00%0.00% 0.00%3.45%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%4.95% 0.00%2.99%
03 S201.09S101.32-0.030719392 0.00%2.05% 0.00%0.00% 0.00%3.54%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%4.87% 0.00%3.07%
03 S201.09S101.18-0.028656408 0.00%2.13% 0.00%0.00% 0.00%3.31%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%4.73% 0.00%2.87%
03 S201.09S101.14-0.027616248 0.00%2.11% 0.00%0.00% 0.00%3.19%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%4.62% 0.00%2.76%
03 S201.09S101.21-0.027503564 0.00%2.07% 0.00%0.00% 0.00%3.17%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%4.56% 0.00%2.75%
03 S201.09S101.39-0.02765092 0.00%
1.97%0.00%0.00%0.00%3.19%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%4.50
%0.00%2.77%
03 S201.09S101.11-0.025899984 0.00%2.13% 0.00%0.00% 0.00%2.99%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%4.45% 0.00%2.59% 1-3
03 S201.09S101.33-0.028483048 0.00% 1.80% 0.00%0.00% 0.00%3.29%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%4.42% 0.00%2.85% ci)
03 S201.09S101.38-0.02674078 0.00%
1.91%0.00%0.00%0.00%3.09%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%4.35
%0.00%2.67%
oe
03 S201.09S101.24-0.024114376 0.00%2.13% 0.00%0.00% 0.00%2.78%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%4.28% 0.00%2.41% CB;
03 S201.09S101.43-0.025189208 0.00% 1.80% 0.00%0.00% 0.00%2.91%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%4.10% 0.00%2.52%
4
0
E. E.
c.)
03S201.09S101.31-0.024157716 0.00% 1.83% 0.00%0.00% 0.00%2.79%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%4.02% 0.00%2.42%
03S201.09S101.13-0.022476124 0.00% 1.74% 0.00%0.00% 0.00%2.59%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%3 .77%0.00%2.25%
03S201.09S101.29-0.021635328 0.00% 1.74% 0.00%0.00% 0.00%2.50%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%3.69% 0.00%2.16%
03S201.09S101.47-0.021696004 0.00% 1.24% 0.00%0.00% 0.00%2.50%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%3 .25% 0.00%2.17%
*All Max values were calculated based on theoretical maximum formulas
disclosed in this application. Total Max Propyl Cannabinoids
reflects the additive content of decarboxylated equivalents of THCVA, THCV,
CBDVA, CBDV, CBGVA, and CBGV as defined in
earlier sections of this document.
'80
Table 6 Cannabinoid Contents of Plants from the ' 03.S2.16X09.S1. 01' Line
0
c
I.)
pp pp pp
t
M E-1
0 3 S216.09S101.02-0.03861594 0.00%4.73% 0.00%0.00% 0.00%4.46%0.00% 0.00%0.00%
0.00% 0.00%0.00% 0.00%0.00% 0.00% 0.00% 8.01% 0.00%3.86%
03 S216.09S101.09-0.043969184 0.12%3.36% 0.17%0.14% 0.22%4.67%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.16%0.00%0.00% 0.00%7.72% 0.11%4.40%
03 S216.09S101.07-0.037307072 0.00%4.39% 0.00%0.00% 0.00%4.30%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%7.58% 0.00%3.73%
03 S216.09S101.09-0.045585012 0.00%3.39% 0.00%0.00% 0.00%5.26%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%7.53% 0.00%4.56%
03 S216.09S101.08-0.0430452880.00%3.29% 0.00%0.00% 0.00%4.97%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%7.19% 0.00%4.30%
03 S216.09S101.25-0.0307714 0.00% 4.01%0.00%0.00% 0.00% 3.55%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%6.59% 0.00%3.08%
03 S216.09S101.18-0.034385956 0.00%3.41% 0.00%0.00% 0.00%3.97%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%6.43% 0.00%3.44%
03 S216.09S101.16-0.0345939880.00%3.30% 0.00%0.00% 0.00%3.99%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%6.35% 0.00%3.46%
03 S216.09S101.01-0.037870492 0.00%2.91% 0.00%0.00% 0.00%4.37%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%6.34% 0.00%3.79%
03 S216.09S101.24-0.028977124 0.00%3 .86% 0.00%0.00% 0.00%3.34%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%6.28% 0.00%2.90%
03 S216.09S101.13-0.033319792 0.00%3.29% 0.00%0.00% 0.00%3.84%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%6.21% 0.00%3.33%
03 S216.09S101.17-0.0301733080.00%3.56% 0.00%0.00% 0.00%3.48%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%6.14% 0.00%3.02%
03 S216.09S101.32-0.034264604 0.00%3.01% 0.00%0.00% 0.00%3.95%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%6.07% 0.00%3.43%
03 S216.09S101.26-0.03289506 0.00%3.13% 0.00%0.00% 0.00%3.80%0.00% 0.00%0.00%
0.00% 0.00%0.00% 0.00%0.00% 0.00% 0.00% 6.04% 0.00%3.29%
03 S216.09S101.14-0.031828896 0.00%3.21% 0.00%0.00% 0.00%3.67%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%6.00% 0.00%3.18%
03 S216.09S101.03-0.036726316 0.00%2.38% 0.00%0.00% 0.00%4.24%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%5.76% 0.00%3 .67%
03 S216.09S101.11-0.0309100880.00%3.01% 0.00%0.00% 0.00%3.57%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%5.73% 0.00%3.09%
03 S216.09S101.29-0.0273128680.00%3.37% 0.00%0.00% 0.00%3.15%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%5.68% 0.00%2.73%
ci)
03 S216.09S101.47-0.028535056 0.00%3.19% 0.00%0.00% 0.00%3.29%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%5.66% 0.00%2.85%
oe
03 S216.09S101.23-0.03332846 0.00%2.52% 0.00%0.00% 0.00%3.85%0.00% 0.00%0.00%
0.00% 0.00%0.00% 0.00%0.00% 0.00% 0.00% 5.54% 0.00%3.33%
03 S216.09S101.36-0.029618556 0.00%2.87% 0.00%0.00% 0.00%3.42%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%5.48% 0.00%2.96%
03 S216.09S101.38-0.028197004 0.00%3.01% 0.00%0.00% 0.00%3.25%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%5.46% 0.00%2.82%
CA 03085010 2020-06-05
WO 2019/113574
PCT/US2018/064704
*s1
luu"3 Vdma (-5)) cc.2
c,-,Nc,NNNNNNNNNNNNN.NN,--;N,--;,--;
*irtu Jai o = o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
*sal/NAND g 4 g 4
IVIOT C C N C 1- N N c:" 00 N
DILL-sa
c7; c7; c7; c7; c7; c7; c7; c7; c7; c7; c7; c7; c7; c7; c7; c7; c7; c7; c7;
c7; c7; c7; c7;
NED o = o
o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
AOED o = o
o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
MIED o = o
o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o
ADIII o = o
o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
DED o = o
o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
OED o = o
o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
QED o = o
o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o
o o o o o o o
3111 o = o
o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
VADED o = o
o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
VMIED o N N 71- No N oC N C Ccn
o
VADILL o = o
o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o
VDED o = o
co o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
VOED o = o
N o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
VaED C N 1- o co 71- o o o 71- 71-
NNNN
VDILL o = o
o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
71- 71- co co co 71- co 71- 71- NC N co
71-
N 0 0 0 0 0 ..C) 00 71- N N c,õ c,õ 71-
N N 71- 71- N N or 1-
;lc 0 0 71- .1") N 7 0 0
0 CO cT ltD N 71- CO CO
N
CD
00 .,ncTm co,CD c0 71- cT 0 0 00 71- =
71- c,") N 71- .r) 71- N 71- C N N
.s:) co (7, .r)
N N
N
= 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0
N N c,E; N cc N 4
3ifiUN icpuUA
0
0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Cl)ci) V) V) ci)
C/) c/) c/) c/) c/) Cl) Cl) Cl) Cl) Cl)
Cl) Cl) Cl) Cl) (7, Cl) Cl) Cl)
cT
= 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0
N
c/) Cl)
c/)
Cl) Cl) Cl) Cl) Cl) Cl) Cl)
Ou'Ou'Ou'Ou'Ou'Ou'Ou'Ou'Ou'OcI)Sal 880000 000
103
1-4
t
0
MI MI C.) A (.7
MI E-14
03S216.09S101.06-0.016703236 0.00% 1.69% 0.00%0.00% 0.00% 1.93%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%3.15% 0.00% 1.67%
03S216.09S101.30-0.014466892 0.00% 1.67% 0.00%0.00% 0.00% 1.67%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00%2.91% 0.00% 1.45%
03 S216.09S101.21-0.01490896 0.00% 1.56% 0.00%0.00% 0.00% 1.72%0.00%
0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 0.00% 0.00% 2.86% 0.00% 1.49%
03S216.09S101.19-0.010678976 0.00%0.90% 0.00%0.00% 0.00% 1.23%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00%0.00%0.00% 0.00% 1.86%0.00% 1.07%
*All Max values were calculated based on theoretical maximum formulas
disclosed in this application. Total Max Propyl Cannabinoids
reflects the additive content of decarboxylated equivalents of THCVA, THCV,
CBDVA, CBDV, CBGVA, and CBGV as defined in
earlier sections of this document.
1-d
CA 03085010 2020-06-05
W02019/113574 PCT/US2018/064704
*SCIUu"D ISdIlld i7 = CO' .r.1 (-) 4 .T, R '- 1 r I:, r4-n;7-)r,',-
r,¨,,r,)
71- 71- cf.) 4 71- 4 71- cf.) 71- cf.) cf.) 71:m4c,-:rn cn4c..) c=, 4 c,i
*xutu Diu
o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o
õsavmmvp ge,4ggc-,-,-,c-c-Kg4c-44c-gc-c-
Ivial m.. ,r) 71- 71- cf") N =¨i =¨i =¨i =¨i 0 0 CO CO N N N .t:)
.t:) ,r)
oeSt-t--t--t--t--t--t--t--t--t--t---..t--t-- .ci
DITI-8(1 o = o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o O o o o o o o o o o o o
NED o = o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o
O O O O O O O O O O O O O O O O O O O O O O
ADEID o = o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o O o o o o o o o o o o o
AGED o = o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o
ADHI o = o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o
O O O O O O O O O O O O O O O O O O O O O O
DED o = o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o
O O O O O o O O O O O O O o O O O O O o O O
DEED o = o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o
o GEED o = o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
= - O O O O O o O O O O O O O o O O O O O o O O
DHI o = o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o
c) o o o o o o o o o o o o o o o o o o o o o o
--,=
ci)
VADED o = o o o o o o o o o o o o o o o o o o o o o
Ch o o o o o o o o o o o o o o o o o o o o o o
O O O O O O O O O O O O O O O O O O O O O O
ec' ec' ec' ec' ec' ec' ec' ec' ec' ec' ec' ec' ec' ec' ec' ec' ec' ec' ec'
ec' ec' ec'
VAGEID N ,r) .t:) 71- N cT c n cT CA N C 0 N =¨i , ¨ ¨ i 0 C 71- ,r) CA N
71- 71- CA
,¨I 71- .C) 0 0 =¨i NNNNNN ,r)
(:7 .ri 4 4 .ri .ri .ri .ri 4 4 4 4 .ri 4 4 4 4 c=, .ri 4 4 4 c,i
c.i VADHI
O o = o o o o O o o o o O o o O o o o o o O o o
o VDEID
ci-, o o o o o o o o o o o o o o o o o o o o o o
u) A-,
o VIIED N
71- cn 71- cn .t:) .t:) N c=,) 0 0 c=,) N ce: ce: N N
Ct =¨i =¨i .C) .C) 71- CA 0 CO cT N CO cT =¨i =¨i N ,r, cT N cT ltD
CO cT
P-1 4 4 4 cf-) cf.) cf.--, mcf--, r-Ni cf.--, C.--; r-Ni 4 mcf.) c,-
) cf.--, r...i r-Ni cf.--, r...i 4
c-1-1
o VDHI o = o o o o o o o o o o o o o o o o o o o o o
u) o o o o o o o o o o o o o o o o o o o o o o A-,
.c) N .c) .71- oe) .c) oe) N N oe) .c)
.c) N .c)
N o N a)
,r) cD c .r) ,r) 0 ,r) CA c:7 c=,) cT ,r,
A¨, c:" N 71- N CA CA f") 0 .C) cf") .C) 0
cT c=,)
c=,) c N
CO
C CA c:" 71- Ce: C CA =¨i CA 71- 71- ,__ N
,''C' .C),__, 0
O , - .--, , - ..-, c D c D CO con ,r, c=,) c=,) ,--i cT ,r, CA
,r, ,r, 71- N cf") N CA =¨i
/ t c=,) CA N N
cf") N N N N
N 0 ,r) cf") 71- c:" .t:J a C r= = 1 C: 0 ,r,
71- CA cf") N 71- ,r) 0 = =¨i CO
,r, ltD N cf") N ,r, =¨i =¨i
c=,)
7i 71- 71- c=,) 71- 71- g 71- c=,) 71- c=,) 0 71- c=,) g c=,) c=,)
c=,) 71- c=,) c, 71- CA
= 5 c D c D c D c D c D=c
D c D c D c D , , c D c D =c D c D c D c D c D =c D c D
,; = ;
cf") 71' CO CO
0
CA .17 0 ,.,1 CA =¨i 0 =¨i CA CA uloN A-TourA,-; 2 ,:l 2
,':; E,; ,:l ,':; 2 ,¨; ,E; ,:l
ct
. . .
. . . . . . . . . . . . . . c, . . . . . . . . .
,__,
c9 Cl) Cl) Cl) Cl) c, C/)
cT Cl) Cl) Cl) Cl) C=, Cl) Cl) C/)
cT Cl) Cl) Cl) Cl) Cl) C/)
cT Cl) Cl)
C¨.) cT cT cT cT cT cT cT cT cT 0 cT cT cT cT cT cT cT
cT cT
0 0 0 0 0 = 0 0 0 0 = 0 0 = 0 0 0 0 0 = 0 0
N O O O O O ,9_,, O O O O O , O O
. . . . . . . . . ,.., . . . . . . .
. .
1.) cT cT cT cT cT cT cT cT cT cT 0 cT cT cT cT cT cT cT cT cT cT cT
0 0 0
0 0 0 0 N 0 0 0 0 0 0 0 0 0
CA CA
7:51 = = = = = N
N N N N N ,__, N N N N . N N ,__, N N N N N ,__, N N
c It 0
00 000 0 000 00 00 000 00
105
CA 03085010 2020-06-05
WO 2019/113574
PCT/US2018/064704
*squu"D ISdlud a- A- co2 4 '1,) 4 ";-) (-71'
71-mmmNNmNNNNNNNNNNNNNNNN
*xutu Diu o = o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
õstpiNviD
71- 71- C N N C N N N QC h 7r.
DILL-8(1 o = o
o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
MUD o = o
o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
ADEID o = o
o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
AMID o = o
o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
ADHI o = o
o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
DUD o = o
o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
DUD o = o
o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
GHD o = o
o o o o o o o o o o o o o o o o o o o o o
o o o o
o o o o o o o o o o o o o o o
o o o o
DILL o = o
o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
VADHD o = o
o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
VAGHD
N N N co N N 71-
c=, c=,
VADHI o = o
o o o o o o o o o o o o o o o o o o o o o
c= c= c= c= c= c= c= c= c= c= c= c= c= c=
c= c= c= c= c=
o o o o
o o o o o o o o o o o o o o o
VDEID o = o
o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
VOHD o = o
o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
WIRD N .r) (7, N N
= coc 71- N 7i-
VDHI o = o
o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
oo .r) o oo oo o .C) (T
.r)
(7, N 71- N N N
N 71- o C C N
(7, co (7, N N (7, N Co
N o o .r) N o
o N 71- 71- 71- N o
71-
o o o o
o o o o o o o o o o o o o o o
= o 71" N N N N cc 7r o o
MN ,='; 2
cp,
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
O 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0, 0,
0 0
0 0 0 cl 0 0 0 0 0 0 0 0 cl cl cl
0 0 0 0 0 0 0
CA CA N N CA CA CA CA CA CA N N N CA
CA CA CA CA CA
O0000000000000000000000
106
ci)
c-) f:0 f:0 f:0
c-) f:0 E. E. 4
E-1 C..)
g
0120910.09S101.14-0.016824588 0.00%1.49%0.00%0.00%0.00% 1.94%0.00% 0.00%0.00%
0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%2.99% 0.00% 1.68%
0120910.09S101.52-0.018350156 0.00% 1.17% 0.00% 0.00%0.00% 2.12%0.00%
0.00%0.00% 0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%2.86% 0.00% 1.84%
0120910.09S101.31-0.023698312 0.00%0.00% 0.00% 0.00%0.00% 2.73%0.00%
0.00%0.00% 0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%2.37% 0.00%2.37%
0120910.09S101.30-0.021791352 0.00%0.00% 0.00% 0.00%0.00% 2.51%0.00%
0.00%0.00% 0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%2.18% 0.00%2.18%
0120910.09S101.47-0.0149523 0.00%0.70%0.00%0.00%0.00%
1.73%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%2.11%0.00% 1.50%
0120910.09S101.55-0.019685028 0.00%0.00% 0.00% 0.00%0.00% 2.27%0.00%
0.00%0.00% 0.00%0.00%0.00% 0.00%0.00%0.00% 0.00% 1.97%0.00% 1.97%
0120910.09S101.36-0.0161484840.00%0.00%0.00%0.00%0.00% 1.86%0.00% 0.00%0.00%
0.00%0.00%0.00% 0.00%0.00%0.00% 0.00% 1.61%0.00% 1.61%
0120910.09S101.53-0.0147095960.00%0.00%0.00%0.00%0.00% 1.70%0.00% 0.00%0.00%
0.00%0.00%0.00% 0.00%0.00%0.00% 0.00% 1.47%0.00% 1.47%
0120910.09S101.45-0.0129326560.00%0.00%0.00%0.00%0.00% 1.49%0.00% 0.00%0.00%
0.00%0.00%0.00% 0.00%0.00%0.00% 0.00% 1.29%0.00% 1.29%
0
0120910.09S101.44-0.00749782 0.00%0.51% 0.00% 0.00%0.00% 0.87%0.00% 0.00%0.00%
0.00%0.00%0.00% 0.00%0.00%0.00% 0.00% 1.19%0.00%0.75%
0120910.09S101.39-0.008763348 0.00%0.34%0.00%0.00%0.00% 1.01%0.00% 0.00%0.00%
0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%1.17% 0.00%0.88%
0120910.09S101.39-0.0115111040.00%0.00%0.00%0.00%0.00% 1.33%0.00% 0.00%0.00%
0.00%0.00%0.00% 0.00%0.00%0.00% 0.00% 1.15%0.00% 1.15% 0
0120910.09S101.56-0.01144176 0.00%0.00%0.00%0.00%0.00%
1.32%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00% 1.14%0.00% 1.14%
0120910.09S101.42-0.009179412 0.00%0.00%0.00%0.00%0.00% 1.06%0.00% 0.00%0.00%
0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%0.92% 0.00%0.92%
*All Max values were calculated based on theoretical maximum formulas
disclosed in this application. Total Max Propyl Cannabinoids
reflects the additive content of decarboxylated equivalents of THCVA, THCV,
CBDVA, CBDV, CBGVA, and CBGV as defined in
earlier sections of this document.
oe
Table 8 Cannabinoid Contents of Plants from the `V24.S1.P09X09.S1.01' Line
0
ci)
V24S1P09.09S101.41-0.039734112 0.00%4.14% 0.00%0.00%0.00% 4.58%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%7.61%0.00% 3.97%
V24S1P09.09S101.30-0.025735292 0.00%3.59% 0.00%0.00%0.00% 2.97%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%5.72%0.00% 2.57%
V24S1P09.09S101.45-0.02942786 0.00%2.90% 0.00%0.00%0.00% 3.40%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%5.49%0.00% 2.94%
V24S1P09.09S101.05-0.033250448 0.00%2.32%0.00%0.00%
1.28%2.55%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%5.36%0.00% 3.33%
V24S1P09.09S101.42-0.03376186 0.00%2.13%0.00%0.00%
1.40%2.50%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%5.24%0.00% 3.38%
V24S1P09.09S101.16-0.028847104 0.00%2.59% 0.00%0.00% 1.08% 2.25%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%5.15%0.00% 2.88%
V24S1P09.09S101.43-0.029063804 0.00%2.51%0.00%0.00% 1.15% 2.20%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%5.11%0.00% 2.91%
oe V24S1P09.09S101.28-0.0283877 0.00%2.51%0.00%0.00% 1.10%
2.17%0.00%0.00% 0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%5.04%0.00% 2.84%
V24S1P09.09S101.13-0.02422706 0.00%2.87% 0.00%0.00%0.00% 2.80%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%4.94%0.00% 2.42%
V24S1P09.09S101.18-0.03007796 0.00% 1.90%0.00%0.00% 1.20% 2.27%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%4.68%0.00% 3.01%
V24S1P09.09S101.09-0.022458788 0.00%2.71% 0.00%0.00%0.00% 2.59%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%4.62%0.00% 2.25%
V24S1P09.09S101.32-0.025518592 0.00%2.31% 0.00%0.00%0.00% 2.94%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%4.58%0.00% 2.55%
V24S1P09.09S101.34-0.023689644 0.00%2.51% 0.00%0.00%0.00% 2.73%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%4.57%0.00% 2.37%
V24S1P09.09S101.22-0.023178232 0.00%2.49% 0.00%0.00%0.00% 2.67%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%4.50%0.00% 2.32%
V24S1P09.09S101.25-0.023429604 0.00%2.35% 0.00%0.00%0.00% 2.70%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%4.40%0.00% 2.34%
V24S1P09.09S101.26-0.026030004 0.00%2.01%0.00%0.00%0.00% 3.00%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%4.37%0.00% 2.60%
V24S1P09.09S101.02-0.022250756 0.00%2.43% 0.00%0.00%0.00% 2.57%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%4.35%0.00% 2.23% 1-3
V24S1P09.09S101.14-0.020161768 0.00%2.63% 0.00%0.00%0.00% 2.33%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%4.33%0.00% 2.02%
V24S1P09.09S101.31-0.02284018
0.00%2.30%0.00%0.00%0.00%2.64%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00
%4.30%0.00%2.28%
oe
V24S1P09.09S101.23-0.027182848 0.00% 1.74%0.00%0.00% 1.14% 2.00%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%4.24%0.00% 2.72%
V24S1P09.09S101.03-0.025925988 0.39% 1.24% 0.10%0.09%0.92% 2.07%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%4.18%0.34% 2.59%
V24S1P09.09S101.44-0.022571472 0.00%2.15% 0.00%0.00%0.98% 1.63%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%4.14%0.00% 2.26%
a:
o
..
E
..
s. c.)
A* un
--.1
V24S1P09.09S101.33-0.025154536 0.00% 1.80%0.00%0.00%0.98%
1.93%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%4.10%0.00%2.52% 4.
V24S1P09.09S101.04-0.025067856 0.00% 1.59%0.00%0.00%0.93% 1.97%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%3.90%0.00% 2.51%
V24S1P09.09S101.27-0.020231112 0.00% 1.92% 0.00%0.00%0.00% 2.33%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%3.71%0.00% 2.02%
V24S1P09.09S101.19-0.02587398 0.00% 1.27%0.00%0.00% 1.05% 1.93%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%3.70%0.00% 2.59%
V24S1P09.09S101.03-0.027806944 0.00% 1.05%0.00%0.00% 1.06% 2.15%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%3.70%0.00% 2.78%
V24S1P09.09S101.08-0.026922808 0.00% 1.12%0.00%0.00% 1.04% 2.07%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%3.68%0.00% 2.69%
V24S1P09.09S101.15-0.020187772 0.00% 1.83% 0.00%0.00%0.00% 2.33%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%3.62%0.00% 2.02%
P
V24S1P09.09S101.46-0.02487716 0.00% 1.29%0.00%0.00% 1.04% 1.83%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%3.62%0.00% 2.49% 0
L.
0
0
..
V24S1P09.09S101.38-0.0190696 0.00% 1.91%
0.00%0.00%0.00% 2.20%0.00%0.00% 0.00%0.00%0.00%0.00% 0.00%0.00%0.00%
0.00%3.58%0.00% 1.91% u,
0
o 1-
o 0
V24S1P09.09S101.21-0.022354772 0.00% 1.52%0.00%0.00%0.84% 1.74%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%3.57%0.00% 2.24%
0
r.,
V24S1P09.09S101.17-0.026316048 0.00% 1.03%0.00%0.00% 1.02% 2.02%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%3.54%0.00% 2.63% 0
,
0
V24S1P09.09S101.06-0.023334256 0.00% 1.33%0.00%0.00%0.97% 1.72%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%3.50%0.00% 2.33% ,
0
u,
V24S1P09.09S101.12-0.021167256 0.00% 1.53% 0.00%0.00%0.00% 2.44%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%3.46%0.00% 2.12%
V24S1P09.09S101.01-0.019485664 0.00% 1.69% 0.00%0.00%0.00% 2.25%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%3.43%0.00% 1.95%
V24S1P09.09S101.36-0.023160896 0.00% 1.27%0.00%0.00%0.98% 1.70%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%3.43%0.00% 2.32%
V24S1P09.09S101.35-0.018194132 0.00% 1.72% 0.00%0.00%0.00% 2.10%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%3.33%0.00% 1.82%
V24S1P09.09S101.40-0.022987536 0.00% 1.17%0.00%0.00%0.96% 1.70%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%3.33%0.00% 2.30%
V24S1P09.09S101.39-0.021817356 0.00% 1.17%0.00%0.00%0.84%
1.68%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%3.21%0.00%2.18% IV
n
V24S1P09.09S101.07-0.019303636 0.00%
1.43%0.00%0.00%0.00%2.23%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%3.19
%0.00% 1.93% 1-3
V24S1P09.09S101.10-0.014267528 0.00% 1.72%0.00%0.00%0.00% 1.65%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%2.93%0.00% 1.43% ci)
n.)
o
V24S1P09.09S101.11-0.014397548 0.00% 1.12%0.00%0.00%0.00% 1.66%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%2.43%0.00% 1.44% ..
oe
CB;
V24S1P09.09S101.20-0.017058624 0.00%0.68% 0.00%0.00%0.79% 1.18%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%2.30%0.00% 1.71% o
4.
--.1
V24S1P09.09S101.29-0.012932656 0.00%0.97%0.00%0.00%0.00%
1.49%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%2.15%0.00% 1.29%
4.
ci)
"
C.)
.4 f:cl
-tt
C
4
= E-1 C.)
C.) 7,
V24S1P09.09S101.24-0.011216392 0.00%0.97%0.00%0.00%0.00%
1.29%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00% 1.97%0.00% 1.12%
V24S1P09.09S101.37-0.00407396 0.00%0.32% 0.00%0.00%0.00% 0.47%0.00%0.00%
0.00%0.00%0.00%0.00% 0.00%0.00%0.00% 0.00%0.69%0.00% 0.41%
*All Max values were calculated based on theoretical maximum formulas
disclosed in this application. Total Max Propyl Cannabinoids
reflects the additive content of decarboxylated equivalents of THCVA, THCV,
CBDVA, CBDV, CBGVA, and CBGV as defined in
earlier sections of this document.
Table 9 Cannabinoid Contents of Plants from the `V24.S2.26X09.S1.01' Line
0
c.) c..7
4 -tt .tt
c") c.) c..7 c-)
E-1 E-1
E-1
oe 0 4 c-) c")
V24S226.09S101.42-0.0543570281.17% 3.31%0.00% 0.00%2.25% 4.02% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 9.37% 1.03%5.44%
V24S226.09S101.42-0.0478384921.14% 3.11%0.46% 0.18%2.00% 3.37% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.13%0.00% 0.00%0.00% 9.08% 1.00%4.78%
V24S226.09S101.52-0.0444321680.95% 3.30%0.00% 0.00% 1.61% 3.51% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 8.17%0.83%4.44%
V24S226.09S101.39-0.0408821040.79% 2.33%0.35% 0.13% 1.64% 2.94% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.12%0.00% 0.00%0.00% 7.24%0.69%4.09%
V24S226.09S101.39-0.0482547560.00% 2.42%0.00% 0.00% 1.89% 3.68% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 6.94%0.00%4.83%
V24S226.09S101.59-0.0421091440.00% 2.78%0.00% 0.00% 1.54% 3.32% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 6.65%0.00%4.21%
V24S226.09S101.11-0.0392833760.00% 3.08%0.00% 0.00% 1.46% 3.08% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 6.63%0.00%3.93%
V24S226.09S101.13-0.0384945880.00% 3.12%0.00% 0.00% 1.39% 3.05% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 6.59%0.00%3.85%
V24S226.09S101.47-0.0406182480.00% 2.72%0.00% 0.00% 1.63% 3.05% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 6.45%0.00%4.06%
V24S226.09S101.46-0.0384252440.00% 2.81%0.00% 0.00% 1.34% 3.09% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 6.31%0.00%3.84%
V24S226.09S101.54-0.0401068360.00% 2.39%0.00% 0.00% 1.39% 3.24% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 6.11%0.00%4.01%
V24S226.09S101.36-0.0413116880.00% 2.15%0.00% 0.00% 1.60% 3.17% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 6.01%0.00%4.13%
V24S226.09S101.48-0.03826922 0.00%2.47%0.00%0.00%
1.32%3.10%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%5.99%0.00%3.83%
V24S226.09S101.08-0.04134636 0.00% 1.96%0.00%0.00% 1.68%3.10% 0.00%0.00% 0.00%
0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00%5.86%0.00%4.13%
V24S226.09S101.55-0.0349927160.00% 2.59%0.00% 0.00% 1.19% 2.85% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 5.77%0.00%3.50% 1-3
V24S226.09S101.44-0.0356774880.00% 2.42%0.00% 0.00% 1.34% 2.78% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 5.69%0.00%3 .57%
V24S226.09S101.06-0.0335885 0.00%2.66%0.00%0.00%
1.10%2.78%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%5.69%0.00%3.36%
oe
V24S226.09S101.33-0.0362842480.00% 2.34%0.00% 0.00% 1.17% 3.02% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 5.68%0.00%3.63%
V24S226.09S101.38-0.0339438880.00% 2.48%0.00% 0.00% 1.13% 2.79% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 5.57%0.00%3.39%
V24S226.09S101.17-0.0376017840.00% 2.01%0.00% 0.00% 1.26% 3.08% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 5.52%0.00%3 .76%
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
c'' c'' c'' c c c''
õsquuuuD vidoij ,..F) ,,E.= . ,cri .2, .L,1 ,(2.
cr; ,(2. ,s4R2,,s,g,,..c,,,4p,7,-,),=,,,,c7,,p
. . . . . . . . . . . . . . . .
. . . . . . .
,Nc,c,-1,-.NNN¨,Nc,¨,¨,¨,¨,
õrum Diu o = o o o o o o o o o o o o o o o o o o o .71- o N
o o o o o o o o o o o o o o o o o o o o cl cl cl
o o o o o o o o o o o o o o o o o o o o o o o
õ saymNyD c c c c c c c c c c
4 `,F1 `4 "c
'c , r8 `,,F .` F¨' 7,' 7,' 4 Z r F 4 4' `,F1 'c , rc,
IViat .n .n .ri .ri .ri .ri .n 4 4 4 4 4 4 4 m c=-: c=-: c=-: c=-: c,-
; c,i c,i c,i
DIII-8(1 o = o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
NED o = o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
A "J D o = o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
O O O O O O O O O O O O O O O O O O O O O O O
A a El D o = o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
AD HI o = o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
D HD o = o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
O O O O O O O O O O O O O O O O O O O O O O O
-9 HD o = o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
:=.,`.'77.' :=.,`.'77.' :=.,`=77N' :=.,`=77N' :=.,`=77N'
:=.,`=77N' :=.,`.'77.' :=.,`=77N' :=.,`=77N' :=.,`=77N'
:=.,`=77N' :=.,`=77N' :=.,`=77N' :=.,`=77N' :=.,`.'77.'
:=.,`=77N' :=.,`=77N' :=.,`=77N' :=.,`=77N' :=.,`=77N'
:=.,`.'77.' :=.,`=77N' :=.,`.'77.'
MID o o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
D HI o = o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
VA "J D o = o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
VAGEID o = oo o c.,,-).o.71- o,..c N ocN,..c o N.1- ocococoo..
N.71- N N
N N N N N N N N N N N N N N N N ,--; N
V A D HI oc = -, ,..c ,..c .71- oo (-) . N .71- .71- o ,..c) ,..c) ,..c o
cT ,--i 0 0 0 0 N
N. 0 ,¨ i. 0 cT c:" N. 0 cT 0 0 0 C c'," 0 0 ..SD N ..SD
=¨i =¨i ,- -i ,- -i ,- -i , - - i =¨i ,- - i ,- -i P P ,- -i ,- -i P =¨i P P ,-
-i P P P c:j c:j
VD/ID o = o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
O O o o o o O o o o o o o o O o o o o o O o O
VD/ID
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 =¨i =¨i 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
VatID .71- = oo cT 0 CO lt:C .r) lt:C N N c:7 N N m
c:7 N N c:" N 0 N N cT
VD HI
o o o o o o o o o o o o o o o o o o o o NN (-)
O O O O O O O O O O O O O O O O O O O O O O O
.71- oo N oc oc .71- ,..c) ,..c) oo ,..c) ,..c) oo ,..c) ,..c) cl oo .71- .71-
.71- N .71- oc oo
oo .r) =¨i ..C) CO 71- .r) cT lt:C .r) N 0 N cn 71- CO 0 CO 71- N 71- CD cT
71- CO ..C) N .1. m .r) 71- 71- N =¨i 0 N 0 cn cT ..C) cn c., ..C) ,r)
cn 71- m lt:C cn 71- mC r COO 0 ..C)
CO lt:C N Ce: 0 N =¨i
71- N ..CJ=71- ..t D mcnN71- m .r) 0 71- ..C) Ce: N 0 N N
m =¨i =¨i ..C) ..C) c:" c., N CO ,--i c:7 N ,--i N c:7 ,,c, ..Cc
.r) ,--i 71- cx, =¨i N
m m .r) =¨i N =¨i cl 0 =¨i =¨i ..C) N N ..C) cl N m 71- N .r) ,__,
cc;) r01 cc;) r01 r01 = -'N cc;)
71- N 71- .r) .r) 71- `=(:' 71- ¨i .r) .r) .r) o o c') o 71- N o .r) ' N N
,__, o o o o o o o ,__, o o o o o ,__,
,¨i ,¨i ,¨i ,¨i ,¨i ,¨i ,¨i ,¨i ,¨i ,¨i ,¨i ,¨i ,¨i ,¨i ,¨i ,¨i ,¨i
Cl) Cl) Cl)
Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl)
cT cT cT cT cT cT
cT cT cT cT cT cT cT cT cT cT cT cT cT cT cT cT cT
0 0 0 0 0 0
N
,':1 ,':1 NN N N,':1 NN N N N N N,':1 NN N N N,':1 N(-I
N N N N
71- N N N N N N N N N N
N
Cl)c/) Cl)c/) Cl)c/) Cl)c/) c/)
Cl)Cl)Cl)Cl)Cl)Cl)Cl)c/)
Cl)Cl)Cl)Cl)Cl)c/)
Cl) 71- 71- 71- 71-
71- 71- 71- 71- 71- 71- 71- 71- 71- 71- 71- 71- 71- 71- 71- 71- 71-
1 = 1 rl rl rl rl 1 rl rl rl rl rl rl rl 1 rl rl rl rl rl 1 rl 1
112
.tt
rso
V24S226.09S101.31-0.01724932 0.00% 1.19% 0.00%0.00% 0.00% 1.99% 0.00%0.00%
0.00% 0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00%2.77%0.00% 1.72%
V24S226.09S101.27-0.027191516 0.00% 0.00%0.00% 0.00%0.94% 2.20% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 2.72%0.00%2.72%
V24S226.09S101.22-0.011381084 0.00% 0.41%0.00% 0.00%0.40% 0.92% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 1.50%0.00%1.14%
V24S226.09S101.25-0.014830948 0.00%0.00%0.00%0.00%0.00% 1.71% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 1.48%0.00%1.48%
V24S226.09S101.18-0.013496076 0.00%0.00%0.00%0.00%0.00% 1.56% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 1.35%0.00%1.35%
V24S226.09S101.14-0.00940478
0.00%0.41%0.00%0.00%0.25%0.84%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00
% 1.30%0.00%0.94%
V24S226.09S101.10-0.0097515
0.00%0.36%0.00%0.00%0.26%0.86%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00
% 1.29%0.00%0.98%
V24S226.09S101.19-0.008919372 0.00% 0.39%0.00% 0.00%0.18% 0.85% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 1.23%0.00%0.89%
0
V24S226.09S101.26-0.011710468 0.00%0.00%0.00%0.00%0.00% 1.35% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 1.17%0.00%1.17%
V24S226.09S101.28-0.008720008 0.00% 0.34%0.00% 0.00%0.21% 0.80% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 1.17%0.00%0.87% 0
V24S226.09S101.21-0.007341796 0.00% 0.40%0.00% 0.00%0.24% 0.61% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 1.09%0.00%0.73%
V24S226.09S101.01-0.008954044 0.00% 0.14%0.00% 0.00%0.24% 0.79% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 1.01%0.00%0.90%
V24S226.09S101.63-0.007185772 0.00% 0.34%0.00% 0.00%0.23% 0.60% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 1.01%0.00%0.72%
V24S226.09S101.03-0.008416628 0.00% 0.17%0.00% 0.00%0.23% 0.74% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 0.99%0.00%0.84%
V24S226.09S101.25-0.006899728 0.00% 0.20%0.00% 0.00%0.20% 0.60% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 0.87%0.00%0.69%
V24S226.09S101.02-0.005088116 0.00% 0.21%0.00% 0.00%0.11% 0.47% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 0.70%0.00%0.51%
V24S226.09S101.04-0.006258296 0.00% 0.00%0.00% 0.00%0.14% 0.59% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 0.63%0.00%0.63%
V24S226.09S101.20-0.003432528 0.00% 0.23%0.00% 0.00%0.02% 0.38% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 0.55%0.00%0.34%
V24S226.09S101.12-0.002609068 0.00% 0.14%0.00% 0.00%0.00% 0.30% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 0.38%0.00%0.26%
ci)
V24S226.09S101.03-0.002591732 0.00% 0.08%0.00% 0.00%0.00% 0.30% 0.00%0.00%
0.00%0.00%0.00% 0.00% 0.00%0.00% 0.00%0.00% 0.33%0.00%0.26%
oe
CB;
*All Max values were calculated based on theoretical maximum formulas
disclosed in this application. Total Max Propyl Cannabinoids
reflects the additive content of decarboxylated equivalents of THCVA, THCV,
CBDVA, CBDV, CBGVA, and CBGV as defined in 0
earlier sections of this document.
,0
,
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
õsquuuuD
o . (-4 C., N .r) 71- 71- =¨i .r) c:" N C \ C \ cf") ..r) cf") 0 ..r) ltD 0
N
'AO id ..C) C \ ,--i =¨i ..C) ..C) .r) 0 .r) 0 0 N 0 =¨i C \ ,--i C
\ =¨i cT N 0 N
N 4
* xuul Dili E,= r2,';',EEEEEEEEEEEEEEEEEEE
õ stpiNviD 4 g 4 c'. 4 4 ! , g 4 4 c'.
g g 4
I vi al . oo . ,- ,- ,- c..) N . . . ..., ..., oo oo , , , , . . .r)
cT ceS ceS ceS ceS ceS ceS ceS ceS ceS oeS t---: t---: t---: t---: t---: t---:
t---: t---: t---: t---: t---:
DILL-8(1 o = o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o
NED o = o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o
AD BD o = o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o
O O O O O O O O O O O O O O O O O O O O O O
AG ED
o o o o o o o o o o o o o o o o o o o o o o
A D HI o = o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o
O O O O O O O O O O O O O O O O O O O O O O
D ED o = o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o
-9 El D o = o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o
a)
= - a El D o o o o o o o o o o o o o o o o o o o o o o
O O O O O O O O O O O O O O O O O O O O O O
c)
D HI o = o o o o o o o o o o o o o o o o o o o o o
,-, o o o o o o o o o o o o o o o o o o o o o o
cip o o o o o o o o o o o o o o o o o o o o o o
O VA "U" o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o
O O O O O O O O O O O O O O O O O O O O O O
c)
NN
cnN = NOCC= N
VAG El D ,..c c:C.1 c:7,--i.r) v=-) 0 C 0
C 71- cT cn,--iO
,¨I
C/D
O V A D HI
0 N cn 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
O 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
CIJ
VDED o N
E O O O O O O O O O O O O O O O O O O O O O O
5-
4¨ VDDE
v,
c
F_ WED o 00 00 m N cT .r) m m .r)
71- 0 ..C) 0 N N N 0\
C \ C \ 71- N N =¨i N ..C) 0 .r) 71- ..C) N 0 N 0 71- =¨i =¨i N C \ CA
cf-: c,i c,i cf-:
0
til
4-, V D HI
c
CIJ 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
I. CO CA CO CO CA CA CA CA 71-
CA CO CO 71-
C 0 ltD N C \ cf") cf") 71-
=¨i 71- 0 N ..C) cf")
0 ..C) N 4 ,..c, . ,-, oc N .1- N
u o .r) ce: cf") cT .r) cT 0
..r) N =¨i ..r) 0 CO C \ Ce: N 0 =¨i
m ce: cT
..C) =¨i cf") 0 CO 0 ..C) .r) N
N Cc) =¨i ,..C) ,..C) 71- 0 C71 71- C71
0\ N 71- 71- m 0 .r) CO N 0\ Ce: N ,__Thr Cc)
.r) cT =¨i ..C) ..C) .r) 0 .r)
0 0 N 0 =¨i C \ cT ,--i N 0 N
.r) 71-
0 .r) 71- .r) .r) 71- .r) .r) .r) .r) .r) ..r) 71- ..r) ..r)
71- N7I-
C 0 0 = 0 0 0 0 0 0 0 0 0 0 0 0 = 0 0 = 0 0 0
.-
5;5;5;
co 71- 00 cT
71- cf") .1. .r) N C \ ..C) 0 ..C) cf") N CO CO ..r) C \ .1. CA
c MTV N AlourA .17 -.. ,__; ,r. ,r. ,r. N. cf.). cf"? -". ,r. c:). cf"?
cf.). N .
c . . . ,__; -"
'r? ,__;
. . . . . . . . . . . . . . . . .
as o o o
o o ,__, o o o o o o o o o o o o ,__, o o ,__, o o o
u . . . . . . . . . . . . . . . . . . .
Cl)c/) c/)
Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl)
Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl)
CD cT cT cT cT cT cT cT cT cT cT cT cT cT cT cT cT cT cT cT cT
cT cT
0 0 0
1-1;;;
1.) . .
o . . . . . . . . . . . .
o . .
o . . .
c/)
Cl)
. . . . . . . . . . . . . . . . . c/)
et
Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl)
Cl)
cT cT cT cT cT cT cT cT cT cT cT cT cT cT cT cT cT cT cT cT cT cT
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
115
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
õsquuuuD
o o Ncf=-. cf=-.
ltDN Ncf=-.
IS(10.1(1 cf") CO cT .r) co co (-1 (-1 cf") h cf=-. h
xuul Dili !;EEEEEEEEEEEEEEEEEEEEEE
õstpiNviD
N N 0 0 c:r c:r co N N t N C N
o = o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o
o o
MUD o = o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
AD/ID o = o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
AMID o = o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o
ADHI o = o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
DUD o = o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o
o o
DUD o = o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
MID o = o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
DI-II o = o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
VADilD o = o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
VAMID o N cf=-. 71- 71- .t:) 0 CO CA ltD c cf=-
. f=-. CO cT
71- cf=-. C C N C C N cC c f") N N.r) N N c
O`.=77,' O`.=77,' O`.=77,' O`.=77,' O`.=77,' O`.=77,'
O`.=77,' O`.=77,' O`.=77,' O`.=77,' O`.=77,' O`.=77,'
O`.=77,' O`.=77,' O`.=77,' O`=77,' O`=77,' O`=77,' O`=77,'
O`=77,' O`=77,' O`=77,' O`=77,'
VADHI o o o o
o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o
o o
VDEID = o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o
VDEID = o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o
VafID = N o o o o co co c:7 N
71- 0 CO h CO cf=-. cf=-.
(-4 c,-; c,-; (-4
c,-; (-4 (-4 c,-; (-4 (-4 c,-; (-4 (-4 (-4 (-4 c,-; (-4 (-4 (-4 (-4 (-4 (-4
VDHI = o o o o o o o o o o o o o o o o o o o o o o
o o o o o o o o o o o o o o o o o o o o o o o
000000000000000000
71- 71- N 1- N 1- N 1- (-171-CONOC
N 71- CO cT cf=-. .r) co
c o o
71-
f") CO 0 71- o 71- o N N N N N o
o 71-c N N C N N E
.t:) cf.) 71- 71- o
N cf") .. ltD
CA CA cf=-. E r a" oc) s
71- C C N C 71- 71- 71- N C c N
71- 71- 71- 71- o 71- 71- 71- 71- 71- o 71- 71- 71- 71- 71-
N = o c N N N N N N 71- 71-
uMN A1.0 ur A N. 7r. cf.). '¨'. cf? '¨'. '¨'.
7r. '¨'.
o o o o o
o o o o o o o o o o o o o o
Cl) c./)
C/) c/) c/) c/) Cl) C Cl) Cl) Cl) Cl) Cl) C Cl) Cl) Cl) Cl)
Cl) Cl) Cl) Cl) Cl)
cT cT cT
0. 0 0 0 0. 0. 0. 0. 0. 0. 0. 0.
0 0. 0. 0. 0. 0. 0.
0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0
Cl) Cl)
Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl) Cl)
Cl) Cl) Cl) Cl) Cl) Cl) Cl)
cT0 c:7 cT
0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0
116
ci)
0
tx1 E-1 C.) C.)
C.) fx1 fx1 CL 4 .)E
= E-1 C.)
C.) "' c:,t)
09S101.09S101.24-0.031343488 0.00% 2.38%0.00%0.00% 0.00%3.62%0.00% 0.00%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00% 0.00%5.22% 0.00%3.13%
09S101.09S101.19-0.034533312 0.00% 1.98%0.00%0.00% 0.00%3.98%0.00% 0.00%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00% 0.00%5.19% 0.00%3.45%
09S101.09S101.09-0.031369492 0.00% 2.30%0.00%0.00% 0.00%3.62%0.00% 0.00%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00% 0.00%5.15% 0.00%3.14%
09S101.09S101.07-0.033181104 0.00% 1.67%0.00%0.00% 0.00%3.83%0.00% 0.00%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00% 0.00%4.78% 0.00%3.32%
09S101.09S101.18-0.030979232 0.00% 1.55%0.00%0.07% 0.15%3.28%0.00% 0.00%0.00%
0.00%0.00%0.00% 0.13%0.00% 0.00% 0.00%4.52% 0.00%3.10%
09S101.09S101.01-0.025197876 0.00% 1.26%0.00%0.00% 0.00%2.91%0.00% 0.00%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00% 0.00%3.63% 0.00%2.52%
09S101.09S101.05-0.019060932 0.00% 0.79%0.00%0.00% 0.00%2.20%0.00% 0.00%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00% 0.00%2.60% 0.00% 1.91%
09S101.09S101.02-0.016789916 0.00% 0.00%0.00%0.00% 0.00% 1.94%0.00% 0.00%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00% 0.00% 1.68%0.00% 1.68%
09S101.09S101.02-0.005686208 0.00% 0.24%0.00%0.00% 0.00%0.66%0.00% 0.00%0.00%
0.00%0.00%0.00% 0.00%0.00% 0.00% 0.00%0.78% 0.00%0.57%
*All Max values were calculated based on theoretical maximum formulas
disclosed in this application. Total Max Propyl Cannabinoids
reflects the additive content of decarboxylated equivalents of THCVA, THCV,
CBDVA, CBDV, CBGVA, and CBGV as defined in
earlier sections of this document.
1-d
Table 11 Terpene Contents of Plants of the '03. S2. 1 6X09. S1.01 ' Line
0
i.)
o
,-,
w
w a) +..
C
c w
c a) 0.1 c 7
c92 c F., cw 0 jc - Z. S ; ; - al w
1-,
1-,
w EI w
: a+
E w _,.., c
c =-= aj
w cu w - c
0.1
0
cis c
-4
z i t t r .c IL .0
2 1.) E. E 0. 8 F., 8 (.2 .6.
.. c 7u T g .. 0- w =0.
Lai o. .?.), 3 (73 = Li .5
..
w It 15. O 1.1.3 E n' .2
+' (V 0 E co "c =c 2" >^ dj
*C a+ = E cm 2 V.)
4- r,tv -c 2 c.) - 0. E c
cis a) co aj
w
> .. .c .0 E 70 0-
-D - 0- o
o. cis 70
70 To 11 12-
70 bA
-ca cis
U
w
1-
03S216.09S101.09-0.043969184 0.00% 0.00% 0.01% 0.00% 0.06% 0.00% 0.00% 0.00%
0.01% 0.00% 0.00% 0.00% 0.20% 0.62% 0.06% 0.00%0.02%0.98%
Bolded boxes indicate dominant terpene.
P
.
.
Table 12 Terpene Contents of Plants of the ' 012.09. 1 OX09. S1 .01 ' Line
.3
.
,-,
,
,-,
.
oe
,,
a)
w w +.. .
N)
C
C w
w c 7 .
w ,
w 11) a) c w
w cu c aj 73 C 0 7c +.. .
E w _,.., c
c =-= aj ajc c (A
c w cu w - o c .
,
cis w ci E w c .t2- t .-
w c7) . . 1 . 7/ t t µ 3 .
u,
z z _ ._ c w w .- E. .0 .o =
_ 0- o 4.) a) -
>. c T.) 61 1.1 g 4_, =0-
o.) 0. 'E o. ,T, 3 fi.3 . 76 = Li 5
+ . .
w
=E *EL 15. ns 2 Et v
.20. i .4.1 a EIE 2 1 5 _. c 2 "0 . Ca i
+..
cis CIJ co w
w
> .. .c .0 E 70 0-
-D - 0- o
o. cis 70
70 To 11 12-
70 bA
.ca cis
U
w
1-
0120910.09S101.28-0.04585372 0.00% 0.00% 0.00% 0.00% 0.05% 0.00% 0.00% 0.00%
0.01% 0.00% 0.00% 0.00% 0.17% 0.51% 0.04% 0.00%0.01%0.79%
od
n
Bolded boxes indicate dominant terpene.
cp
i.)
o
,-,
oe
c,
.6.
-4
=
.6.
Table 13 Terpene Contents of Plants of the '09. S 1.01X09. S 1 .01 ' Line
a)
a) w 4-. 0
c a)
C a)
0.1 c C
7
a) N
a) i a) C1.1 0 C
aj 73 c w R 4-,
-
o
E w c
c 0 a) C C C1)
c aj 0 471) 7,... 0 C I-,
w
al VD
CO c a) õ, ,- ..7. a) .c
õ, - c . S 3 =
Z 2 tv E 'a' 1 1-1- .c EL
a 2 w E. E 0. 8 F., 8 u .
, 2 T.) R a, C 41.' E t
.E. '-' 15. al 3 g . 5 1-
c.,.)
4-.
17. CTS 2 E ,,, .2 ry
2 F.) E +4 "c ' c 2" c>" w vii
.-
--,1
I- t co 4() = E a .c w
.4- m -c -2 2 " a '- c .6.
co ... E t7s 12-
-D u 0- o. ns o a)
> .0 Xi
0. CO To
To (I 1.' Et
To bA
.0 CO
U
a)
I-
09S101.09S101.44-0.05123424 0.00% 0.00% 0.00% 0.00% 0.05% 0.00% 0.00% 0.00%
0.00% 0.00% 0.00% 0.00% 0.37% 1.29% 0.06% 0.00% 0.02% 1.79%
09S101.09S101.13-0.049115232 0.00% 0.00% 0.01% 0.00% 0.07% 0.00% 0.00% 0.00%
0.01% 0.00% 0.00% 0.00% 0.23% 0.87% 0.04% 0.00% 0.02% 1.25%
09S101.09S101.27-0.051000204 0.00% 0.00% 0.00% 0.00% 0.07% 0.00% 0.00% 0.00%
0.01% 0.00% 0.00% 0.00% 0.24% 0.84% 0.03% 0.00% 0.03% 1.23%
P
Bolded boxes indicate dominant terpene
.
.
u9
,-,
.
,
,-,
.
rõ
N)
.
,
,
5',
1-d
n
1-i
cp
t..)
o
,-,
oo
-,i-::--,
o
.6.
-4
o
.6.
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
Example 7. Specialty Cannabis Hemp Cannabinoid Compositions
103711 Flowers from several Specialty Cannabis hemp lines of the present
disclosure were
carefully removed from the stems and ground in a blender prior to extraction.
Plants from high
propyl lines 09. S1 . 01X09. Sl. 01' and 'V24. S2. 26X09. S1.01' were
extracted for this example.
103721 Ground material was packed into a CO2 extraction vessel and tightly
closed before
allowing flow of CO2 to run in increasing pressure until it reaches
manufacturer settings. Three
fractions were collected separately. The first two fractions were cannabinoid
enriched fractions,
and the last fraction was a terpene-enriched fraction. The terpene fraction
was immediately
analyzed as described in Example 1, and was stored for later blending.
103731 Cannabinoid containing fractions were decarboxylated at high
temperatures (175 C) for a
period of about 90 minutes. In addition to decarboxylating, this process also
allows for water
removal from samples prior to winterization. In the winterization process, the
two cannabinoid
fractions were pooled and incubated with ethanol at -20 C for a period of at
least 24 hours for
proper separation of fats and waxes. After incubation, samples were filtered
to remove solidified
material.
[03741 After the filtering procedure was finished, excess ethanol was removed
by a rotary
evaporator, and the remainder of the material is transferred to a round bottom
flask for distillation.
The cannabinoid and terpene fractions were separately analyzed according to
the methods of
Example 1. These results, together with an analysis of the starting plant
material are provided as
Tables 14 and 15. Once the distillation process was finished, the cannabinoid
and terpene samples
were pooled for patient use.
103751 Single fraction ethanol extractions are within the scope of the instant
invention, and were
discussed in earlier sections of the specification. The analysis of Specialty
Cannabis as described
in Example 1, includes making an ethanol extract as part of the analysis.
These extracts can be
concentrated or diluted by adjusting the quantity of ethanol used in the
extraction.
120
Table 14. Cannabinoid Analyses
0
*.
4;,g
< > u
wu > > > u
u
w 12. WUu
CO CO ea W
co 1- 2 .S
I CO CO
U
o
09S101.XX FLOWER 0.28% 7.43%0.16%0.36%0.36% 8.63%
0.00% 0.00% 0.00% 0.00%0.00% 0.00% 0.07% 0.00% 0.24%
7.87%
Cannabinoid Frac. 0.00% 0.00%0.00%0.00%0.00% 0.00%
0.00% 5.85% 33.76% 0.67%1.82% 1.62%43.48% 0.00%
5.85%45.09%
Terpene Frac. 0.00% 0.00%0.00%0.00%0.00% 0.00%
0.00% 1.78% 5.81% 0.13%0.28% 0.28% 6.73% 0.00% 1.78%
7.01%
V24S226.xx FLOWER 0.19% 4.02% 0.60% 0.22% 3.66% 5.40%
0.00% 0.00% 0.00% 0.00%0.00% 0.10% 0.17% 0.00% 0.17%
8.14%
Cannabinoid Frac. 0.00% 0.00%0.00%0.00%0.00% 0.00%
0.00% 3.37% 23.34% 3.27%0.84%21.41%31.54%
0.00% 3.37%52.95% 0
L.
Terpene Frac. 0.00% 0.00%0.00%0.00%0.00% 0.00%
0.00% 1.18% 3.66% 0.46%0.17% 3.47% 5.34% 0.00% 1.18%
8.82%
*All Max values were calculated based on theoretical maximum formulas
disclosed in this application. Total Max Propyl Cannabinoids
u,
reflects the additive content of decarboxylated equivalents of THCVA, THCV,
CBDVA, CBDV, CBGVA, and CBGV as defined in
earlier sections of this document.
1-d
oe
CO-3
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
Table 15. Terpene Analyses
0.1 w w 4..
C 0.1 c
C w a.) c 7 0.1
II a) C1) a) C aj Z c w R
....
a) _ c a, c c a) C w 2 2 o c
w c 3 aj .- a) c a, - _c -
a.) w 0
2 (.1 E 2 (7j E- E Z. . 2 ,a) EL E a. cY, u
g.2_ 2 .67, 1., 0- ....a, *ma- 13 a 3
as c ,
4, .0 Z. _ >. IT w
E c'' _c a s . Cs 3 al as co
co .'= _c c.'"
= E 0. _c _c - a ' 09
0.1 co rj
'w _c _a E <1 0- - 0- a. as
0. as To ti 7x, r, ,"
0.
'071
76 t1,13 -CS as
L.) i-
09S101.XX
0.00 0.00 0.00 0.00 0.57 0.00 0.04 0.00 0.08 0.05 0.01 0.05 0.50 1.39 0.16
0.03 0.28 3.15
FLOWER % %
% % % % % % % % % % % % % % % %
Cannabinoid
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.00 0.00 0.00
Frac. % %
% % % % % % % % % % % % % % % %
0.00 0.00 0.00 0.00 12.10 0.00 2.12 0.00 1.42 1.65 0.56 1.45 9.53 21.11 4.27
0.48 8.08 62.77
Terpene Frac. % %
% % % % % % % % % % % % % % % %
V24S226.xx
0.00 0.00 0.73 0.00 0.14 0.00 0.24 0.00 0.08 0.01 0.00 0.02 0.16 0.62 0.07
0.00 0.62 2.68
FLOWER % %
% % % % % % % % % % % % % % % %
Cannabinoid
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.00 0.00 0.00
Frac. % %
% % % % % % % % % % % % % % % %
0.00 0.00 0.00 0.00 3.69 0.00 13.04 0.00 1.60 0.44 0.00 0.46 3.55 12.44 2.19
0.00 21.70 59.10
Terpene Frac. % %
% % % % % % % % % % % % % % % %
122
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
Example 8. Chemical Analysis of Named Specialty Cannabis
193761 Additional specialty cannabis varieties created through the methods
described in this
specification are disclosed. The following specialty cannabis were derived
from the high propyl
cannabinoid varieties disclosed in this specification, and were selected for
their unique predicted
physiological and organoleptic experiences. Each selected line was named prior
to being submitted
for competition in the 2017 Emerald Cup. The cannabinoid and Terpene Profiles
for the Named
Specialty Cannabis lines were measured as described in Example 1. The level of
cannabinoids for
each of the high propyl cannabinoid lines was measured by EIPLC, and is
presented in Table 16.
Terpenes were measured using GC-FID, and are presented as absolute content
measurements
based on the percent content by weight of dry inflorescences in Table 17.
103771 These Named Specialty Cannabis lines were previously disclosed in U.S.
62/596,561,
which is hereby incorporated by reference in its entirety for all purposes.
123
Table 16 Cannabinoid Contents of Named Specialty Cannabis (Partial Analysis)
g e n.)
g
1-,
c..) A Z PO PO
PO PO o =I 1-, E-le =I
et -4
.6.
c-)
Guava Jam 0.44% 9.31% 0.26% 0.24% 4.61%
0.00% 0.09% 0.08% 0.00% 0.00% 0.00% 0.38% 4.20%
*All Max values were calculated based on theoretical maximum formulas
disclosed in this application. Total Max Propyl Cannabinoids
reflects the additive content of decarboxylated equivalents of THCVA, THCV,
and CBDVA as defined in earlier sections of this
document.
P
.
.
Table 17 Terpene Contents of Named Specialty Cannabis 09
,-,
.
.
.6.
rõ
"5 r.,0
-8 *
,
0.
. .
E 0. µ.
-as 0.
= 0.
= 0.
= =
0. 0.
0. 0. o .
0.
7, o I
m = 0. 0. ..
= 0. 0.
-8 = = c.) 0,
4 m E
E0.
o .5
u = , c..,
m ,
-i.-i. = 7,
m m m E , = u =
E u m .. = u E
=2. =
-i.
u
= -a E
u
, ,
-Flt a -a m
E.
Guava Jam 0.00% 0.00% 0.00% 0.00% 0.26% 0.00% 0.03% 0.00% 0.04% 0.04% 0.01%
0.04% 0.17% 0.16% 0.13% 0.02% 0.07% 0.97%
Iv
n
1-i
cp
t..)
o
,-,
oo
-,i-::--,
o
.6.
-4
o
.6.
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
Example 9. Survey of Closest Check Lines
[0.3781 A series of closest check lines will be analyzed according to the
methods of Example 1 to
provide cannabinoid and terpene contents. These values will be compared
against the Specialty
Cannabis hemp lines of the present disclosure.
******
DEPOSIT INFORMATION
103791 A deposit of the cannabis varieties of the present invention, including
the Specialty
Cannabis, and Named Specialty Cannabis disclosed in this specification
(including all lines
referenced in Tables 3-13 and 16-17, and Figures 3-8), is maintained by the
Biotech Institute, LLC
5655 Lindero Canyon Road, Suite 226, Westlake Village, CA 91362.
103801 In addition, a sample of one or more varieties of this invention
(including all lines
referenced in Tables 3-13 and 16-17, and Figures 3-8) have-or will be-
deposited with an
International Depositary Authority as established under the Budapest Treaty
according to 37 CFR
1.803(a)(1), at the National Collections of Industrial, Food and Marine
Bacteria Ltd. (NCIMB) in
Aberdeen Scotland and/or at the National Center for Marine Algae and
Microbiota (NCMA) in
East Boothbay, Maine.
[03811 A sample of seed from 03.52.01x09.S1.01 was deposited as NCIMB 43258 on
November
9, 2018. A sample of seed from 03.52.16x09.S1.01 was deposited as NCIMB 43259
on November
9, 2018. A sample of seed from 012.09.10x09.S1.01 was deposited as NCIMB 43260
on
November 9, 2018.
103821 To satisfy the enablement requirements of 35 U.S.C. 112, and to certify
that the deposit of
the isolated strains (i.e., cannabis varieties) of the present invention meets
the criteria set forth in
37 CFR 1.801-1.809 and Manual of Patent Examining Procedure (MPEP) 2402-
2411.05,
Applicants hereby make the following statements regarding the deposited
cannabis varieties:
103831 If the deposit is made under the terms of the Budapest Treaty, the
instant invention will be
irrevocably and without restriction released to the public upon the granting
of a patent.
125
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
103841 If the deposit is made not under the terms of the Budapest Treaty,
Applicant(s) provides
assurance of compliance by following statements:
103851 1. During the pendency of this application, access to the invention
will be afforded to
the Commissioner upon request;
10386] 2. All restrictions on availability to the public will be
irrevocably removed upon
granting of the patent under conditions specified in 37 CFR 1.808;
103871 3. The deposit will be maintained in a public repository for a
period of 30 years or 5
years after the last request or for the effective life of the patent,
whichever is longer;
10388] 4. A test of the viability of the biological material at the time of
deposit will be
conducted by the public depository under 37 CFR 1.807; and
103891 5. The deposit will be replaced if it should ever become
unavailable.
103901 Access to this deposit will be available during the pendency of this
application to persons
determined by the Commissioner of Patents and Trademarks to be entitled
thereto under 37 C.F.R.
1.14 and 35 U.S.C. 122. Upon granting of any claims in this application, all
restrictions on the
availability to the public of the variety will be irrevocably removed by
affording access to a deposit
of at least 2,500 seeds of the same variety with the depository.
10391] Unless defined otherwise, all technical and scientific terms herein
have the same meaning
as commonly understood by one of ordinary skill in the art to which this
invention belongs.
Although any methods and materials, similar or equivalent to those described
herein, can be used
in the practice or testing of the present invention, the non-limiting
exemplary methods and
materials are described herein.
103921 All publications and patent applications mentioned in the specification
are indicative of the
level of those skilled in the art to which this invention pertains. All
publications and patent
applications are herein incorporated by reference to the same extent as if
each individual
publication or patent application was specifically and individually indicated
to be incorporated by
reference. Nothing herein is to be construed as an admission that the present
invention is not
entitled to antedate such publication by virtue of prior invention. U.S.
patent 9,095,554 and U.S.
published patent applications 15/593,344 and 15/539,346 are each hereby
incorporated in their
entireties for all purposes.
126
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
1093] Many modifications and other embodiments of the inventions set forth
herein will come to
mind to one skilled in the art to which these inventions pertain having the
benefit of the teachings
presented in the foregoing descriptions and the associated drawings.
Therefore, it is to be
understood that the inventions are not to be limited to the specific
embodiments disclosed and that
modifications and other embodiments are intended to be included within the
scope of the appended
claims. Although specific terms are employed herein, they are used in a
generic and descriptive
sense only and not for purposes of limitation.
193941 While the invention has been described in connection with specific
embodiments thereof,
it will be understood that it is capable of further modifications and this
application is intended to
cover any variations, uses, or adaptations of the invention following, in
general, the principles of
the invention and including such departures from the present disclosure as
come within known or
customary practice within the art to which the invention pertains and as may
be applied to the
essential features hereinbefore set forth and as follows in the scope of the
appended claims.
Further Embodiments of the Invention
1.03951 Other subject matter contemplated by the present disclosure is set out
in the following
numbered embodiments:
1. A cannabis hemp plant, or an asexual clone of said cannabis hemp plant, or
a plant part, tissue,
or cell thereof, which is capable of producing a female inflorescence, said
inflorescence
comprising:
a) a functional BD allele;
b) a propyl cannabinoid max content of at least 1.0% by weight;
c) a tetrahydrocannabinol (THC max) content of no more than 0.3% by weight,
wherein the contents of all cannabinoids are measured by high performance
liquid
chromatography (HPLC) and calculated based on dry weight of the inflorescence.
1.1 The cannabis hemp plant, or an asexual clone of said cannabis hemp
plant, or a plant part,
tissue, or cell thereof of embodiment 1, wherein a representative sample of
seed producing said
plant has been deposited under NCIMB Nos. 43258, 43259, and 43260.
1.2 A terpene producing, diploid cannabis hemp plant cell from a female
inflorescence (i) a
cannabis hemp plant, (ii) an asexual clone of the plant, or (iii) a part of
the plant, wherein said
127
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
cannabis hemp plant, asexual clone of the plant or part of the plant produces
the female
inflorescence, said inflorescence comprising:
a) a functional BD allele;
b) a propyl cannabinoid max content of at least 1.0% by weight;
c) a tetrahydrocannabinol (THC max) content of no more than 0.3% by weight,
wherein the contents of all cannabinoids are measured by high performance
liquid
chromatography (HPLC) and calculated based on dry weight of the inflorescence;
wherein and
wherein samples of seed that produce plants comprising a), b), and c) have
been deposited under
NCIMB Nos. 43258, 43259, and 43260.
1.3 A dry sinsemilla cannabis inflorescence comprising:
a) a BD allele;
b) a propyl cannabinoid max content of at least 1.0% by weight;
c) a tetrahydrocannabinol (THC max) content of no more than 0.3% by weight,
wherein the contents of all cannabinoids are measured by high performance
liquid
chromatography (HPLC) and calculated based on dry weight of the inflorescence;
wherein and
wherein samples of seed that produce plants comprising a), b), and c) are
obtainable from seed
deposited under NCIMB Nos. 43258, 43259, and 43260.
2. The cannabis hemp plant, or an asexual clone of said cannabis hemp plant,
or a plant part,
tissue, or cell thereof of embodiment 1 or 1.1, wherein the plant does not
comprise a functional BT
allele.
2.1 The cannabis hemp plant, or an asexual clone of said cannabis hemp
plant, or a plant part,
tissue, or cell thereof of embodiment 1 or 1.1, wherein the plant comprises a
BD/BD genotype.
2.2 The cannabis hemp plant, or an asexual clone of said cannabis hemp
plant, or a plant part,
tissue, or cell thereof of embodiment 1 or 1.1, wherein the plant comprises a
Bo/BD genotype.
3. The cannabis hemp plant, or an asexual clone of said cannabis hemp plant,
or a plant part, tissue,
or cell thereof of embodiment 1 or 1.1, wherein the inflorescence comprises a
terpene oil content
greater than about 1.0% by weight;
128
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
wherein the terpene oil content is the additive content of terpinolene, alpha
phellandrene,
beta ocimene, carene, limonene, gamma terpinene, alpha pinene, alpha
terpinene, beta pinene,
fenchol, camphene, alpha terpineol, alpha humulene, beta caryophyllene,
linalool,
caryophyllene oxide, and myrcene as measured by GC-FID and calculated based on
dry
weight of the inflorescence.
4. The cannabis hemp plant, or an asexual clone of said cannabis hemp plant,
or a plant part, tissue,
or cell thereof of embodiment 3, wherein the inflorescence comprises a terpene
oil content greater
than about 1.5% by weight.
5. The cannabis hemp plant, or an asexual clone of said cannabis hemp plant,
or a plant part, tissue,
or cell thereof of embodiment 3, wherein the inflorescence comprises a terpene
oil content greater
than about 2.0% by weight.
6. The cannabis hemp plant, or an asexual clone of said cannabis hemp plant,
or a plant part, tissue,
or cell thereof of any one of embodiments 1-5, wherein the inflorescence
comprises a propyl
cannabinoid max content of at least 2% by weight.
7. The cannabis hemp plant, or an asexual clone of said cannabis hemp plant,
or a plant part, tissue,
or cell thereof of any one of embodiments 1-6, wherein the inflorescence
comprises a propyl
cannabinoid max content of at least 3% by weight.
8. The cannabis hemp plant, or an asexual clone of said cannabis hemp plant,
or a plant part, tissue,
or cell thereof of any one of embodiments 1-7, wherein the inflorescence
comprises a THC max
content of no more than 0.2% by weight.
9. The cannabis hemp plant, or an asexual clone of said cannabis hemp plant,
or a plant part, tissue,
or cell thereof of any one of embodiments 1-7, wherein the inflorescence
comprises a THC max
content of no more than 0.1% by weight.
10. The cannabis hemp plant, or an asexual clone of said cannabis hemp
plant, or a plant part,
tissue, or cell thereof of any one of embodiments 1-7, wherein the
inflorescence comprises a THC
max content of no more than 0.01% by weight.
129
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
11. The cannabis hemp plant, or an asexual clone of said cannabis hemp
plant, or a plant part,
tissue, or cell thereof of any one of embodiments 1-7, wherein the
inflorescence comprises a THC
max content of no more than 0.00% by weight.
12. The cannabis hemp plant, or an asexual clone of said cannabis hemp
plant, or a plant part,
tissue, or cell thereof of any one of embodiments 1-11, wherein the
inflorescence comprises a
Terpene Profile in which myrcene is not the dominant terpene; wherein the
Terpene Profile is
defined as terpinolene, alpha phellandrene, beta ocimene, carene, limonene,
gamma terpinene,
alpha pinene, alpha terpinene, beta pinene, fenchol, camphene, alpha
terpineol, alpha humulene,
beta caryophyllene, linalool, caryophyllene oxide, and myrcene.
13. The cannabis hemp plant, or an asexual clone of said cannabis hemp
plant, or a plant part,
tissue, or cell thereof of embodiment 12, wherein the first or second most
abundant terpene in the
Terpene Profile is terpinolene.
14. The cannabis hemp plant, or an asexual clone of said cannabis hemp
plant, or a plant part,
tissue, or cell thereof of embodiment 12, wherein the first or second most
abundant terpene in the
Terpene Profile is alpha phellandrene.
15. The cannabis hemp plant, or an asexual clone of said cannabis hemp
plant, or a plant part,
tissue, or cell thereof of embodiment 12, wherein the first or second most
abundant terpene in the
Terpene Profile is beta ocimene.
16. The cannabis hemp plant, or an asexual clone of said cannabis hemp
plant, or a plant part,
tissue, or cell thereof of embodiment 12, wherein the first or second most
abundant terpene in the
Terpene Profile is carene.
17. The cannabis hemp plant, or an asexual clone of said cannabis hemp
plant, or a plant part,
tissue, or cell thereof of embodiment 12, wherein the first or second most
abundant terpene in the
Terpene Profile is limonene.
130
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
18. The cannabis hemp plant, or an asexual clone of said cannabis hemp
plant, or a plant part,
tissue, or cell thereof of embodiment 12, wherein the first or second most
abundant terpene in the
Terpene Profile is gamma terpinene.
19. The cannabis hemp plant, or an asexual clone of said cannabis hemp
plant, or a plant part,
tissue, or cell thereof of embodiment 12, wherein the first or second most
abundant terpene in the
Terpene Profile is alpha pinene.
20. The cannabis hemp plant, or an asexual clone of said cannabis hemp
plant, or a plant part,
tissue, or cell thereof of embodiment 12, wherein the first or second most
abundant terpene in the
Terpene Profile is alpha terpinene.
21. The cannabis hemp plant, or an asexual clone of said cannabis hemp
plant, or a plant part,
tissue, or cell thereof of embodiment 12, wherein the first or second most
abundant terpene in the
Terpene Profile is beta pinene.
22. The cannabis hemp plant, or an asexual clone of said cannabis hemp
plant, or a plant part,
tissue, or cell thereof of embodiment 12, wherein the first or second most
abundant terpene in the
Terpene Profile is fenchol.
23. The cannabis hemp plant, or an asexual clone of said cannabis hemp
plant, or a plant part,
tissue, or cell thereof of embodiment 12, wherein the first or second most
abundant terpene in the
Terpene Profile is camphene.
24. The cannabis hemp plant, or an asexual clone of said cannabis hemp
plant, or a plant part,
tissue, or cell thereof of embodiment 12, wherein the first or second most
abundant terpene in the
Terpene Profile is alpha terpineol.
25. The cannabis hemp plant, or an asexual clone of said cannabis hemp
plant, or a plant part,
tissue, or cell thereof of embodiment 12, wherein the first or second most
abundant terpene in the
Terpene Profile is alpha humulene.
131
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
26. The cannabis hemp plant, or an asexual clone of said cannabis hemp
plant, or a plant part,
tissue, or cell thereof of embodiment 12, wherein the first or second most
abundant terpene in the
Terpene Profile is beta caryophyllene.
27. The cannabis hemp plant, or an asexual clone of said cannabis hemp
plant, or a plant part,
tissue, or cell thereof of embodiment 12, wherein the first or second most
abundant terpene in the
Terpene Profile is linalool.
28. The cannabis hemp plant, or an asexual clone of said cannabis hemp
plant, or a plant part,
tissue, or cell thereof of embodiment 12, wherein the first or second most
abundant terpene in the
Terpene Profile is caryophyllene oxide.
29. The cannabis hemp plant, or an asexual clone of said cannabis hemp
plant, or a plant part,
tissue, or cell thereof of any one of embodiments 1-11, wherein the
inflorescence comprises a
Terpene Profile in which myrcene is the first or second most abundant terpene
in the Terpene
Profile; wherein the Terpene Profile is defined as terpinolene, alpha
phellandrene, beta ocimene,
carene, limonene, gamma terpinene, alpha pinene, alpha terpinene, beta pinene,
fenchol,
camphene, alpha terpineol, alpha humulene, beta caryophyllene, linalool,
caryophyllene oxide, and
myrcene.
29.1 A method of producing a cannabis extract, said method comprising the
steps of: contacting
the inflorescence of any one of embodiments 1-29 with a solvent, thereby
producing a cannabis
extract.
29.2 The method of embodiment 29.1, comprising the step of heating said
extract, thereby
decarboxylating at least 70% of the cannabinoid content of the extract.
29.3 The method of embodiment 29.1, comprising the step of winterizing said
extract.
132
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
30. A cannabis extract from the cannabis hemp plant, plant part, tissue, or
cell of any one of
embodiments 1-29.
31. The cannabis extract of embodiment 30, wherein said extract is selected
from the group
consisting of kief, hashish, bubble hash, solvent reduced oils, sludges, e-
juice, and tinctures.
32. The cannabis extract of embodiments 30 or 31, wherein said extract
comprises greater than
10% propyl cannabinoid max content, greater than 10% terpene oil content, and
less than 1% THC
max content as measured by 1-11PLC and based on weight of the extract.
33. A method of breeding cannabis hemp plants with high propyl cannabinoid
content max and
low THC max content, said method comprising:
(i) making a cross between a first cannabis hemp plant of any one of
embodiments 1-29,
and a second cannabis plant to produce an Fl plant
(ii) harvesting the resulting seed;
(iii) growing said seed; and
(iv) selecting for high propyl cannabinoid content max and low THC max
content;
wherein the resulting selected cannabis hemp plant comprises at least 1.0%
propyl cannabinoid
max content by weight, and no more than 0.3% THC max content by weight.
34. A method of producing cannabis hemp plants with high propyl cannabinoid
content max and
low THC max content, said method comprising:
(i) obtaining a cannabis seed, or cutting from a first cannabis hemp plant of
any one of
embodiments 1-29,
(ii) placing said cannabis seed or cutting in an environment conducive to
plant growth;
(iii) allowing said cannabis seed or cutting to produce a new cannabis plant;
(iv) selecting for high propyl cannabinoid content max and low THC max
content;
wherein the resulting selected cannabis hemp plant is comprises at least 1.0%
propyl cannabinoid
max content by weight, and no more than 0.3% THC max content by weight.
35. A cannabis hemp female inflorescence, said inflorescence comprising:
a) a functional BD allele;
133
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
b) a propyl cannabinoid max content of at least 1.0% by weight;
c) a tetrahydrocannabinol (THC max) content of no more than 0.3% by weight,
wherein the contents of all cannabinoids are measured by high performance
liquid
chromatography (HPLC) and calculated based on dry weight of the inflorescence.
35.1 The cannabis hemp female inflorescence of embodiment 35, wherein a
representative sample
of seed producing plants with said inflorescence has been deposited under
NCIMB Nos. 43258,
43259, and 43260.
36. The cannabis hemp female inflorescence of embodiment 35 or 35.1,
wherein the
inflorescence does not comprise a functional BT allele.
36.1 The cannabis hemp female inflorescence of embodiment 35 or 35.1,
wherein the
inflorescence comprises a BD/BD genotype.
36.2 The cannabis hemp female inflorescence of embodiment 35 or 35.1, wherein
the plant
comprises a Bo/BD genotype.
37. The cannabis hemp female inflorescence of embodiment 35 or 35.1,
wherein the
inflorescence comprises a terpene oil content greater than about 1.0% by
weight;
wherein the terpene oil content is the additive content of terpinolene, alpha
phellandrene,
beta ocimene, carene, limonene, gamma terpinene, alpha pinene, alpha
terpinene, beta pinene,
fenchol, camphene, alpha terpineol, alpha humulene, beta caryophyllene,
linalool,
caryophyllene oxide, and myrcene as measured by GC-FID and calculated based on
dry
weight of the inflorescence.
38. The cannabis hemp female inflorescence of embodiment 37, wherein the
inflorescence
comprises a terpene oil content greater than about 1.5% by weight.
39. The cannabis hemp female inflorescence of embodiment 37, wherein the
inflorescence
comprises a terpene oil content greater than about 2.0% by weight.
40. The cannabis hemp female inflorescence of any one of embodiments 35-39,
wherein the
inflorescence comprises a propyl cannabinoid max content of at least 2% by
weight.
134
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
41. The cannabis hemp female inflorescence of any one of embodiments 35-40,
wherein the
inflorescence comprises a propyl cannabinoid max content of at least 3% by
weight.
42. The cannabis hemp female inflorescence of any one of embodiments 35-41,
wherein the
inflorescence comprises a THC max content of no more than 0.2% by weight.
43. The cannabis hemp female inflorescence of any one of embodiments 35-42,
wherein the
inflorescence comprises a THC max content of no more than 0.1% by weight.
44. The cannabis hemp female inflorescence of any one of embodiments 35-43,
wherein the
inflorescence comprises a THC max content of no more than 0.01% by weight.
45. The cannabis hemp female inflorescence of any one of embodiments 35-44,
wherein the
inflorescence comprises a THC max content of no more than 0.00% by weight.
46. The cannabis hemp female inflorescence of any one of embodiments 35-45,
wherein the
inflorescence comprises a Terpene Profile in which myrcene is not the dominant
terpene; wherein
the Terpene Profile is defined as terpinolene, alpha phellandrene, beta
ocimene, carene, limonene,
gamma terpinene, alpha pinene, alpha terpinene, beta pinene, fenchol,
camphene, alpha terpineol,
alpha humulene, beta caryophyllene, linalool, caryophyllene oxide, and
myrcene.
47. The cannabis hemp female inflorescence of embodiment 46, wherein the
first or second
most abundant terpene in the Terpene Profile is terpinolene.
48. The cannabis hemp female inflorescence of embodiment 46, wherein the
first or second
most abundant terpene in the Terpene Profile is alpha phellandrene.
49. The cannabis hemp female inflorescence of embodiment 46, wherein the
first or second
most abundant terpene in the Terpene Profile is beta ocimene.
50. The cannabis hemp female inflorescence of embodiment 46, wherein the
first or second
most abundant terpene in the Terpene Profile is carene.
135
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
51. The cannabis hemp female inflorescence of embodiment 46, wherein the
first or second
most abundant terpene in the Terpene Profile is limonene.
52. The cannabis hemp female inflorescence of embodiment 46, wherein the
first or second
most abundant terpene in the Terpene Profile is gamma terpinene.
53. The cannabis hemp female inflorescence of embodiment 46, wherein the
first or second
most abundant terpene in the Terpene Profile is alpha pinene.
54. The cannabis hemp female inflorescence of embodiment 46, wherein the
first or second
most abundant terpene in the Terpene Profile is alpha terpinene.
55. The cannabis hemp female inflorescence of embodiment 46, wherein the
first or second
most abundant terpene in the Terpene Profile is beta pinene.
56. The cannabis hemp female inflorescence of embodiment 46, wherein the
first or second
most abundant terpene in the Terpene Profile is fenchol.
57. The cannabis hemp female inflorescence of embodiment 46, wherein the
first or second
most abundant terpene in the Terpene Profile is camphene.
58. The cannabis hemp female inflorescence of embodiment 46, wherein the
first or second
most abundant terpene in the Terpene Profile is alpha terpineol.
59. The cannabis hemp female inflorescence of embodiment 46, wherein the
first or second
most abundant terpene in the Terpene Profile is alpha humulene.
60. The cannabis hemp female inflorescence of embodiment 46, wherein the
first or second
most abundant terpene in the Terpene Profile is beta caryophyllene.
136
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
61. The cannabis hemp female inflorescence of embodiment 46, wherein the
first or second
most abundant terpene in the Terpene Profile is linalool.
62. The cannabis hemp female inflorescence of embodiment 46, wherein the
first or second
most abundant terpene in the Terpene Profile is caryophyllene oxide.
63. The cannabis hemp female inflorescence of any one of embodiments 35-45,
wherein the
inflorescence comprises a Terpene Profile in myrcene is the first or second
most abundant terpene
in the Terpene Profile; wherein the Terpene Profile is defined as terpinolene,
alpha phellandrene,
beta ocimene, carene, limonene, gamma terpinene, alpha pinene, alpha
terpinene, beta pinene,
fenchol, camphene, alpha terpineol, alpha humulene, beta caryophyllene,
linalool, caryophyllene
oxide, and myrcene.
63.1 A method of producing a cannabis extract, said method comprising the
steps of: contacting
the inflorescence of any one of embodiments 35-63 with a solvent, thereby
producing a cannabis
extract.
63.2 The method of embodiment 63.1, comprising the step of heating said
extract, thereby
decarboxylating at least 70% of the cannabinoid content of the extract.
63.3 The method of embodiment 63.1, comprising the step of winterizing said
extract
64. A cannabis extract from the cannabis hemp female inflorescence of any one
of embodiments
35-63.
65. The cannabis extract of embodiment 64, wherein said extract is selected
from the group
consisting of kief, hashish, bubble hash, solvent reduced oils, sludges, e-
juice, and tinctures.
66. The cannabis extract of embodiments 64 or 65, wherein said extract
comprises greater than
10% propyl cannabinoid max content, greater than 10% terpene oil content, and
less than 1% THC
max content as measured by HPLC and based on weight of the extract.
137
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
67. A terpene producing, diploid cannabis hemp plant cell from a female
inflorescence (i) a
cannabis hemp plant, (ii) an asexual clone of the plant, or (iii) a part of
the plant, wherein said
cannabis hemp plant, asexual clone of the plant or part of the plant produces
the female
inflorescence, said inflorescence comprising:
a) a functional BD allele;
b) a propyl cannabinoid max content of at least 1.0% by weight;
c) a tetrahydrocannabinol (THC max) content of no more than 0.3% by weight,
wherein the contents of all cannabinoids are measured by high performance
liquid
chromatography (HPLC) and calculated based on dry weight of the inflorescence;
wherein and
wherein samples of seed that produce plants comprising a), b), and c) have
been deposited under
NCIMB Nos. 43258, 43259, and 43260.
68. The terpene producing, diploid cannabis hemp plant cell of embodiment
67, wherein the
cell does not comprise a functional BT allele.
68.1 The terpene producing, diploid cannabis hemp plant cell of embodiment
67, wherein the
cell comprises a 13D/BD genotype.
68.2 The terpene producing, diploid cannabis hemp plant cell of embodiment
67, wherein the
cell comprises a Bo/BD genotype.
69. The terpene producing, diploid cannabis hemp plant cell of embodiment
67, wherein the
inflorescence comprises a terpene oil content greater than about 1.0% by
weight;
wherein the terpene oil content is the additive content of terpinolene, alpha
phellandrene,
beta ocimene, carene, limonene, gamma terpinene, alpha pinene, alpha
terpinene, beta pinene,
fenchol, camphene, alpha terpineol, alpha humulene, beta caryophyllene,
linalool,
caryophyllene oxide, and myrcene as measured by GC-FID and calculated based on
dry
weight of the inflorescence.
70. The terpene producing, diploid cannabis hemp plant cell of embodiment
69, wherein the
inflorescence comprises a terpene oil content greater than about 1.5% by
weight.
138
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
71. The terpene producing, diploid cannabis hemp plant cell of embodiment
69, wherein the
inflorescence comprises a terpene oil content greater than about 2.0% by
weight.
72. The terpene producing, diploid cannabis hemp plant cell of any one of
embodiments 67-
71, wherein the inflorescence comprises a propyl cannabinoid max content of at
least 2% by
weight.
73. The terpene producing, diploid cannabis hemp plant cell of embodiments
67-71, wherein
the inflorescence comprises a propyl cannabinoid max content of at least 3% by
weight.
74. The terpene producing, diploid cannabis hemp plant cell of embodiments
67-71, wherein
the inflorescence comprises a THC max content of no more than 0.2% by weight.
75. The terpene producing, diploid cannabis hemp plant cell of embodiments
67-71, wherein
the inflorescence comprises a THC max content of no more than 0.1% by weight.
76. The terpene producing, diploid cannabis hemp plant cell of embodiments
67-71, wherein
the inflorescence comprises a THC max content of no more than 0.01% by weight.
77. The terpene producing, diploid cannabis hemp plant cell of embodiments
67-71, wherein
the inflorescence comprises a THC max content of no more than 0.00% by weight.
78. The terpene producing, diploid cannabis hemp plant cell of any one of
embodiments 67-
77, wherein the inflorescence comprises a Terpene Profile in which myrcene is
not the dominant
terpene; wherein the Terpene Profile is defined as terpinolene, alpha
phellandrene, beta ocimene,
carene, limonene, gamma terpinene, alpha pinene, alpha terpinene, beta pinene,
fenchol,
camphene, alpha terpineol, alpha humulene, beta caryophyllene, linalool,
caryophyllene oxide, and
myrcene.
79. The terpene producing, diploid cannabis hemp plant cell of embodiment
78, wherein the
first or second most abundant terpene in the Terpene Profile is terpinolene.
80. The terpene producing, diploid cannabis hemp plant cell of embodiment
78, wherein the
first or second most abundant terpene in the Terpene Profile is alpha
phellandrene.
139
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
81. The terpene producing, diploid cannabis hemp plant cell of embodiment
78, wherein the
first or second most abundant terpene in the Terpene Profile is beta ocimene.
82. The terpene producing, diploid cannabis hemp plant cell of embodiment
78, wherein the
first or second most abundant terpene in the Terpene Profile is carene.
83. The terpene producing, diploid cannabis hemp plant cell of embodiment
78, wherein the
first or second most abundant terpene in the Terpene Profile is limonene.
84. The terpene producing, diploid cannabis hemp plant cell of embodiment
78, wherein the
first or second most abundant terpene in the Terpene Profile is gamma
terpinene.
85. The terpene producing, diploid cannabis hemp plant cell of embodiment
78, wherein the
first or second most abundant terpene in the Terpene Profile is alpha pinene.
86. The terpene producing, diploid cannabis hemp plant cell of embodiment
78, wherein the
first or second most abundant terpene in the Terpene Profile is alpha
terpinene.
87. The terpene producing, diploid cannabis hemp plant cell of embodiment
78, wherein the
first or second most abundant terpene in the Terpene Profile is beta pinene.
88. The terpene producing, diploid cannabis hemp plant cell of embodiment
78, wherein the
first or second most abundant terpene in the Terpene Profile is fenchol.
89. The terpene producing, diploid cannabis hemp plant cell of embodiment
78, wherein the
first or second most abundant terpene in the Terpene Profile is camphene.
90. The terpene producing, diploid cannabis hemp plant cell of embodiment
78, wherein the
first or second most abundant terpene in the Terpene Profile is alpha
terpineol.
140
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
91. The terpene producing, diploid cannabis hemp plant cell of embodiment
78, wherein the
first or second most abundant terpene in the Terpene Profile is alpha
humulene.
92. The terpene producing, diploid cannabis hemp plant cell of embodiment
78, wherein the
first or second most abundant terpene in the Terpene Profile is beta
caryophyllene.
93. The terpene producing, diploid cannabis hemp plant cell of embodiment
78, wherein the
first or second most abundant terpene in the Terpene Profile is linalool.
94. The terpene producing, diploid cannabis hemp plant cell of embodiment
78, wherein the
first or second most abundant terpene in the Terpene Profile is caryophyllene
oxide.
95. The terpene producing, diploid cannabis hemp plant cell of any one of
embodiments 67-
77, wherein the inflorescence comprises a Terpene Profile in which myrcene is
the first or second
most abundant terpene in the Terpene Profile; wherein the Terpene Profile is
defined as
terpinolene, alpha phellandrene, beta ocimene, carene, limonene, gamma
terpinene, alpha pinene,
alpha terpinene, beta pinene, fenchol, camphene, alpha terpineol, alpha
humulene, beta
caryophyllene, linalool, caryophyllene oxide, and myrcene.
95.1 A method of producing a cannabis extract, said method comprising the
steps of: contacting
the cell of any one of embodiments 67-95 with a solvent, thereby producing a
cannabis extract.
95.2 The method of embodiment 95.1, comprising the step of heating said
extract, thereby
decarboxylating at least 70% of the cannabinoid content of the extract.
95.3 The method of embodiment 95.1, comprising the step of winterizing said
extract
96. A cannabis extract from the terpene producing, diploid cannabis hemp plant
cell of any one
of embodiments 67-95.
141
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
97. The cannabis extract of embodiment 96, wherein said extract is selected
from the group
consisting of kief, hashish, bubble hash, solvent reduced oils, sludges, e-
juice, and tinctures.
98. The cannabis extract of embodiments 96 or 97, wherein said extract
comprises greater than
10% propyl cannabinoid max content, greater than 10% terpene oil content, and
less than 1% THC
max content as measured by HPLC and based on weight of the extract.
99. A dry, non-viable (i) cannabis hemp plant or (ii) part thereof, wherein
said cannabis hemp
plant or part thereof, comprises at least a portion of a female inflorescence,
said inflorescence
comprising:
a) a BD allele;
b) a propyl cannabinoid max content of at least 1.0% by weight;
c) a tetrahydrocannabinol (THC max) content of no more than 0.3% by weight,
wherein the contents of all cannabinoids are measured by high performance
liquid
chromatography (HPLC) and calculated based on dry weight of the inflorescence,
wherein samples
of seed that produce plants comprising a), b), and c) have been deposited
under NCIMB Nos.
43258, 43259, and 43260.
100. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of
embodiment 99, wherein
the inflorescence does not comprise a BT allele.
100.1 The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of
embodiment 99, wherein
the inflorescence comprises a BD/BD genotype.
100.2 The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of
embodiment 99, wherein
the inflorescence comprises a Bo/Bb genotype.
101. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of any
one of embodiments
99-100, wherein the inflorescence comprises a terpene oil content greater than
about 1.0% by
weight;
wherein the terpene oil content is the additive content of terpinolene, alpha
phellandrene,
beta ocimene, carene, limonene, gamma terpinene, alpha pinene, alpha
terpinene, beta pinene,
fenchol, camphene, alpha terpineol, alpha humulene, beta caryophyllene,
linalool,
142
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
caryophyllene oxide, and myrcene as measured by GC-FID and calculated based on
dry
weight of the inflorescence.
102. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of
embodiment 101, wherein
the inflorescence comprises a terpene oil content greater than about 1.5% by
weight.
103. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of
embodiment 101, wherein
the inflorescence comprises a terpene oil content greater than about 2.0% by
weight.
104. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of any
one of embodiments
99-103, wherein the inflorescence comprises a propyl cannabinoid max content
of at least 2% by
weight.
105. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of any
one of any one of
embodiments 99-103, wherein the inflorescence comprises a propyl cannabinoid
max content of
at least 3% by weight.
106. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of any
one of any one of
embodiments 99-105, wherein the inflorescence comprises a THC max content of
no more than
0.2% by weight.
107. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of any
one of any one of
embodiments 99-105, wherein the inflorescence comprises a THC max content of
no more than
0.1% by weight.
108. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of any
one of any one of
embodiments 99-105, wherein the inflorescence comprises a THC max content of
no more than
0.01% by weight.
109. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of any
one of any one of
embodiments 99-105, wherein the inflorescence comprises a THC max content of
no more than
0.00% by weight.
110. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of any
one of any one of
embodiments 99-109, wherein the inflorescence comprises a Terpene Profile in
which myrcene is
143
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
not the dominant terpene; wherein the Terpene Profile is defined as
terpinolene, alpha
phellandrene, beta ocimene, carene, limonene, gamma terpinene, alpha pinene,
alpha terpinene,
beta pinene, fenchol, camphene, alpha terpineol, alpha humulene, beta
caryophyllene, linalool,
caryophyllene oxide, and myrcene.
111. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of any
one of embodiment
110, wherein the first or second most abundant terpene in the Terpene Profile
is terpinolene.
112. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of any
one of embodiment
110, wherein the first or second most abundant terpene in the Terpene Profile
is alpha
phellandrene.
113. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of any
one of embodiment
110, wherein the first or second most abundant terpene in the Terpene Profile
is beta ocimene.
114. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of any
one of embodiment
110, wherein the first or second most abundant terpene in the Terpene Profile
is carene.
115. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of any
one of embodiment
110, wherein the first or second most abundant terpene in the Terpene Profile
is limonene.
116. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of any
one of embodiment
110, wherein the first or second most abundant terpene in the Terpene Profile
is gamma terpinene.
117. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of any
one of embodiment
110, wherein the first or second most abundant terpene in the Terpene Profile
is alpha pinene.
118. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of any
one of embodiment
110, wherein the first or second most abundant terpene in the Terpene Profile
is alpha terpinene.
119. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of any
one of embodiment
110, wherein the first or second most abundant terpene in the Terpene Profile
is beta pinene.
144
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
120. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of any
one of embodiment
110, wherein the first or second most abundant terpene in the Terpene Profile
is fenchol.
121. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of any
one of embodiment
110, wherein the first or second most abundant terpene in the Terpene Profile
is camphene.
122. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of any
one of embodiment
110, wherein the first or second most abundant terpene in the Terpene Profile
is alpha terpineol.
123. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of any
one of embodiment
110, wherein the first or second most abundant terpene in the Terpene Profile
is alpha humulene.
124. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of any
one of embodiment
110, wherein the first or second most abundant terpene in the Terpene Profile
is beta
caryophyllene.
125. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of any
one of embodiment
110, wherein the first or second most abundant terpene in the Terpene Profile
is linalool.
126. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of any
one of embodiment
110, wherein the first or second most abundant terpene in the Terpene Profile
is caryophyllene
oxide.
127. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of any
one of any one of
embodiments 99-109, wherein the inflorescence comprises a Terpene Profile in
which myrcene is
the first or second most abundant terpene in the Terpene Profile; wherein the
Terpene Profile is
defined as terpinolene, alpha phellandrene, beta ocimene, carene, limonene,
gamma terpinene,
alpha pinene, alpha terpinene, beta pinene, fenchol, camphene, alpha
terpineol, alpha humulene,
beta caryophyllene, linalool, caryophyllene oxide, and myrcene.
145
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
127.1 A method of producing a cannabis extract, said method comprising the
steps of: contacting
the inflorescence of any one of embodiments 99-127 with a solvent, thereby
producing a cannabis
extract.
127.2 The method of embodiment 127.1, comprising the step of heating said
extract, thereby
decarboxylating at least 70% of the cannabinoid content of the extract.
127.3 The method of embodiment 127.1, comprising the step of winterizing said
extract
128. A cannabis extract from the cannabis the dry, non-viable (i) cannabis
hemp plant or (ii)
part thereof of any one of embodiments 99-127.
129. The cannabis extract of embodiment 129, wherein said extract is selected
from the group
consisting of kief, hashish, bubble hash, solvent reduced oils, sludges, e-
juice, and tinctures.
130. The cannabis extract of embodiments 128 or 129, wherein said extract
comprises greater
than 10% propyl cannabinoid max content, greater than 10% terpene oil content,
and less than 1%
THC max content as measured by HPLC and based on weight of the extract.
131. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of any
one of embodiments
99-127, wherein said inflorescence is sinsemilla.
132. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of any
one of embodiments
99-127, wherein said inflorescence is seedless.
133. The dry, non-viable (i) cannabis hemp plant or (ii) part thereof of any
one of embodiments
99-127, wherein said inflorescence is unpollinated.
134. A composition comprising:
a) a propyl cannabinoid max content of at least 20% by weight;
b) a cannabidiol (CBD max) content of at least 10% by weight; and
c) a tetrahydrocannabinol (THC max) content of no more than 10% by weight;
146
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
wherein the contents of all cannabinoids are measured by high performance
liquid
chromatography (HPLC) and calculated based on weight of the composition.
135. The composition of embodiment 134, wherein the composition comprises a
terpene oil
content greater than about 10% by weight;
wherein the terpene oil content is the additive content of terpinolene, alpha
phellandrene, beta
ocimene, carene, limonene, gamma terpinene, alpha pinene, alpha terpinene,
beta pinene, fenchol,
camphene, alpha terpineol, alpha humulene, beta caryophyllene, linalool,
caryophyllene oxide, and
myrcene as measured by GC-FID and calculated based on weight of the
composition.
136. The composition of embodiment 135, wherein the composition comprises a
terpene oil
content greater than about 15% by weight.
137. The composition of embodiment 135, wherein the composition comprises a
terpene oil
content greater than about 20.0% by weight.
138. The composition of any one of embodiments 134-137, wherein the
composition comprises
a propyl cannabinoid max content of at least 30% by weight.
139. The composition of any one of embodiments 134-137, wherein the
composition comprises
a propyl cannabinoid max content of at least 40% by weight.
140. The composition of any one of embodiments 134-137, wherein the
composition comprises
a propyl cannabinoid max content of at least 50% by weight.
141. The composition of any one of embodiments 134-140, wherein the
composition comprises
a propyl THC max content of no more than 0.5% by weight.
142. The composition of any one of embodiments 134-140, wherein the
composition comprises
a propyl THC max content of no more than 0.3% by weight.
143. The composition of any one of embodiments 134-140, wherein the
composition comprises
a propyl THC max content of no more than 0.2% by weight.
147
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
144. The composition of any one of embodiments 134-143, wherein the
composition comprises
a Terpene Profile in which myrcene is not the dominant terpene; wherein the
Terpene Profile is
defined as terpinolene, alpha phellandrene, beta ocimene, carene, limonene,
gamma terpinene,
alpha pinene, alpha terpinene, beta pinene, fenchol, camphene, alpha
terpineol, alpha humulene,
beta caryophyllene, linalool, caryophyllene oxide, and myrcene.
145. The composition of embodiment 144, wherein the first or second most
abundant terpene in
the Terpene Profile is terpinolene.
146. The composition of embodiment 144, wherein the first or second most
abundant terpene in
the Terpene Profile is alpha phellandrene.
147. The composition of embodiment 144, wherein the first or second most
abundant terpene in
the Terpene Profile is beta ocimene.
148. The composition of embodiment 144, wherein the first or second most
abundant terpene in
the Terpene Profile is carene.
149. The composition of embodiment 144, wherein the first or second most
abundant terpene in
the Terpene Profile is limonene.
150. The composition of embodiment 144, wherein the first or second most
abundant terpene in
the Terpene Profile is gamma terpinene.
151. The composition of embodiment 144, wherein the first or second most
abundant terpene in
the Terpene Profile is alpha pinene.
152. The composition of embodiment 144, wherein the first or second most
abundant terpene in
the Terpene Profile is alpha terpinene.
153. The composition of embodiment 144, wherein the first or second most
abundant terpene in
the Terpene Profile is beta pinene.
148
CA 03085010 2020-06-05
WO 2019/113574 PCT/US2018/064704
154. The composition of embodiment 144, wherein the first or second most
abundant terpene in
the Terpene Profile is fenchol.
155. The composition of embodiment 144, wherein the first or second most
abundant terpene in
the Terpene Profile is camphene.
156. The composition of embodiment 144, wherein the first or second most
abundant terpene in
the Terpene Profile is alpha terpineol.
123. The composition of embodiment 144, wherein the first or second most
abundant terpene in
the Terpene Profile is alpha humulene.
157. The composition of embodiment 144, wherein the first or second most
abundant terpene in
the Terpene Profile is beta caryophyllene.
158. The composition of embodiment 144, wherein the first or second most
abundant terpene in
the Terpene Profile is linalool.
159. The composition of embodiment 144, wherein the first or second most
abundant terpene in
the Terpene Profile is caryophyllene oxide.
160. The composition of any one of embodiments 134-143, wherein the
composition comprises
a Terpene Profile in which myrcene is the first or second most abundant
terpene in the Terpene
Profile; wherein the Terpene Profile is defined as terpinolene, alpha
phellandrene, beta ocimene,
carene, limonene, gamma terpinene, alpha pinene, alpha terpinene, beta pinene,
fenchol,
camphene, alpha terpineol, alpha humulene, beta caryophyllene, linalool,
caryophyllene oxide, and
myrcene.
149
